EVALUATION OF ANTI-PROLIFERATIVE ACTIVITY AND HEPATOTOXICITY OF BOTANICALS AND BOTANICAL HEALTH PRODUCTS by PATEL DHAVALKUMAR NARENDRABHAI
  
EVALUATION OF                                     
ANTI-PROLIFERATIVE ACTIVITY 
AND HEPATOTOXICITY OF 








PATEL DHAVALKUMAR NARENDRABHAI 
 






A THESIS SUBMITTED  
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF PHARMACY 










My PhD dissertation would not have been possible without the invaluable 
contribution and support of several individuals who directly or indirectly played an 
important role in this journey. I would like to express my sincerest gratitude to 
following people from the bottom of my heart for making this expedition, a most 
memorable and rewarding journey. 
First and foremost, I extend my sincerest gratitude to my supervisor, Associate 
Professor Koh Hwee Ling, for all the support, guidance, encouragement and advices 
throughout my studies whilst giving me the freedom to work in my own way. There 
were moments of disappointment at professional and personal levels, but I would have 
never been able to overcome them without her, kind heartiness, understanding and 
support. It has been a really great pleasure to work under her supervision. Thank you 
Prof Koh, you have been a source of inspiration and motivation for me! 
I would like to express my sincerest gratitude to Assistant Professor Ho Han-
Kiat for his valuable guidance and suggestions for work related to hepatotoxicity 
screening. Thank you, Dr. Ho for offering your expert comments and always agreeing 
to meet up for a discussion even after short notices! I would also like to extend 
sincerest gratitude to Assistant Professor Lin Hai-Shu for his help and guidance on 
work related to pharmacokinetics. Thank you Dr. Lin, for imparting your expert in 
vivo work related skills to me! I would also like to thank my thesis committee 
members, Professor Ho Chi Lui, Paul and Associate Professor Chui Wai Keung 
for their valuable comments and advices on my project. I would also like to extend 
my heartiest gratitude to Associate Professor Chan Sui-Yung, the Head of the 
Department, for all her guidance, not only to pursue graduate studies but also for 
motivating me to participate in co-curricular activities. 
I would like to extend my heartfelt thanks to the Health Sciences Authority 
(HSA), Singapore for providing financial support for the work related to 
hepatotoxicity testing.  I would like to thank our kind collaborators, Associate 
Professor Chan Cheng-Leng, Ms. Tan Lebei Liesbet, Ms. Tan Mui-Mui Belinda 
and Dr. Zhang Qian from the Health Products Regulation Group of HSA for 
providing botanical health products samples for hepatotoxicity testing and their 
insightful discussions during project meetings.  I am also grateful to Ms. Low Min-
Yong from the Applied Sciences Group, HSA for her perpetual help and generous 
support to use advanced analytical instruments and other facilities of her laboratory at 
HSA.  
I am extremely indebted to the National University of Singapore (NUS) and 
to the Department of Pharmacy for giving me financial support, research 
ii 
 
scholarship and the best learning facilities and ambience to pursue PhD. I am also 
thankful to all other faculty members, lab technicians, office staffs, and department 
friends for their cooperation and assistance in my project. Thank you, Molly (Ms. 
Nam Wan Chern), for smoothly taking care of all the purchase orders. Thank you, Ms. 
Ng Sek Eng, for being always there, to fix all problems of different instruments of the 
department. I would also like to thank Mdm. Napsiah Binte Suyod, Ms. Chew Ying 
Ying, Mrs. Teo Say Moi, Ms. Chan Wei Ling, Mdm. Nor Hazliza Binte Mohamad 
and Mr. Li Guanggyang Timothy for their kind help in various administrative matters 
pertaining to my studies. 
I would like to express my sincerest gratitude to our collaborator Dr. Alvin 
Teo from the Nanyang Polytechnic and senior research fellow of our lab, Dr. Neo 
Soek Ying for their valuable advices and guidance in anti-proliferative screening 
related cell culture work. I am also thankful to my laboratory mates for their 
friendship and moral support! I was fortunate to have wonderful seniors, Dr. Toh 
Ding-Fung, Dr. Ching Jianhong and Dr. Li Lin and Mr Johannes Murti Jaya, who 
patiently taught me various experiments in my early days in the laboratory and 
provided useful advices in my project.  Dr. Sogand Zareisedehizadeh, Ms. Klara Hess, 
Ms. Siew Yin Yin and Mr. Seetoh Wei Guang, I enjoyed every conversations and 
outings with you all and thank you for taking care of my experiments when I was not 
around. I am also thankful to the undergraduate students, Ms. Song Jeilin, Ms. Low 
Wai Ling and Ms. Goh Sok Hiang, who have worked with me during my PhD for 
their helping hand and curiosities that stimulated ideas in my research work.  
Doing research would have been difficult without the company of some of my 
close friends. Thanks to Ishaque, Nikhil, Kishore, Mainak, Sudipto, Tarang, Prashant, 
Atul, Pintu, Amrita, Sweta, Sandeep, Varun, Ramsevak, Bee Jen, Li Fang, Hua Pey, 
Hong May, Yangfan, Hui-Ting, Sathish and others. All my friends and well wishers 
back in India, thank you so much. Thanks to the AAPS-NUS Student Chapter and 
Pharmacy Graduate Society, where I built friendships with fellow graduate students! 
Last but not least, I would also like to express my warmest thanks to my 
family members for their unwavering love, encouragement, and understanding over 
the years which kept me focused and helped me become what I am today. My mom 
and dad, Nayanaben and Narendrabhai, always supported me unconditionally in all 
my pursuits. At this moment, I would like to pay homage to my dad whom I lost 
during the final stage of my PhD. Although, he is not with us today in this world, I am 
sure he would have been very proud father to see me completing my studies. Despite 
his ill health, he used to encourage me to concentrate on my studies. His unflinching 
courage would always inspire me. I am fortunate to have loving younger brother 
Brijesh, who brave heartedly took care of my mom and dad in difficult times while I 
was away. I cannot forget encouragement of my maternal aunt (Amita aunty), to study 
iii 
 
ever since my first day in school when I was five years old.  I would also like to thank 
my parents-in-law for their love, affection and support. 
I can‟t express my gratitude for my wife Riddhi in words, whose unconditional 
love has been my greatest strength. Her support, encouragement, quiet patience and 
unwavering love were undeniably the backbone upon which the past few years of my 
life have been built. Her tolerance of my occasional rude moods and single handedly 
taking care of our daughter Kashvi, before and after her birth, without complaining is 
a testament in itself of her unremitting devotion and love. I also cannot forget the joy 
and happiness given by cute, sweet one month old Kashvi, while we were jubilantly 
waiting for her felicitous birth, which helped to ease stress during my difficult times.  
Finally, my greatest regards to the God for bestowing upon me the courage to 
face the complexities of life and showering infinite graces which have helped me to 

































1. Patel DN, Lin HS, Koh HL. Quantification of ginsenosides Rh4 and Rk3 in 
rat plasma by liquid chromatography-tandem mass spectrometry: Application 
to pre-clinical pharmacokinetic study. Journal of Mass Spectrometry, 2012; 
47:1510-1517. 
 
2. Patel DN, Low WL, Tan LL, Tan MB, Zhang Q, Low MY, Chan CL, Koh HL. 
Adverse events associated with the use of complementary medicine and health 
supplements: An analysis of reports in the Singapore pharmacovigilance 
database from 1998-2009. Clinical Toxicology, 2012; 50: 481-489.  
 
3. Toh DF, Patel DN, Chan EC, Teo A, Neo SY, Koh HL. Anti-proliferative 
effects of raw and steamed extracts of Panax notoginseng and its ginsenoside 
constituents on human liver cancer cells. Chinese Medicine. 2010; 6:4.  
 
4. Patel DN, Song J, Tan LL, Tan MB, Zhang Q, Low MY, Chan CL, Koh HL. 
Analysis of five anthraquinones in dietary supplements implicated in drug-
induced liver injury using high performance liquid chromatography and gas 






1. Patel DN, Song J, Tan LL, Tan MB, Zhang Q, Low MY, Chan CL, Ho HK, 
Koh HL. Botanical health products implicated in drug induced liver injury 
(DILI) in Singapore: Chemical and toxicological analyses to identify potential 
toxic components.  Oral presentation: 7th proceedings of PharmSci@Asia 
(Singapore, 6-7 June, 2012), Podium presentation award. 
 
2. Patel DN, Song J, Tan LL, Tan MB, Zhang Q, Low MY, Chan CL, Ho HK 
and Koh HL. Chemical and toxicological evaluations of botanical health 
products implicated in drug induced liver injury. Poster presented at the annual 
meeting and exposition 2011 of the American Association of Pharmaceutical 
Scientist (AAPS), Washington DC (USA, 23-27 October 2011). 
 
3. Patel DN, Song J, Tan LL, Tan MB, Zhang Q, Low MY, Chan CL and Koh 
HL. High performance liquid chromatography and gas chromatography-mass 
spectrometry analyses of botanical health products implicated in adverse drug 
v 
 
reactions. Poster presented at:  5th proceedings of PharmSci@Asia (China, 27-
28 May, 2010).  Poster award. 
 
4. Patel DN, Toh DF, New LS, Chan EC, Koh HL. Effect of steaming on 
ginsenoside content of Panax notoginseng. Poster presented in an international 
conference on “Recent Development in Chinese Herbal Medicine” at Nanyang 
Technological University (Singapore, 25-26 January-2010).  
 
5. Patel DN, Toh DF, New LS, Chan EC, Koh HL. Quality control of Panax 
notoginseng using metabolomics approach. Poster presented at the 
PharmSci@Asia Symposium held at China Pharmaceutical University, 
Nanjing (China, 26-27 May-2009). 
 
6. Song J, Patel DN, Tan LL, Tan MB, Zhang Q, Low MY, Chan CL, Ho HK, 
Koh HL. Evaluation of hepatotoxicity of botanical health products. Poster 
presented at the 6
th
 AAPS-NUS Student Chapter Scientific Symposium held at 




7. Goh SH, Patel DN, Tan CH, Koh HL. A survey and chemical analyses of 
“ginseng” and related products in Singapore. Poster presented at the 7th AAPS-
NUS Student Chapter Scientific Symposium held at National University of 
Singapore (Singapore, 6
th





1. Podium presentation award at the 7th proceedings of PharmSci@Asia, 
Singapore, 6-7 June, 2012. 
2. Poster award at the 5th proceedings of PharmSci@Asia, China, 27-28 May, 
2010. 
3. Teaching assistant (Part-time) award in AY2009/2010 award from the 
Faculty of Science, NUS in appreciation for outstanding and excellent 













TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS i 
LIST OF PUBLICATIONS, CONFERENCE PRESENTATIONS AND AWARDS iv 
TABLE OF CONTENTS vi 
SUMMARY x 
LIST OF TABLES xiii 
LIST OF FIGURES xvi 
LIST OF ABBREVIATION xx 
  
1.   Introduction 1 
      1.1    Herbal medicine 1 
 1.2    Safety of herbal medicine 3 
        1.2.1   Intrinsic toxicity of herbal medicine 4 
        1.2.2   Herb-drug interaction 5 
        1.2.3   Misidentification and substitution 7 
        1.2.4   Standardization 8 
        1.2.5   Contamination 9 
        1.2.6   Adulteration 10 
1.3    Hepatotoxicity of herbal medicine 11 
1.4    Drug discovery from medicinal plants 19 
              1.4.1   Plants as a potential source of anticancer agents 20 
         1.4.2   Panax notoginseng  21 
                         1.4.2.1   Processing of P. notoginseng 22 
                         1.4.2.2   Chemical Constituents of P. notoginseng 23 
                         1.4.2.3   Pharmacological actions of P. notoginseng 26 
  
2.   Hypothesis and objectives 31 
 2.1   Hypotheses 32 
 2.2   Objectives 33 
  
3.   Chemical analyses and anti-proliferative activity of steamed P. notoginseng 34 
 3.1    Introduction 34 
          3.1.1   Liver cancer 35 
          3.1.2   Anti-proliferative activities of P. notoginseng 36 
vii 
 
               3.1.3   Combined effects of ginsenosides and currently used  
                     chemotherapeutic agents  
38 
3.2     Objectives 40 
  3.3    Experimental 41 
              3.3.1   Materials and reagents 41 
              3.3.2   Methods 41 
     3.4    Results and discussion 50 
              3.4.1   Isolation, purification and identification of ginsenosides 50 
           3.4.2   Anti-proliferative effects of P. notoginseng root extracts and   
                      ginsenosides against cancer cells 
53 
                         3.4.2.1   Structure-activity relationship (SAR) for anti-proliferative  
                                       activity of ginsenosides 
61 
                         3.4.2.2   Effects of ginsenosides on cell cycle 63 
3.4.2.3    Measurement of cell viability, cytotoxicity and caspase-3/7    
               activation  
67 
              3.4.3  Combined effects of ginsenosides, doxorubicin and paclitaxel 71 
      3.4   Conclusion 82 
  
4.   Pharmacokinetics of ginsenosides Rh4 and Rk3 83 
 4.1   Introduction 83 
 4.2   Objective 84 
   4.3   Experimental 85 
              4.3.1    Materials and reagents 85 
              4.3.2    Methods 85 
      4.4   Results and discussion 89 
              4.4.1    LC method development 89 
           4.4.2    ESI-MS/MS method development 91 
           4.4.3    Method validation 94 
           4.4.4    Pharmacokinetic profiles of ginsenosides Rh4 and Rk3 97 
  4.5   Conclusion 101 
  
5.   Analysis of adverse events reports associated with the use of complementary  
      medicine  and health supplements  
102 
     5.1   Introduction 102 
viii 
 
     5.2   Objective 104 
     5.3   Methods 104 
             5.3.1    Source of data 104 
             5.3.2    Data collection and analyses 106 
     5.4   Results and discussion 108 
          5.4.1   Indications and routes of administration 111 
          5.4.2   Adverse events grouped according to system organ class classification 112 
          5.4.3   Hospitalization and outcomes of adverse events 114 
          5.4.4   Adulterations 115 
     5.5   Conclusion 125 
  
6.   Chemical analyses of the botanical health products implicated in drug  induced  
      liver injury (DILI) 
126 
     6.1   Introduction 126 
     6.2   Objective 126 
     6.3   Identification of potential hepatotoxic compounds in implicated products 127 
   6.3.1    Experimental 127 
                         6.3.1.1   Materials and reagents 127 
                         6.3.1.2   Methods 128 
  6.3.2     Results and discussion 134 
                         6.3.2.1   N-nitrosofenfluramine  137 
                         6.3.2.2   5-hydroxymethylfurfural and caffeine  139 
                         6.3.2.3   Psoralen 142 
                         6.3.2.4   Hesperidin and borneol  144 
                         6.3.2.5   Anthraquinones 145 
       6.3.2.6   Fractionation of methanol extract of Merit 149 
       6.3.2.7   Fractionation of methanol extract of Control Plus 150 
                         6.4.1.8   Alpha and beta-asarones 151 
 6.4.   Quantification of anthraquinones in the products implicated in DILI by  
          High Performance Liquid Chromatography (HPLC) 
152 
           6.4.2   Materials 152 
              6.4.2   Methods 153 
              6.4.3   Results and discussion 155 
                         6.4.3.1   Method development 155 
ix 
 
                         6.4.3.2   Method validation 158 
                         6.4.3.3   Quantification of anthraquinones 163 
    6.5   Quantification of asarones in the baby products by the Gas  
            Chromatography-Mass Spectrometry (GC-MS) 
169 
             6.5.1   Materials 169 
             6.5.2   Methods 171 
             6.5.3   Results and discussion       172 
              6.5.3.1   Method development 172 
              6.5.3.2   Method validation 175 
              6.5.3.3   Quantification of asarones 179 
    6.6   Conclusion 
 
   186 
7.   Evaluation of hepatotoxicity of  botanical health products implicated in DILI 187 
      7.1    Introduction 187 
      7.2    Objective 190 
      7.3    Experimental 190 
               7.3.1   Materials and reagents 190 
               7.3.2    Methods 191 
      7.4    Results and discussion 197 
               7.4.1   Screening for toxicity 197 
                          7.4.1.1    Comparison of different solvents for extraction 197 
                          7.4.1.2    Screening of implicated products and suspected toxic  
                                         components 
198 
                          7.4.1.3   Screening of different fraction of methanol extract of Merit 207 
                          7.4.1.4   Screening of different fractions of methanol extract of  
                                         Control plus 
   208 
             7.4.2    Mechanisms of the observed toxicity 209 
                         7.4.2.1     TBARS assay for the measurement of lipid peroxidation 209 
                         7.4.2.2     Glutathione depletion assay 213 
                         7.4.2.3     Measurement of cell viability and Caspase-3/7 activation  216 
      7.5  Conclusion   224 
8.   Conclusions and future prospects 225 
9.   Bibliography    236 





Botanical medicine has been used since time immemorial for their beneficial 
effects but some may also cause adverse or toxic effects. This study aims to evaluate 
the potential anti-proliferative activity of Panax notoginseng, a well known TCM herb 
as well as to investigate the potential hepatotoxicity of 15 botanical health products 
suspected to cause drug induced liver injury (DILI). 
 Seven major markers of steamed P. notoginseng were successfully isolated 
and screened for their potential anti-proliferative activities against liver, breast, 
colorectal and prostate cancer cell lines. Among these ginsenosides, Rh2, Rk1 and 
Rk3 were found to be more active with IC50 values ranging from 23-36, 65-110 and 
78-105 µg/mL respectively against different cell lines than ginsenoside 20(S)-Rg3 
(IC50 values ranging from 134-145 µg/mL, an approved anti-cancer drug in China and 
Taiwan). Ginsenoside Rk3 was found to induce caspase-3/7 dependant apoptosis by 
arresting cells in sub-G1 phase. In addition, ginsenosides Rg5, Rh4, Rk1 and Rk3 
were found to increase the anti-proliferative activity of doxorubicin by more than two 
folds but did not affect the anti-proliferative actions of paclitaxel on liver cancer cells. 
To the best of our knowledge, this is the first report which shows that concurrent use 
of ginsenosides with doxorubicin could help to reduce the dosage of doxorubicin 
required for chemotherapy. As Rk3 was found to have promising anti-proliferative 
activity, the pharmacokinetic profiles of Rk3 and its structural epimer Rh4 were 
subsequently assessed in Sprague-Dawley rats by validated LC-ESI-MS/MS method. 
Similar to many other ginsenosides, they were found to have low oral bioavailability. 
Upon intravenous administration, they were found to have abundant plasma exposure, 
moderate clearances and moderate terminal elimination half-lives. However, these 
data suggest that higher dose might be required to achieve effective in vivo 
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concentrations even after I.V. administration. This presents additional challenge for 
their clinical use. 
From the perspective of safety of herbal medicine, analysis of adverse events 
reports associated with the use of complementary and alternative medicine (CAM) 
products submitted to the Vigilance branch of HSA, Singapore over a 12-year period 
(1998-2009) is performed for the first time for pharmacovigilance purposes. Only 3.8 
% cases (627 cases) out of a total of 16,696 cases of adverse events were due to CAM 
products. Adulteration of CAM products with conventional medicine and/or their 
synthetic analogues appears to be one of the major known causes of the associated 
adverse events. 22 fatalities were reported and hepatotoxicity was responsible for the 
deaths of 10 patients during the study period.  
15 products suspected of causing drug induced liver injury (DILI) were 
chemically analysed to identify potential toxic components. Potential hepatotoxins 
such as anthraquinones, β-asarone, psoralen, N-nitrosofenfluramine and 5-
hydroxymethylfurfural were identified and confirmed in some of the products. The 
product “Merit” was found to contain 29.52 ± 0.02 mg of anthraquinones per daily 
dose. This is very close to the maximum daily allowance of 30 mg recommended by 
the European Medicines Agency (EMEA) for the safe use of anthraquinones. 
Comparison of two different batches suggested that the implicated product (Merit) 
contains more than 50 times higher amounts of anthraquinones than that of the same 
product that had not been implicated. Anthraquinones and herbs containing 
anthraquinones are reported to be hepatotoxic. β-asarone is also reported as genotoxic 
and hepatocarcinogenic. From the 15 implicated products, two products (including 
one baby product) were found to contain asarones. To further investigate the 
prevalence of asarones in botanical health products for babies, analyses of 20 baby 
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products were carried out. Of the 10 products that were found to contain beta-asarone, 
6 products contained 4 to 25 times more amounts of β-asarone than the recommended 
amount of 2 µg/kg body weight/day by EMEA.  
Ten implicated products and ten potentially toxic components were screened 
for their toxicity on normal liver cells (THLE-2 cells). Four products were found to be 
more toxic than the positive control paracetamol (IC50: 1.52 mM). From the 
components screened, emodin was found to be the most toxic with IC50 value of 0.03 
mM against THLE-2 cells. Results from the lipid peroxidation assay and glutathione 
depletion assay suggest that the observed liver toxicity could be due to the oxidative 
stress.  Studies on the mechanism of cell death suggest that anthraquinones cause 
caspase-3/7 independent cell death while asarones ( and β) cause cell death by 
activation of caspase-3/7.  
In conclusion, in this thesis, the anti-proliferative activity of major marker 
components of steamed P. notoginseng and their effects on the anti-proliferative 
activities of doxorubicin and paclitaxel were scientifically evaluated. These results 
provide a better understanding of the potential anti-proliferative activity of steamed P. 
notoginseng and its potential use in combination therapy. The chemical and 
toxicological evaluations of products suspected to cause DILI have provided the 
important observation that the intrinsic toxicity of components of botanical medicine 
such as anthraquinones (in particular, emodin) and asarones should not be neglected. 
The results of this work demonstrate that the benefits of steamed P. notoginseng 
should be further harnessed, but “natural does not mean totally safe”. The work 
presented in this study is a step towards better understanding of the benefits and risks 
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1.1 Herbal medicine 
Traditional medicine as defined by the World Health Organisation (WHO) 
refers to the sum total of the knowledge, skills, and practices based on the theories, 
beliefs, and experiences indigenous to the different cultures, whether explicable or not, 
used in the maintenance of health as well as in the prevention, diagnosis, 
improvement or treatment of physical and mental illness (WHO, 2008). It is also part 
of the broader term “complementary and alternative medicine (CAM)” which is 
defines as a group of diverse medical and health care systems, practices, and products 
that are not generally considered as part of conventional medicine (NCCAM, 2010). 
Herbal medicine (also known as botanical medicine, phytomedicine or phytotherapy) 
is the most popular form of traditional medicine or CAM. Botanicals refer to different 
types of plants or plant extracts used alone or in combination to treat, diagnose and 
prevent illnesses or to maintain well-being. The products derived from botanicals, 
which are usually sold as over the counter dietary supplements for health promotion 
and well-being are referred to as botanical health products. (Bast et al., 2002; WHO, 
1996; Liu, 2011; NCCAM, 2010). In recent years, there has been a tremendous 
increase in the use of herbal medicine and their derived products such as botanical 
health products. 
In many developing countries, traditional medicine is the primary form of 
healthcare. About 70%- 95%  of people in most of the developing countries in the 
Asia, Africa, Latin America and the Middle East, use  traditional medicine, including 
herbal medicines, for the management of health related issues (Robinson and Zhang, 
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WHO 2011). For example, the Ayurvedic medicine in India, Kampo medicine in 
Japan, Traditional Chinese Medicine (TCM), and Unani medicine in the Middle East 
and South Asia (Mosihuzzaman and Choudhary, 2008). It has also become 
increasingly popular in the developed countries. In Canada, France and Italy, 70-90% 
of people were reported to have used traditional medicine (Robinson and Zhang, 
WHO 2011). In the US, more than 40% of adults take some form of dietary 
supplements to promote their health and wellness or to prevent and treat diseases 
(Mulabagal and Calderón, 2012).  
As per the WHO report, the global sales of herbal medicines were estimated at 
US$ 83 billion in 2008 (Robinson and Zhan, WHO, 2011). The sales of herbal 
medicine is expected to exceed a trillion USD by the year 2028 (Mosihuzzaman and 
Choudhary, 2008). The trade of traditional Chinese herbal medicine was estimated to 
be US$ 31 billion in 2008 (Flower et al., 2011). From the year 1994 to 2005, the 
number of herbs and dietary supplement products marketed in the United States 
jumped from 4000 to 29 000 with an estimated 1000 new products being introduced 
into the American market annually (Morrow, 2005).  
The increased popularity of herbal medicine could be attributed to many 
reasons, including discontentment with the conventional medicine, high cost of 
conventional drugs, patients desire to take medical decision and self-treatment and 
perception of herbal medicine as safe being natural (Barnes, 2003). Growing 
worldwide interest in the use of herbal medicine has resulted in their ready availability 
from the herbalists, herbal medicine shops, pharmacies, health-food outlets, 
supermarkets and even through mail order including online purchase via the Internet 
(Koh and Woo, 2000). However, the increasing popularity of herbal medicine and 
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their derived products raise question regarding their safety. The following section 
discusses various safety issues concerning herbal medicine. 
 
1.2 Safety of herbal medicine 
Herbal medicine including botanicals and botanical health products are 
generally considered as safe on the grounds of their natural origin and long term use 
by various cultures (Willet et al., 2004). However, as medicinal agents, herbal 
medicine and their derived products should be regarded as having the same potential 
for unwanted effects as the conventional drugs. From the statements of Paracelsus in 
the fifteenth century and well-established knowledge in modern toxicology, it is 
realized that dosage determines the toxicity of compounds. Substances considered 
toxic may be harmless in small doses, and conversely an ordinarily harmless 
substance can cause serious adverse effects if over consumed. 
The adverse effects or toxicities resulting from herbal medicines can be 
classified into four categories, namely, Type A, B, C and D (Ernst, 2005). Type A 
adverse effects are the predictable, dose-dependent reactions associated with the 
pharmacological effects of an herb. Intrinsic toxicity of herbal medicine can results in 
Type A adverse effects e.g. tachycardia resulting from the consumption of ephedra 
(Ernst, 2005).Type B involves the idiosyncratic reactions which are not predictable 
from their pharmacological action of a herb such as allergic reactions and anaphylaxis 
e.g. the components of herbal medicine can result in hypersensitivity in some 
individuals causing idiosyncratic reaction. Type C adverse reactions involve those that 
are predictable and develop gradually during long-term use of herbal medicine e.g. 
slowed bowel function upon long term use of stimulant herbal laxatives. Lastly, Type 
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D adverse effects are those having a latency period of months or years before they can 
be observed e.g. carcinogenicity and teratogenicity (Ernst, 2005).  
Some of the factors affecting the safety of herbal medicines include intrinsic 
toxicity, herb–drug interaction, adulteration, substitution, contamination, 
misidentification, lack of standardization, incorrect preparation and/or dosage and 
inappropriate labeling and/or advertising (Koh and Woo, 2000; Mosihuzzaman and 
Choudhary, 2008). The adverse effects associated with the deliberate overdose, 
accidental poisoning and drug interactions with conventional medicine are included in 
Type A. (Drew and Myers, 1997; Myers and Cheras, 2004). 
 
1. 2.1 Intrinsic toxicity of herbal medicine 
Intrinsic toxicity of herbal medicine is one of the most serious safety concerns 
for botanicals (Mosihuzzaman and Choudhary, 2008). Intrinsic toxicities such as 
hepatic toxicity, cardiac toxicity, nephrotoxicity, carcinogenicity, hematologic toxicity,  
idiosyncratic reactions and severe allergic reactions of some  plants used in herbal 
medicine are very well documented (De Smet PAGM, 2002, Ernst, 2005a, Fu et al., 
2009; Nortier et al., 2000; Tovar and Petzel, 2009; Zhou et al., 2007). There have 
been over 140 reports to the FDA of serious adverse events resulting in cardiac 
toxicity associated with the use of Ma Huang (Ephedra sinica) from 1997 to 1999. 
Ten of these events resulted in death and 13 resulted in permanent disability because 
of its sympathomimetic effects (Theoharides et al., 1997). Other herbs reported to 
cause cardiac toxicity (Tovar and Petzel, 2009) include aconite (roots of Aconitum 
carmichaeli, A.kusnezoffiii, A. balfouri Stapf and A. szechenyianum Gay), Fox glove 
or digitalis (Digitalis purpurea), Tripterygium wilfordii Hook (Lei gong teng) and 
Chinese Beetle (Mylabris phalerata or Ban Mao).  
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Other herbs such as Aristolochia fangchi is prohibited from use in many 
countries including Singapore as it is well known to cause nephropathy and 
carcinogenicity (Debelle et al., 2008: Tovar and Petzel, 2009). It contains aristolochic 
acids, which cause renal toxicity and are carcinogenic. One of the most serious 
intrinsic toxicity of herbal medicine is hepatotoxicity. There are many reports of 
herbal medicine associated with hepatotoxicity in the literature. This would be 
discussed in detail in the Section 1.3.  
 
1.2.2 Herb-drug interaction 
Herbal medicine may be taken for health promotion as well as therapeutic 
purposes. This could lead to potential pharmacokinetic and/or pharmacodynamic 
herb-drug interactions (Chen et al., 2012; Gurley, 2012a; 2012b) if the patient is on 
conventional drug therapy. The concurrent consumption of herbal medicine with the 
conventional drugs may increase or decrease the pharmacological or toxicological 
effects of the drugs or herbs. Synergistic or additive therapeutic effects may lead to 
undesirable toxic effects and complicate the dosage regimen of long-term medications 
while antagonistic interactions will result in decreased efficacy and therapeutic failure 
(Chen et al., 2012; Gurley, 2012a; Hu et al., 2005). The risk of potential herb-drug 
interactions poses a serious challenge for the safety evaluation of herbal medicines. In 
particular, interaction of herbal medicine with drugs of narrow therapeutic window 
such as digitoxin and may lead to life threatening adverse effects (Hu et al., 2005). 
More than 150 herbal medicines have been identified to have potential herb-drug 
interactions (Izzo and Ernst 2001). Some of these herb-drug interactions have been 
discussed extensively in the literature (Chen et al., 2012; Gurley, 2012a; De Smet 
PAGM, 2002; 2004, Fugh-Berman, 2000; Hu et al., 2005; Tirona and Bailey, 2006).  
6 
 
Herbs acting as a mechanism based inhibitors of cytochrome P450 enzyme 
activity (e.g. Hydrastis canadensis, Piper nigrum) or work as aligands for orphan 
nuclear receptors (e.g. St John‟s wort) are most likely to cause clinically important 
herb-drug interactions (Gurley, 2012b; Gouws et al., 2012;  Wu et al., 2012).  
Recently, Wu et al., 2012 reviewed the phytochemicals which are reported to inhibit 
various CYP enzymes and their potential to cause herb-drug interactions Three herbs 
most frequently reported to cause herb-drug interactions due to their effects on 
various CYP enzymes include St John's wort, grapefruit juice and garlic (Wu et al., 
2012).  
Hypericum perforatum (hypericum; St John‟s wort) is well known to interact 
with many conventional drugs. Interacting conventional drugs include anticancer 
agents (imatinib and irinotecan), anti-HIV agents (e.g. indinavir, lamivudine and 
nevirapine), anti-inflammatory agents (e.g. ibuprofen and fexofenadine), antimicrobial 
agents (e.g. erythromycin and voriconazole), cardiovascular drugs (e.g. digoxin, 
ivabradine, warfarin, verapamil, nifedipine and talinolol),  drugs acting on central 
nervous system (e.g. amitriptyline, buspirone, phenytoin, methadone, midazolam, 
alprazolam, and sertraline), hypoglycaemic agents (e.g. tolbutamide and gliclazide), 
immuno-modulating agents (e.g. cyclosporine and tacrolimus), proton pump inhibitors 
(omeprazole), drugs acting on respiratory system (theophylline) and statins (e.g. 
atorvastatin and pravastatin) (Chen et al., 2012; Hu et al., 2005). St John‟s wort 
decreased the blood concentrations of ciclosporin (cyclosporin), midazolam, 
tacrolimus, amitriptyline, digoxin, indinavir, warfarin, phenprocoumon and 
theophylline (Chen et al., 2012; Hu et al., 2005). Concomitant consumption of Salvia 
miltiorrhiza (danshen) with warfarin therapy also enhanced the anticoagulation and 
bleeding (Hu et al., 2005).  
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Incidences of herb-drug interactions are increasing due to the presence of 
polypharmacies of conventional drugs and herbal products (Tovar and Petzel, 2009). 
In addition, the increasing inclusion of vitamins, herbs, foods, and over-the-counter 
medications adds to an increased potential for harmful interactions (Tovar and Petzel, 
2009). Therefore, monitoring of herb-drug interaction is important to prevent harmful 
interactions. Potential interactions of herbs should be indicated on their label to alert 
the consumers and healthcare professionals.  
 
1.2.3 Misidentification and substitution   
Herbs are grown, harvested and collected under different environmental, 
cultivation and processing conditions. Therefore, correct identification of plants is 
important to avoid mixing up of related plants in herbal medicinal preparations. 
Likewise, prevention of substitution whereby required plant is replaced by incorrect 
or different herb is also important to ensure the safety and efficacy of herbal medicine.  
Improper identification of the plant material used in herbal medicine would lead to 
substitution. This substitution could lead to reduced efficacy and/or increased toxicity 
(if it is substituted by a toxic herb). Accidental botanical substitution (due to 
misidentification of plant species) or intentional botanical substitution (exchange with 
other plant species) can affect the safety and efficacy profiles of the resultant 
botanical products (Barnes, 2003).  
An example of substitution affecting the safety of product includes a number 
of cases of interstitial renal fibrosis caused by the presence of aristolochic acid. More 
than 70 cases of renal failure following the ingestion of a slimming preparation 
containing Chinese herbs were identified in Belgium between January 1989 and 
January 1994 (Mosihuzzaman and Choudhary, 2008). In this case, nontoxic botanicals 
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including Stephania tetrandra and Clematis armandii were substituted with 
Aristolochia species (Newall et al., 2002). There are numerous reports 
(Mosihuzzaman and Choudhary, 2008) of inadvertent substitution of “gui jiu” 
(Podophyllum emodi Wall) for “long dan cao” (Gentiana spp.). This resulted in severe 
neurological, gastrointestinal, renal, and hepatic manifestations in the consumers 
(Mosihuzzaman and Choudhary, 2008). 
 
1.2.4 Standardization 
Most herbal medicines and herbal products are usually prepared from the 
crude plant extracts, which comprise a complex mixture of different chemical 
constituents. These chemical constituents are responsible for the pharmacological 
actions as well as the adverse effects of herbal medicine. Many factors such as species 
variation, harvesting season, geographical origin, processing methods, part of plant 
used affect the nature and concentrations of chemical constituents (Fong, 2002; Khan, 
2006). These complexities make the standardization of the herbal medicines and their 
derived products indispensable. Standardisation is important to control the 
concentrations of active constituents. This is very important to avoid any adverse 
effects arising from the overdose of active constituents. Sometimes, standardisation is 
also important to control the concentrations of toxic components. For example, 
standardized extracts of Ginkgo biloba contain 22–27% ginkgo flavonoid glycosides, 
5–7% terpene lactones, and less than 5 parts per million of ginkgolic acids, which are 
known to be allergenic (Barnes, 2003). 
The WHO has developed the Guidelines of Good Agriculture Practice (GAP) 
and Good Manufacturing Practice (GMP) 2003 to standardize the different operations 
to have standardized herbal products with good quality to ensure their safety (WHO, 
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2003). In the pharmacopoeias of many countries such as the United States 
Pharmacopoeia (USP 2010), the British Pharmacopoeia (BP 2010) and the Chinese 
Pharmacopoeia (Committee of National Pharmacopeia of PR China 2010), 
monographs of herbal medicine are available which contain the specifications of 
marker compounds for quality control purposes. 
 
1.2.5 Contamination  
Various contaminants found in herbal medicine are of serious safety concern. 
Contaminants most likely to be found in herbal materials or herbal products include 
but are not limited to heavy metals, pesticides, microbes and mycotoxins (Ernst, 
2000a, 2000b; Xue et al., 2008; Zhang et al., 2012a). Mercury, arsenic, and lead are 
the three most commonly detected toxic heavy metals (Koh et al., 2000, Zhang et al., 
2012a). Others include cadmium, copper and thallium (Ernst, 2001 and 2002). 
Contamination could be due to the accumulation of heavy metals in the environment 
(e.g. from contaminated soil or atmosphere), accidental pollution during the 
production process or deliberate addition (Zhang et al., 2012a). Sometimes, heavy 
metals may be intentionally added to products in some traditional medicines as they 
are part of TCM such as the Ayurveda (Ernst 2002; Cooper et al., 2007; Jordan et al., 
2010; Saper et al., 2008) and contamination may occur through inadequate quality 
control.  
Microbial contamination of herbal products can be avoided if the WHO GAP 
and GCP guidelines are properly followed. However, there are reports of extensive 
microbial contamination in the literature. The FDA-initiated investigation of 
commercial ginseng supplements in the US detected a high concentration of yeasts 
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and fungi including Aspergillus flavus well above the microbial limits established by 
the US Pharmacopeia (Tournas et al., 2006).  
 
1.2.6 Adulteration 
Adulteration of herbal medicine is one of the major known causes of the 
adverse effects of herbal medicine and their derived products. Increasing numbers of 
reports of adulteration with undeclared drugs in herbal medicine especially herbal 
slimming and sexual performance enhancement products have been reported in the 
literature and is of serious concern for the regulatory authorities (Chan, 2009; Chitturi 
and Farrell, 2008; Low et al., 2009; Zou et al., 2006). Several undeclared 
conventional drugs have been found in herbal medicines and the incidence of 
adulteration of commercially available herbal preparation was reported to be 23.7 in 
Taiwan (Huang et al., 1997), 7% in California (Ko et al., 1998), 5.5% in New York 
(Miller et al., 2007) and 1.23% in Singapore (Koh et al., 2000). Unsupervised 
consumption of drugs could lead to adverse or toxic effects with even fatal 
consequences (Koh et al., 2000). Drug-drug interaction could also happen as some 
patients may be under the care of conventional medical doctors and receiving 
medications. Undeclared drugs may also lead to overdose. 
Voluntary recall of dietary supplements
 
for sexual performance enhancement 
(e.g. Stamin It, Erectzia, and Vigor 100) were carried out after the products were 
found to contain sulfoaildenafil, an analogue of sildenafil, an FDA-approved drug 
used in the treatment of male erectile dysfunction (US-FDA, 2010). In Singapore, one 
batch of Young‟s Choice Brand Qing Xin Dao Chi Pian, a CPM product, was found 
to contain undeclared drugs paracetamol and chlorpheniramine and was recalled 
(HSA, 2010). From 2000 to 2002, more than 800 clinical cases of serious hepatic 
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injury with necrosis were reported in Japan in patients taking Chinese dietary 
supplements (marketed as Chaso, Onshido, and Sennomoto-kouno) for weight loss 
(Satoh et al., 2006). Most, except for the few patients who died, recovered after the 
supplements were withdrawn. Based on chemical analysis of their components, two 
synthetic products, N-ethyl-a-methyl-3-(trifluoromethyl)benzeneethanamine 
(fenfluramine) and its N-nitroso derivative (N-nitrosofenfluramine) were found to be 
present (Satoh et al., 2006a; 2006b).  
From the above discussion of various factors affecting the safety of herbal 
medicine, it can be appreciated that herbs are not necessarily harmless. In the 
following section, the hepatotoxicity (one of the most serious safety issue) associated 
with the use of botanicals and botanical health products, is discussed. 
 
1.3 Hepatotoxicity of herbal medicine 
The liver is the main organ responsible for the drug biotransformation and 
detoxification of drugs in the body to readily excreted metabolites. Thus, the liver is at 
a high risk for drug-induced liver injury (DILI). DILI can be categorized as 
predictable (high incidence, dose-related) and unpredictable (low incidence that 
might or might not be dose-related) (Willet et al., 2004). The unpredictable reactions 
include idiosyncratic reactions (without allergic features) and immune-mediated 
hypersensitivity reactions (with fever, rash, eosinophilia, and other allergic 
symptoms). Predictable liver toxicities are usually discovered in preclinical and 
clinical testing for drugs. However, at present, no such testing is mandatory for the 
botanicals and botanical health products marketed as herbal remedies. In addition, the 
idiosyncratic hepatotoxicity is very difficult to predict or assess because of its very 
low incidence rate which ranges between 1 in 10,000 to 1 in 100,000 (Hampson and 
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Harvey, 2002). Furthermore, the causality of idiosyncratic hepatotoxicity is 
confounded by various environmental (disease condition, concurrent medication) and 
genetic (polymorphism of metabolizing enzymes or drug transporters) factors 
(Boelsterli, 2003). Regardless of etiology, because of the complex and diverse 
chemistry of herbal medicine, it is often difficult to predict the hepatotoxicity (Willet 
et al., 2004).  
Adverse hepatic events from the conventional pharmaceuticals are well known 
and DILI is the most frequent cause of post-marketing withdrawals and accounts for 
approximately 50% of the total cases of acute liver failure in the United States (Lee, 
2003; Shapiro and Lewis 2007). The frequency is reported to be 15 to 40 cases per 
100,000 persons per year, with 6% mortality rate on average (Makarova, 2008) and as 
high as 12% (Andrade et al., 2005). The pharmaceuticals most often implicated are 
paracetamol and antimicrobial drugs such as amoxicillin, flucloxacillin, telithromycin 
and tetracycline (Norris et al., 2008; Grant and Rockey, 2012). However, in some 
cases herbal medicine is also implicated (Norris et al., 2008; DILIN, USA).   
In the United States, the National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK) has established the Drug-Induced Liver Injury Network 
(DILIN) to stimulate and facilitate research on DILI. The goal of this network is to 
develop standardized procedures to identify and fully characterize suspected cases of 
drug- and CAM-induced liver injury, and to conduct controlled, clinical studies that 
will include extensive collection of data, serum, DNA, and tissue specimens (DILIN, 
USA). 
Despite extensive investigations of hepatotoxicity due to conventional drugs, 
comparatively less is known about the safety of botanical health products. In some 
cases, hepatotoxicity has been related to the presence of undeclared drugs and/or their 
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synthetic analogues (e.g. N-nitrosofenfluramine) and ingestion of botanicals 
containing known hepatotoxins (e.g. pyrrolizidine alkaloids). In many cases, the 
association has not been confirmed and the causation is not known while the 
mechanisms of hepatotoxicity are elusive. There is thus a critical need to develop a 
better understanding of determinants of hepatotoxicity associated, the mechanisms 
involved and how to evaluate and predict the hepatotoxic potential of the botanicals 
and botanical health products to safeguard patient safety. 
Several reports and reviews on the involvement of botanicals and botanical 
health products in DILI have been published (Kaplowitz, 1997; MacGregor et al., 
1989; Navaro, 2009; park et al., 2004; Stedman et al., 2002; Stickel et al., 2005; 
Teschke et al., 2012; Strader et al., 2012). Some of the botanicals and botanical health 
products reported to be involved in DILI along with identified hepatotoxin (if any) 
have been collated and are listed in Table.1. 
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Table.1.1 Botanicals and botanical health products reported to be involved in drug-induced liver injury 
 
No. Herbal Remedy 
Suspected toxic  
herb/component 




Potassium atractylate; and 
gummiferin, Atractylosides 
Inhibition of gluconeogenesis 
through interference with 
oxidative phosphorylation 
Chitturi et al., 2008; Stickel. et al., 2001, 
2005;  Strader et al., 2012 
2. Bajiaolian Podophylotoxin unknown Pittler et al., 2003 
3. Boh-Gol-Zhee Psoralea corylifolia unknown Chitturi et al., 2008 
4. Camphor Cyclic terpenes unknown Chitturi et al., 2008;  Strader et al., 2012 
5. 
Carp capsules  
 
Cyprinol unknown Chitturi et al., 2008 
6. Cascara Sagrada Anthracene –glycosides unknown Pittler et al., 2003; Stickel. et al., 2005 





Inhibition of cyclo-oxygenase 
and several cytochrome P450 
Chitturi et al., 2008; Pittler et al., 2003; 






Induction of mitochondrial 
permeability transition and 
uncoupling of oxidative 
phosphorylation resulting into 
intracellular ATP depletion and 
cell death 
Chitturi et al., 2008; Satoh et al., 2006; 
Lau al., 2004;  Strader et al., 2012 
9. 
Comfrey; gordolobo 
yerba tea; maté tea; 
Chinese herbal tea 
Pyrrolizidine alkaloids unknown 
 Chitturi et al., 2008; Stickel. et al., 2005;  
Strader et al., 2012 
10. Frangula Anthranoids unknown Ernst, 1998 




Chitturi et al., 2008; Pittler et al., 2003;  
Strader et al., 2012;  Teschke et al., 2011 
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No. Herbal Remedy 
Suspected toxic  
herb/component 
Suggested Mechanism References 




Chitturi et al., 2008;  Elinav et al., 2007; 
Schoepfer et al., 2007; Stickel. et al., 
2009; Teschke et al., 2012 
13. Hydroxycut  
Camellia sinesis? , chromium,  
G. Cambogia  (Hydroxycitric acid?) 
unknown Shim and Saab, 2009 
14. 
Jin Bu Huan 
Anodyne tablets 
Lycopodium serratum unknown 
Chitturi et al., 2008; Pittler et al., 2003; 
Stickel. et al., 2005;  Horowitz et al., 
1996;  Teschke et al., 2012 
15. Kava Kavalactones or kava alkaloids 
Not clear, alteration of CYP 
enzymes, formation of activated 
metabolites, idiosyncratic 
Pittler et al., 2003; Stickel. et al., 2005;  








unknown Chitturi et al., 2008 
18. LipoKinetix 
Usnic acid; Ephedra alkaloids 
 
unknown Chitturi et al., 2008 
19 Ma huang Ephedra alkaloids unknown 
Chitturi et al., 2008; Pittler et al., 2003; 
Stickel. et al., 2005;  Nadir et al., 1996;  
Teschke et al., 2012 
20. Margosa oil 
Margosa oil 
 
Mitochondrial damage Chitturi et al., 2008; Pittler et al., 2003 
21. Noni juice 
Morinda citrifolia?,  
anthraquinones 
 
unknown Chitturi et al., 2008 
22. Oil of cloves 
Eugenol (Dose dependant 
hepatotoxicity) 
 
unknown Chitturi et al., 2008 
23. Pennyroyal oil Menthofuran, Pulegone 
Glutathione depletion  through 
electrophillic metabolites 
Chitturi et al., 2008; Pittler et al., 2003; 
Stickel. et al., 2005;  Strader et al., 2012 
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No. Herbal Remedy 
Suspected toxic  
herb/component 
Suggested Mechanism References 
24. Podophyllotoxin 
Found in Chinese remedy 
Bajiaolian 
unknown Ernst, 1998 
25. Polygoni Multiflori 
Anthraquinones (Emodin and 
Physcion) 















Pyrrrolizidine alkaloids and their N-
oxide derivatives 
Metabolic activation followed 
by DNA adduct formation 
 Stickel. et al., 2005 
28. Rhubarb Anthraquinones unknown 
Ernst, 1998;  Wang et al., 2011; Wang et 
al., 2009 
29. Sassafras Sassafras albidum unknown  Pittler et al., 2003 
30. Senna Rhein, anthron unknown 
 Stickel. et al., 2005;  Beuers et al., 1991;  
Teschke et al., 2012 
31. Shou-wu-pian Anthraquinones: emodin, physcion unknown 










Germander toxicity is attributed 
to reactive metabolites 
(epoxides) generated by 
CYP3A metabolism of its 
constituent neoclordane 
diterpenoids. 
Chitturi et al., 2008; Stickel. et al., 2005;  
Strader et al., 2012;  Batchelor et al., 
1995;  Larrey et al., 1992;  Teschke et 
al., 2012 
33. 
Valerian ( Mistletoe 
or skullcap) 
Valeriana officinalis  
Contain alkylating agents that 
inhibit thymidine incorporation 
into DNA, leading to impaired 
mitochondrial function 




Callilepsis laureola, Atractylosides 
Inhibition of gluconeogenesis 
through interference with 
oxidative phosphorylation 
Chitturi et al., 2008; Stickel. et al., 2005;  
Strader et al., 2012 
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Botanicals containing pyrrolizidine alkaloids are believed to be the most 
important plant hepatotoxins and have been well recognized over 70 years. 
Pyrrolizidine alkaloids are distributed in more than 350 plant species, but are 
predominant in plants from the Heliotropium, Senecio, Symphytum, and Crotalaria 
species. Because of the presence of pyrrolizidine alkaloids in comfrey, FDA advised 
companies to remove comfrey products for internal consumption (FDA, 2001; Willet 
et al., 2004).  
Germander (Teucrium chamaedrys) has traditionally been known for its 
choleretic and antiseptic properties. It was marketed in France in 1986 as an adjuvant 
to weight control, but reports of 30 cases of severe hepatitis resulted in its withdrawal 
from the market in 1992 (Stickel et al., 2005). Saponins, glycosides, flavonoids, and 
furano neo-clerodane diterpenoids are reported as the main constituents of germander. 
Formation of reactive metabolites (epoxides) generated by CYP3A metabolism of 
neoclordane diterpenoids (chiefly Teucrin A) as well as the immune mechanisms are 
believed to be responsible for its hepatotoxicity (Kouzi et al., 1994; Lekehal et al., 
1996).   
The rhizome and roots of the pepper plant Piper methysticum known as Kava 
Kava, is used as a narcotic drink in the South Pacific, and extracts of kavalactones are 
sold worldwide in herbal remedies to alleviate anxiety and tension. Kava Kava has 
been implicated in a number of hepatotoxicity events in recent years (Currie and 
Clough, 2003; Humberston et al., 2003; Russmann et al., 2001; Teschke et al., 2009).  
Kava Kava-associated acute liver failure was first reported in 1998. Since then, over 
60 cases of hepatotoxicity have been attributed to Kava Kava (Stickel et al., 2003).  
Kava Kava has thus been banned for use many countries such as Germany, the United 
Kingdom, France, Canada and Singapore (Furbee et al., 2003; HSA, 2002).  In 2002, 
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the Center for Food Safety and Applied Nutrition, U.S. FDA issued a consumer 
advisory entitled “Kava-containing dietary supplements may be associated with 
severe liver injury” to the public (Fu et al., 2009).  
 In May 1, 2009, Iovate Health Sciences USA, Inc. of Blasdell, New York and 
Ontario, Canada voluntarily recalled products (FDA, 2009) called “Hydroxycut” sold 
in the United States upon U.S. FDA assessment of 23 reports about consumers having 
experienced liver-related problems, as well as a small number of published case 
reports of implication of these products in liver toxicity (Dara et al., 2008; FDA. 2009; 
Shim and Saab, 2009). Similarly in Singapore, a slimming product marketed as 
“Slim10” was implicated in a fatal case of hepatic failure. It was also found to contain 
N-nitrosofenfluramine and was subsequently withdrawn from the market (Lau et al., 
2004).  
However, direct attribution of liver injury to a specific herb is difficult and 
often relies on the indirect temporal relationship between the usage of the herbal 
product and appearance of liver injury, and the resolution of injury following 
cessation of the use of the herbal product. More needs to be done to ascertain the 
causality. In a previous study conducted over a 12 month in Singapore, 52 % of the 
patients had DILI presumably arising from the traditional medicines (Wai et al., 2006). 
In a similar two -year local study, Wai et al., (2007) reported that among 31 patients 
who had DILI, 22 cases were attributed to traditional medicines (23 Chinese CAM 
and 8 Jamu or traditional Indonesian medicine). Of 31 CAM medicines implicated in 
DILI in 17 patients, 9 products were found to contain adulterants. Assuming each of 
the 9 products were consumed by a different patient and that the adulterants led to the 
hepatotoxicity, the causative agents for 8 out of 17 patients who had drug-induced 
liver injury were largely unaccounted for.  
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1.4  Drug discovery from medicinal plants 
Many plants used in the traditional medicine for centuries have important 
sources of new drugs. According to the WHO (WHO, 2003a), 25% of conventional 
drugs are either made from or derived from medicinal plants. Drug discovery from the 
medicinal plants has resulted in the discovery of drugs such as morphine, cocaine, 
digitoxin and quinine (Newman et al., 2000, 2012; Butler, 2004; Samuelsson 2004). 
Natural products are important sources of new chemical entities (NCEs). Their high 
chemical diversity and biochemical specificity make them ideal lead structures for 
drug discovery. Between 1981 and 2002, nearly 50% (49%) of the NCEs were either 
natural products or products derived from natural products (Newman et al., 2003). 
Many characteristic features of natural products such as chiral centers, aromatic rings, 
the number and ratio of heteroatoms and degree of saturation have been utilized for 
the drug discovery (Lee et al., 2001; Feher and Schmidt, 2003; Koehn and Carter, 
2005; Newman et al., 2000, 2012).   
Despite increased interest in molecular modeling, combinatorial chemistry and 
other synthetic chemistry techniques by pharmaceutical industries, medicinal plants 
remain an important source of NCEs (Newman et al., 2000, 2012; Butler, 2004; 
Samuelsson 2004). From the analysis from 1981 to 2010, it is evident that the utility 
of natural products as sources of novel structures, but not necessarily the final drug 
entity, is still alive and well (Newman et al., 2012). Drug discovery from medicinal 
plants continues to provide new and important leads against various diseases such as 
cancer, HIV/AIDS, Alzheimer‟s disease, and infectious diseases. Therefore, natural 
products play a dominant role in the discovery of leads for the development of drugs 
for the treatment of human diseases. In the following section, the potential of 
medicinal plants as a source of new anti-cancer drugs is presented. 
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1.4.1 Plants as a potential source of anticancer agents 
Cancer chemoprevention using food and medicinal herbs has been viewed as 
one of the most promising field for cancer control (Jo et al., 2004). Notably, in cancer 
treatments, compounds derived from plants have played an important role, and some 
of the most promising and better drugs have come from plant sources such as 
paclitaxel from Pacific Yew tree (Taxus brevifolia) and vincristine and vinblastin 
from Masagascar periwinkle (Catharanthus roseus). Etoposide and teniposide were 
derived semi-synthetically from epipodophyllotxin isolated from the roots of 
Podophyllum species. Irinotecan and topotecan are also the examples of anticancer 
agents obtained semi-synthetically from camptothecin found in the bark of 
Camptotheca acuminate.   These drugs were discovered based on their ethnomedical 
uses or through anticancer screening. As of 2007, over 60 compounds are in the 
pipeline, as anticancer drugs alone, from plant sources (Saklani and Kutty, 2008). 
Over the time frame from 1940s to 2010, of the 175 small molecules as the anticancer 
agents, 85 or 48.6%, were actually either natural products or directly derived from 
them (Newman et al., 2012). 
Currently used chemotherapeutic agents have serious side effects on fast 
dividing cells such as blood cells and cell lining of the mouth, stomach and intestine 
(Raguz and Yague, 2008). Furthermore, emergence of resistance to currently used 
chemotherapeutic agents is also increasing (Raguz and Yague, 2008). Therefore, there 
is a need for more efficacious and less toxic anticancer agents. Natural products could 
serve as chemical libraries of structurally diverse compounds which could be utilized 
for the new anticancer drug discovery. In this thesis, a TCM herb Panax notoginseng 




1.4.2 Panax notoginseng 
 Panax notoginseng (Burk.) F.H Chen (Family: Araliaceae), also known as 
Sanqi or Tianqi is a highly revered Chinese medicinal herb belonging to the genus 
Panax.  It is mainly cultivated in the Yunnan province of the Southwest China. It is 
collected before flowering in autumn. The roots are cleaned, graded into main root, 
branch root (Jintiao) and rhizome (Jinkou) and then dried (The State Pharmacopoeia 
Commission of People‟s Republic of China, 2010). They are usually sun-dried or 
artificially dried at low temperature (Jia and Zhao, 2009a). It is believed that enzymes 
contained in the root break down the chemical components in the process of drying 
(Jia and Zhao, 2009a).  Sun-drying also changes the roots to a beige colour (Jia and 
Zhao, 2009a). To give them a black shiny appearance, the roots may be darkened 
sometimes by smoking with coal and wax.   
P. notoginseng is available in two different forms: the raw form and steamed 
form or processed form. The raw form and steamed form of P. notoginseng have 
different traditional uses. According to the Chinese Pharmacopoeia, the raw form is 
indicated for hemoptysis, hematemesis, epistaxis, hematochezia, flooding and spotting, 
traumatic bleeding, stabbing pain in chest and abdomen, and for swelling and pain 
caused by injuries from falls (The State Pharmacopoeia Commission of People‟s 
Republic of China, 2010). However, the steamed form is used as a tonic to “nourish” 
blood and to escalate production of various blood cells in anemic conditions (State 
Administration of traditional Chinese Medicine, People‟s Republic of China, 1996). 
As the raw and steamed form of P. notoginseng have different pharmacological 





1.4.2.1 Processing of P. notoginseng 
Traditionally, herbs are processed in many different ways to improve their 
organoleptic properties, reduce toxicity, increase shelf-life, increase efficacy etc. The 
raw and steamed P. notoginseng roots are readily available as Chinese Proprietary 
Medicines (CPMs) in the form of tablets, capsules, powder, beverages etc in the 
market.  However, very limited information could be found in the literature on the 
processing of P. notoginseng. Exact procedures, conditions of steaming or frying, 
duration of treatment are not reported. Therefore, there is no official or standard 
procedure for steam processing of P. notoginseng roots.   
It is reported that the steaming method is better method than frying as the 
concentrations of active constituents (ginsenosides) is more in the steam processed 
roots compared to the fried roots (Zhang, 1989). The chemical composition of herb 
could vary depending on their processing. Lau et al., (2003) reported that the 
chemical composition of raw form of P. notoginseng is different from the steamed 
form. Previous studies (Chan et al., 2007; Lau et al., 2004; Sun et al., 2010) have 
reported that the steaming decreased the contents of notoginsenoside R1, ginsenosides 
Rg1, Re, Rb1, Rc, R2, Rb3 and Rd, but increased the contents of 20(S)-Rh1, 20(R)-
Rh1, Rh2, Rk3, Rh4, 20(S)-Rg3, 20(R)-Rg3, Rk1, and Rg5. Moreover, the chemical 
composition was also affected in terms of type and concentration of the active 
constituents by the duration of steaming. These differences in type and concentration 
of active constituents could have huge impact on the efficacy and safety of an herb, 
Therefore, standardization of processing method is very important to ascertain 
consistent quality and efficacy. There should be more detailed investigations to 




1.4.2.2 Chemical constituents of P. notoginseng 
The roots of P. notoginseng contain saponins, amino acids, polyacetylenes, 
volatile oils, polysaccharides and flavonoids (Zhu, 1998; State Administration of 
Traditional Chinese Medicine, 1996).  The dammarane-type saponins, which include 
ginsenosides and notoginsenosides, are the main bioactive components of the herb, 
contributing to its pharmacological activities. These saponins account for 12 % of the 
total root content (Zhu, 1998; Ma et al., 1999). Many of these ginsenosides are also 
found to be present in other Panax species such as P. ginseng and P. quinquefolium. 
However, P. notoginseng has much higher percentage of total saponins compared to 
P. ginseng and P. quinquefolium (Sun et al., 2011). More than 70 saponins have been 
isolated and characterized from two form of P. notoginseng and more are still being 
discovered (Cui et al., 2008; Liao et al., 2008; Wan et al., 2010; Wang et al., 2006; 
Wang et al., 2009). 
Chemical structures of some of these ginsenosides are shown in Figure 1.1. 
These saponins are the glycosides containing one or more sugar chains on a triterpene 
or sterioidal aglycone backbone. Saponins upon hydrolysis yield corresponding the 
aglycones and sugar moieties. Based on their aglycone moieties, they can be classified 
into three classes, namely, protopanaxadiol (e.g. ginsenosides Rb1, Rb2, Rb3, Rc, Rd, 
Rh2, 20(s)-Rg3, Rk1, Rg5 etc), protopanaxatriol (e.g ginsenosides Rg1, Rg2, Re, Rf, 
Rh4, Rk3) and Oleanolic acid type (ginsenosides Ro) (Christensen, 2009). In addition 
to ginsenosides, another group of saponins such as notoginsenosides R1 to R4, R6 to 
R9 (State Administration of Traditional Chinese Medicine, 1996; Zhou et al., 1981; 
Taniyasu et al., 1982; Matsura et al., 1983; Zhao et al., 1996), notoginsenosides A to 
N (Yoshikawa et al., 1997a; Yoshikawa et al., 1997b; Yoshikawa et al., 2001; Ma et 
al., 1999), notoginsenosides Fa, Fc and Fe (Yang et al., 1983), notoginsenosides ST-
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1, ST-2, ST-3, ST-5 (Liao et al., 2008), notoginsenosides Rw1, Rw2 (Cui et al., 2008), 
floranotoginsenosides A, B, C, D (Wang et al., 2009), 5,6 didehydroginsenosides Rd, 
5,6 didehydroginsenosides Rb1 (Wan et al., 2010)- have also been isolated from P. 
notoginseng. Earlier, the nomenclature of these ginsenosides was based on their Rf 
values on the TLC plates and an index was added to the name with polarity decreasing 
from “a” to “h” (Angelova et al., 2008, Shibata et al., 2001). 
 
 















Figure 1.1 Chemical structures of some of the ginsenosides and notoginsenosides. 
Abbreviations: Glc, glucose; Ara(f), arabinose in furanose form; Ara(p), arabinose in 
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Figure 1.1 (continued) 
Saponins R1 R2 




























































































Saponins R1 R2 
Ginsenoside Rg5 -Glc-Glc -H 
Ginsenoside Rh4 -H -O-Glc 
Saponins R1 R2 
Ginsenoside Rk1 -Glc-Glc -H 
Ginsenoside Rk3 -H -O-Glc 
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The relative concentration of particular ginsenosides or presence of certain 
ginsenosides can be used for authentication and differentiation of different species of 
Panax. The ratio of ginsenosides Rb1/Rg1 could be used to differentiate Asian 
ginseng (P. ginseng) and American ginseng (P. quinquefolium). Rb1/Rg1 value 
between 1 and 3 is indicative of the Asian ginseng while values around 10 or greater 
are characteristic of the American ginseng (Jia and Zhao, 2009). The presence of 
notoginsenosides R1 is characteristic of P. notoginseng (Lau et al., 2003, 2004). The 
ratio of ginsenosides Rg1/Re can also be used to differentiate different Panax species. 
Rg1/Re values between 4 and 5 are characteristic of P. notoginseng, while values 
close to 0.5 are indicative of P. ginseng (Lau et al., 2003, 2004). A value below 0.1 is 
characteristic feature for P. quiquefolium (Lau et al., 2003, 2004). 
Besides saponins, various amino acids such as dencichine (β-N-oxalyl-L-α,β-
diaminopropionic acid), polyacetylenes (e.g. falcarinol, panaxydol, panaxytriol), 
polysaccharides (e.g. sanchinan-A, arabinogalactan), sesquiterpene essential oils or 
volatile oils, common flavanoids (e.g. quercetin, kaempferol) and sterols (e.g. β-
sitosterol, stigmasterol, daucosterol) have been isolated from P. notoginseng  (Gao et 
al., 1996; Long et al., 1996; State Administration of Traditional Chinese Medicine, 
1996; Washida and Kitanaka, 2003;  Zhang et al., 1990; Zhu, 1998). Dencichine is an 
important amino acid which is believed to be the main active constituent for the 
haemostatic activities of P. notoginseng (Koh et al., 2007). 
 
1.4.2.3 Studies on pharmacological actions of P. notoginseng 
Most of the studies have focused on the raw form as it is more commonly used. 
Its haemostatic properties have been evaluated (White et al., 2000; White et al., 2001; 
Fan et al., 2005). The alcoholic extract of raw P. notoginseng was found to be most 
active to reduce the bleeding time in transected rat tail (White et al., 2000; White et 
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al., 2001). Furthermore, many beneficial cardiovascular effects have also been studied. 
P. notoginseng extract lowered blood pressure in animal studies, exerted an anti-
arrhythmic action, alleviates atherosclerosis and angina pectoris and helps in 
craniocerebral trauma (Dou et al., 2012; Liu et al., 2010; Liu and Chen, 1984; Li and 
Zhang, 1988; Pan et al., 2012; Zhu, 1998; Tang and Eisenbrand, 1992; Yuan et al., 
2011). 
In addition, raw P. notoginseng extracts and its total saponins are reported to 
have many pharmacological actions such as inhibition of  platelet aggregation and 
blood coagulation (Sun et al., 1996; Ma and Xiao, 1998; Wang et al., 2004, Lau et al., 
2009), anti-inflammatory and analgesic actions (Tang and Eisenbrand, 1992; Zhu, 
1998; Jung et al., 2009), immunological adjuvant activities (Yoshikawa et al., 2001, 
Sun et al., 2003, 2004, 2005, 2006),  hepatoprotective effects (Liu et al., 1994; 
Yoshikava et al., 2003; Lin et al., 2003; Park et al., 2005), and hypoglycaemic 
activity ( Gong et al., 1991; Liu et al., 2004).  
Besides the above mentioned effects, raw P. notoginseng root extract also 
exhibits anti-proliferative and anti-cancer activities (Konoshima et al., 1999; Chen et 
al., 2001; Chung et al., 2004; Yang et al., 2006; Wang et al., 2007a, 2007b).  
Konoshima et al., (1999) studied the inhibitory effect of P. notoginseng root in vivo 
on mouse skin tumors. However, their study was only limited to the crude extract and 
evaluation of anti-proliferative properties of its components was not undertaken. In a 
few studies which investigated active components of P. notoginseng root, Chen et al., 
(2001) observed that crude extract and its component ginsenosides Rb1 increased the 
sensitivity of an experimental tumor to ionizing radiations. Likewise, Yang et al. 
(2006) also reported the anti-proliferative activity of ginsenoside Rb1 against HeLa 
cancer cells. P. notoginseng was also found to be the most cytotoxic ingredient of 
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multiple component herbal preparation Pc SPES for the treatment of prostate cancer, 
toward PC3 human prostate cancer cells (Chung et al., 2004). Although these studies 
investigated effects of P. notoginseng and ginsenosides Rb1, they did not consider the 
detailed evaluation of the observed anti-proliferative effects by screening other major 
ginsenosides.  
Wang et al., (2007a) studied the anti-proliferative effects of P. notoginseng 
and its major constituents such as notoginsenoside R1, ginsenosides Rg1 and Rb1 
against SW480 human colorectal cancer cells. Their study also included preliminary 
investigations of possible mechanisms of anti-proliferative activity of PNS. In 
addition, Wang et al., (2007a, 2007b) also reported that P. notoginseng root and 
flower extracts enhances the anti-cancer activity of two chemotherapeutic agents, 5-
fluorouracil and irrinotecan against colorectal cancer cells. These significant findings 
shed light on the fact that P. notoginseng root and flower extract could be used to 
reduce the dose and hence the side effects of currently used chemotherapeutic agents.  
However, in contrast to the raw P. notoginseng, the steamed form has been 
less studied. Therefore, fewer studies compared the pharmacological actions of the 
two different forms. In such studies, Chen et al., (1984) showed that the steamed form 
increased the cholesterol and triglycerides in rats compared to the raw form. In 
contrast, Zhang et al., (1989) found that total saponins of the raw form significantly 
increased protein synthesis compared to the steamed form. However, these studies did 
not adequately explain the plausible reasons for these observed differences in activity 
of the two forms. Subsequent studies (Lau et al., 2003; Chan et al., 2007; Liao et al., 
2008; Toh et al., 2010) to explore the differences between the two forms provided 
showed that the chemical profiles of the raw and steamed P. notoginseng are different.   
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Steaming or heat processing of P. notoginseng results in the formation of new 
marker components which are normally not present in the raw form. The quantities of 
various saponins are reduced and new marker components such as less polar 
ginsenosides Rg3, Rk1, Rk3 and Rg5 are produced after steam processing. This could 
be the reason for differences in the activities of the two forms. This is further 
supported by the studies which compared the two forms for their hematological and 
anti-cancer effects. Lau et al., (2009) found that the steamed P. notoginseng has 
significantly more potent antiplatelet and anticoagulant effects than the raw extract, 
and the activity increases with increasing steaming durations up to 9 hours.  
Likewise, Sun et al., (2010) investigated the effect of steaming for different 
duration (up to 6 hours) on the anti-cancer activity of P. notoginseng against colon 
cancer cells HCT-116. They observed that the anticancer effects of the steamed form 
significantly increased compared to the raw form upon steaming. However, the study 
of Sun et al., (2010) was limited to only few ginsenosides of steamed form and 
therefore screening of other major ginsenosides formed upon steaming is warranted. 
As the formation of less polar ginsenosides increases with increased duration of 
steaming, Toh et al., (2011), extended the duration of steaming up to 24 hours to 
study the anti-proliferative activity of the steamed P. notoginseng against the liver 
cancer cells (SNU449, SNU182 and HepG2 cells). They found that the anti-
proliferative activity increases with increased duration of steaming.  The 24 hours 
steamed form has the highest activity (Toh et al., 2011). In addition, they also 
investigated the anti-proliferative activity of some of the ginsenosides (such as 
ginsenosides Rg3, Rk1, Rk3 and Rh2) which are predominantly formed upon 
steaming.   
30 
 
However, some of the ginsenosides which are also formed predominantly 
upon steaming such as Rh4 and Rg5 were not screened for their anti-proliferative 
activity against liver cancer cells. In addition, the mechanism and selectivity of anti-
proliferative activity of some ginsenosides such as Rk3 are also not known. Moreover, 
the pharmacokinetics of some of the ginsenosides such as ginsenosides Rh4, Rk1 and 
Rk3 have not been reported. Pharmacokinetic profiling of ginsenosides using animal 
models is important for the further evaluation of their medicinal applications. 
Furthermore, no study has compared the relative activities of all major ginsenosides 
formed upon steaming. It is very crucial to better understand the increased anti-cancer 
activity of the steamed P. notoginseng as well as the development of novel anti-cancer 
drugs from P. notoginseng. Therefore, further work is required to compare the 
differential activity of all major ginsenosides formed upon steam processing and their 
possible mechanism of action.  
Furthermore, although the synergistic effects of the raw P. notoginseng with 
currently used chemotherapeutic agents have been reported, little is known about the 
synergistic actions of ginsenosides present in the steamed P. notoginseng. As the 
steamed form is found to possess more anti-cancer effects, investigations effects of 
ginsenosides formed upon steaming on the activity of currently used 
chemotherapeutic agents is required. This would provide better insights into the 
possible combination therapies to reduce the side effects of currently used 









Hypotheses and objectives 
 
 
Botanicals and botanical health products are of natural origin but may not be 
totally safe due to deficiencies in quality assurance or their intrinsic toxicity. From the 
holistic viewpoint, some botanicals may have potential therapeutic effects (e.g. anti-
proliferative), but some may cause adverse or toxic effects, e.g. hepatotoxicity.  
A review of P. notoginseng is presented in Section 1.3. Steamed P. 
notoginseng has been reported to possess anti-proliferative activity. Some of the 
marker constituents or saponins formed upon steaming have also been identified. 
However, not all the known ginsenosides formed upon steaming (e.g. Rh4) are 
screened for their anti-proliferative activity against the liver cancer cells. In addition, 
the mechanisms and selectivity of some of the ginsenosides reported to possess anti-
proliferative activity are also not known (e.g. ginsenoside Rk3). Therefore further 
work is required to explore the differential activity of the major ginsenosides formed 
upon steaming against cancer cells and their mechanisms of action. In addition, the 
pharmacokinetic profiles of some of the ginsenosides such as Rh4, Rk1 and Rk3 are 
not known.  
Furthermore, although the synergistic actions of raw P. notoginseng with other 
drugs have been reported, little is known about the effects of steamed P. notoginseng 
and its constituents on the anti-proliferative effects of chemotherapeutic agents. As 
discussed in Chapter 1, botanicals the sources of novel anti-cancer drugs like 
paclitaxel and vincristine. Therefore, it is worthwhile to extend the study on anti-
proliferative activities of herbs such as P. notoginseng to identify new lead molecules 
for anti-cancer drug discovery.  
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A review of the safety of botanicals and botanical health supplements with 
more emphasis on hepatotoxicity has been presented in Sections 1.2 and 1.3. Along 
with the increased usage of botanicals and their products, several reports of adverse 
events have been reported. An international or national database of reported adverse 
events is an effective tool for the surveillance of adverse events associated with the 
use of herbal medicine. Therefore, national databases such as the Singapore 
Pharmacovigilance Database of adverse events can be used to identify signals and 
trends of adverse events associated with the use of herbal products.  
Among the most serious safety concern of botanicals is their hepatotoxicity. In 
some cases, the hepatotoxicity has been related to the presence of undeclared drugs 
and/or their analogues and the ingestion of botanicals containing known hepatotoxins. 
Some of the botanicals and their derived products have also been reported to have 
intrinsic hepatotoxicity e.g. pyrrolizidine alkaloids. However, in many cases, the 
cause-effect relationship has not been established and the mechanisms of 
hepatotoxicity are poorly understood. The botanical health products which are free 
from adulteration and contamination yet implicated in Drug induced liver injury (DILI) 
require further evaluation using various in vitro cell culture models to assess their 
hepatotoxic potential. In addition, chemical analysis using various analytical 
platforms such as HPLC, GC-MS and LC-MS is also required to identify potential 
intrinsic hepatotoxic components of the implicated products. 
 
2.1 Hypotheses 
Some ginsenosides have been found to have anti-proliferative effects. It is 
hypothesized that some of the ginsenosides of steamed P. notoginseng may also have 
anti-proliferative effects and may affect the anti-proliferative effects of 
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chemotherapeutic agents (e.g. doxorubicin and paclitaxel). In addition, some CAM 
products and their components have been found to cause DILI. Therefore, it is 
hypothesized that there exists some hepatotoxic compounds in the botanical health 
products suspected to cause DILI that can be detected and identified by various 
chemical analyses and in vitro bioassays. 
 
2.2 Objectives 
The overall objective of this work is to study the efficacy and safety of 
botanicals and their products, in particular, to evaluate the anti-proliferative effects of 
steamed P. notoginseng and to assess the hepatotoxicity of some botanical health 
products implicated in drug induced liver injury (DILI). The specific objectives are: 
1. to isolate, purify and identify ginsenosides of steamed Panax notoginseng and to 
evaluate their anti-proliferative effects alone and in combination with currently 
used chemotherapeutic agents against liver cancer cell lines using an in vitro cell 
culture model. 
2. to study the pre-clinical pharmacokinetics of selected ginsenosides in rats.  
3. to collate and analyze adverse event reports associated with the use of 
complementary medicine and health supplements submitted to the Health Sciences 
Authority of Singapore for the period 1998-2009.  
4. to perform chemical analyses of selected botanical health products implicated in 
DILI to identify potential toxic components using various analytical techniques 
such as HPLC, LC-MS and GC-MS. 
5. to evaluate the hepatotoxicity of botanical health products implicated in DILI in 
vitro using normal human hepatocytes (THLE-2 cells) and to elucidate the 





Chemical analyses and anti-proliferative 
activity of steamed P. notoginseng 
 
3.1 Introduction 
Extensive phytochemical studies by various research groups have been 
conducted to identify various chemical constituents of two different forms of P. 
notoginseng. Detailed chemical investigations on steamed P. notoginseng have led to 
the isolation of 30 dammarane-type saponins (Lau et al., 2004; Liao et al., 2008) and 
many more are being discovered. As discussed in Chapter 1 (Section 1.4), the steamed 
form has different chemical profiles and different pharmacological activities (Lau et 
al., 2004; Lau et al., 2009; Toh et al., 2010; Sun et al., 2010) as compared to the raw 
form. These differences in their pharmacological actions could be attributed to 
differential chemical composition of the two forms due to the formation of more less 
polar saponins upon steaming (Lau et al., 2004; Lau et al., 2009; Toh et al., 2010; Sun 
et al., 2010).  
Ginsenosides are believed to be the main active compounds for the reported 
activities of P. notoginseng. As discussed in the Chapter 1 (Section 1.4.2.3), many 
studies have been conducted to study the activity of ginsenosides present in the 
steamed form. However, not all of the ginsenosides identified in the steamed P. 
notoginseng have been screened for various activities. Therefore, there is a need to 
investigate the pharmacological activities of different ginsenosides identified in the 
steamed P. notoginseng. One possible reason for not screening all of the ginsenosides 
of steamed P. notoginseng could be the limited availability of some ginsenosides 
which are pre-dominantly formed in the steamed form. For example, less polar 
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ginsenosides such as ginsenosides Rk1, Rk3, Rh4 and Rg5 are not commercially 
available. Therefore, it is important to isolate these marker compounds to evaluate 
their pharmacological actions. Moreover, comparison of differential activities of all 
major ginsenosides formed upon steaming is important to understand the differences 
in the activities of two forms of P. notoginseng. 
 
3.1.1 Liver cancer 
Liver cancer or hepatocellular carcinoma (HCC) is a serious health problem 
worldwide (WHO Mortality database, 2010). It is the fourth most common of deaths 
due to cancer, accounting for 610,000 deaths every year (WHO, 2009). In Singapore, 
it is also the fourth most common cancer in males (7.6% of the cancer cases) 
(Singapore Cancer registry Interim report, 2005-2009). However, HCC is the third 
most fatal cancer with an annual mortality rate of 14.8 per 100,000 cases in Singapore 
(Singapore Cancer registry Interim report, 2005-2009). 
Various risk factors for HCC include chronic viral infection by hepatitis B 
virus (HBV) and hepatitis C virus (HCV), liver diseases, exposure to carcinogen from 
the environment (e.g. vinyl chloride, aflatoxin B1), hereditary genetic disorders such 
as Wilson‟s disease, hemochromatosis, α-1-anti-trypsin deficiency, tyrosenemia, 
alcohol abuse (Clark, 2006; Donato et al., 2006; Gomma et al., 2009; McGlynn and 
London, 2005; Motola-kuba et al., 2006). HCC development involves multi-step 
process which starts from chronic hepatitis or cirrhosis to hyperplastic change, 
dysplasia to early HCC and finally progressing into HCC. Treatment of HCC largely 
depends on the size and extent of disease spread and functional health of a liver 
(Parikh et al., 2008).  If the tumour is localised and surgically operable (patients 
without liver cirrhosis), partial hepatectomy to remove the tumour is usually 
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performed. In the case of patients with liver cirrhosis and/or malignant tumours which 
have not spread beyond the liver, liver transplantation is the first choice of treatment.  
Other options such as chemotherapy (doxorubicin, 5-fluorouracil and 
cisplatin), percutaneous ethanol injection, chemoembolization and inclusion in 
clinical trials are considered in the cases where liver transplantation is not possible 
(Parikh et al., 2008). In addition, HCC due to HBV infection can be prevented by 
vaccination. However, most of the time, HCC is diagnosed at the advanced stage of 
the disease which overturns the options of surgical removal or liver transplantation. 
Therefore, due to limited treatment options and poor patient compliance to 
chemotherapy (due to their numerous side effects), there is a critical need to search for 
newer anti-cancer agents for alternative therapies. As discussed in the Chapter 1 
(Section 1.4.1), plants have been an important source for new anti-cancer drugs. 
Cancer prevention using food and medicinal herbs has become most promising field 
for cancer control (Jo et al., 2004).  
 
3.1.2 Anti-proliferative activities of P. notoginseng 
The two forms of P. notoginseng have been reported to possess anti-cancer 
activities. The raw form has been reported to have anti-proliferative activity against 
skin (Konoshima et al., 1999), colorectal (Wang et al., 2007a; 2007b; Sun et al., 
2010), lung (Park et al., 2009), gastric (Wang et al., 2004; Li et al., 2005), prostate 
(Wang et al., 2008b), liver (Chen et al., 2006). The steamed of P. notoginseng form is 
reported to have anti-proliferative activities against colorectal (Sun et al., 2010) and 
liver (Toh et al., 2010) cancer cells. In addition recent studies by Sun et al., (2010) 
and Toh et al., (2010) have shown that the steam processing of enhances its anti-
cancer activity against colon cancer cells and liver cancer cells in vitro.  
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As discussed in the Chapter 1 (Section 1.4.2.2), the dammarane-type saponins 
or ginsenosides are the main active constituents. The steam processing increases the 
concentration of less polar saponins such as ginsenosides Rh2, Rh4, Rk1, Rk3, 20(S)-
Rg3 and Rg5. Toh et al., (2010) also tested the anti-proliferative activities of 
ginsenosides Rk1, Rk3, Rh2 and 20(S)-Rg3. They found that ginsenosides Rk1, Rk3 
and Rh2 are more active than the ginsenoside 20(S)-Rg3 which is approved for 
clinical use as an anti-cancer agent in China (Wang et al., 2008b). However, other 
major ginsenosides formed upon steaming such as ginsenosides Rh4 and Rg5 are yet 
to be screened against liver cancer cells (Toh et al., 2010). Moreover, the mechanism 
of action of some of the ginsenosides such as Rk3 is not investigated. There is also a 
need to compare the activity of all major ginsenosides formed upon steaming to better 
understand the enhanced anti-cancer activity of steamed P. notoginseng and its 
correlation with the formed ginsenosides.   
Furthermore, it is also reported that the P. notoginseng root and flower 
extracts enhances the anti-cancer activity of two chemotherapeutic agents, 5-
fluorouracil and irrinotecan against colorectal cancer cells (Wang et al., 2007a; 
2007b). These findings suggest that P. notoginseng could be used to reduce the dose 
and hence the side effects of currently used chemotherapeutic agents. Moreover, only 
few studies investigated the effects of ginsenosides on the activity of currently used 
chemotherapeutic agents. In such study by Xie et al., (2006) reported that 
ginsenosides Rh2 have synergistic activity with Paclitaxel against prostate cancer 
cells. Since the steamed form of P. notoginseng is reported to possess better anti-
cancer activity, it is worthwhile to investigate the effects of ginsenosides formed upon 




3.1.3 Combined effect of ginsenosides and currently used chemotherapeutic 
agents 
Drug combination chemotherapy is widely adopted for cancer treatment. The 
probability of achieving a desired clinical improvement is significantly higher if two 
or more anti-cancer agents are combined into one regimen. The criteria for selecting 
cytotoxic drugs to make up the anticancer drug combination have been based on the 
principle proposed by Frei and co-workers in 1965 (Frei, 1991). These principles 
include a) the use of two drugs with different mechanisms of action to reduce the 
development of possible broad spectrum drug resistance and b) delivering two or 
more drugs in the combination regimen at near maximal tolerated dose (MTD) of each 
drug (Frei, 1991; DeVita, 1997) by escalating the doses of individual agents to 
maximum tolerated dose.  However, reported studies suggest that the MTD approach 
often results in serious toxicity instead of providing superior efficacy (Delbaldo et al., 
2004; Breathnach et al., 2001; Mayer et al., 2006). Because of the above mentioned 
problems of MTD approach, alternative approach of dose optimization to achieve 
synergistic interactions among the combined drugs is being used.  
Therapeutic efficacy of combination regimen is dependent on the 
concentration ratios of the individual drugs at the site of action (Mayer et al., 2006; 
Tardi et al., 2009). The interaction at the tumor site could be synergistic, additive or 
antagonistic depending on the molar ratio of individual drugs (Mayer et al., 2006; 
Tardi et al., 2009). Synergism refers to the effect where two drugs in combination 
have greater effect than that achieved with either drug alone under identical treatment 
condition. Additive interaction refers to the effect where two drugs used in 
combination have an effect that is sum of the effects of individual agents. Antagonism 
refers to the effect where two drugs used in combination have an effect that is less 
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than that of either drug alone (Chou and Talalay, 1984). Therefore, it is very 
important to identify whether the drug combination will lead to synergistic, additive 
or antagonistic effect. The two most widely used mathematical models to identify the 
type of interactions are isobologram method (Berenbaum 1985; Berenbaum 1989) and 
the median-effect principle based method (Chou and Talalay, 1984).  The advantage 
of isobologram method is that it is easy to plot, and synergism, additivity and 
antagonism can be easily visualized from the graph. However, the isobologram 
method can only be used for fixed ratio combinations and it fails to quantify the 
extent of synergism and antagonism. The median-effect principle developed by Chou 
and Talalay can be used to determine drug interaction in fixed as well as non-fixed 
ratio (Chou and Talalay, 1984).  
The quantitative determination of drug interaction is indicated by the 
combination index (CI). CI is a measure of the synergy, additive or antagonistic 
interactions of the combined drugs. A drug combination is synergistic if its CI value is 
below or equal to 0.9; the combination is additive where the CI is between 0.9 and 
1.1; and the combination is antagonistic if its CI values are above 1.1 (Chou and 
Talalay, 1984). 
Increasing interest in investigating the combination regimen of natural 
products with chemotherapeutic agents can be found in the literature. Natural products 
have the ability to act on multiple targets or pathways that regulate cancer 
progression. Therefore, they could increase the efficacy of chemotherapeutic drug as 
well as reduce the development of resistance. Hence, combining natural products with 
conventional chemotherapeutic agent might lead to improved efficacy and reduced 
toxicity. Examples of combinations of natural products and chemotherapeutic agents 
include parthenolide and vinorelbine (Liu et al., 2008) quercetin and irinotecan 
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(Wong and Chiu, 2011), American ginseng and 5-fluorouracil (5-FU) (Li et al., 
2009a), P. notoginseng and 5-FU and irinotecan (Wang et al., 2007a; 2007b).  
Some of the ginsenosides such as ginsenosides Rh2 (Musende et al., 2010) 
and ginsenosides Rg3 (Kim et al., 2010) have been reported to enhance the anti-
cancer activity of chemotherapeutic agent docetaxel, a semi-synthetic taxoid produced 
from the European yew (Taxus baccata) tree. These studies highlight the potential 
beneficial interactions of ginsenosides with the currently used chemotherapeutic 
agents. Therefore, it would be interesting to investigate the effects of ginsenosides 
identified in the steamed P. notoginseng on the activity of cytotoxic drugs such as 
doxorubicin and paclitaxel. Doxorubicin, cisplatin and 5-FU are the three most 
commonly used chemotherapeutic agents for the treatment of liver cancer (Parikh et 
al., 2008). However, these drugs are reported to have only 10% response rate and no 
survival benefits (Parikh et al., 2008). Combination of ginsenosides with these drugs 
might help to increase their efficacy. Combination regimen may also help to reduce 
the side effects of chemotherapeutic agents by reducing the dose required to achieve 
the clinical response. 
From the above discussion, it is evident that P. notoginseng has the potential 
to provide new lead molecules for the anti-cancer drug discovery. 
 
3.2 Objectives 
The objective of this study is to isolate, purify and identify the ginsenosides of 
steamed Panax notoginseng using various separation techniques such as column 
chromatography and preparative-HPLC and to evaluate their anti-proliferative effects 
as well as their effect on actions of currently used chemotherapeutic agents (namely, 




3.3.1 Materials and reagents 
The raw P. notoginseng roots were obtained as a single batch from a Chinese 
medical shop in Singapore. The solvents used for extraction and separation were of 
analytical grades, while the solvents used for the HPLC were of HPLC grade. HPLC 
grade methanol and acetonitrile were purchased from Tedia Company (Fairfield, OH, 
USA). The water was treated with Milli-Q water purification system (Millipore, 
Bedford, USA). The analytical grade (ACS) hexane, dichloromethane, ethyl acetate 
and methanol were purchased from the Tedia Company (Fairfield, OH, USA). Silica 
gel 60 (63-200 µm, 70-230 mesh) for column chromatography, and TLC aluminum 
sheets pre-coated with silica gel 60 (layer thickness 0.2 mm, 20 x 20 cm) were 
purchased from Merck KGaA (Darmstadt, Germany). Ginsenosides 20(S)-Rg3, 20(S) 
Rh1, 20(R)-Rh1, Rh2 were purchased from ChromaDex, Inc (USA).  Other 
ginsenosides used as standards were in-house isolated and characterised as reported 
previously (Lau et al., 2004). 
 
3.3.2 Methods 
3.3.2.1 Extraction and fractionation 
Raw P.notoginseng powder was steamed for 15 hours at 120˚C using an 
autoclave (Hirayama, Japan) and then dried in a vacuum oven at 80˚C until constant 
weight. 150 g of steamed P. notoginseng powder was extracted with 500 mL of 95% 
ethanol for 2 hours and filtered under vacuum. This step was repeated for a total of 
five times. The combined filtrates were evaporated to dryness under vacuum to obtain 
a crude ethanol extract (5.4 g, 10.4% w/w). The crude residue was dissolved in 30 mL 
of water and sequentially partitioned with 200 mL (three times) of n-hexane, ethyl 
acetate and n-butanol using liquid-liquid partitioning method. A small portion (5 mg) 
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of ethyl acetate and n-butanol extract was reconstituted with 1ml of methanol and 
analyzed by HPLC as described below.  
 
3.3.2.2 HPLC analyses  
An Agilent 1100 liquid chromatograph (Palo Alto, CA, USA) equipped with 
quaternary gradient pump autosampler, and photodiode array detection (DAD) system 
was used. A HPLC method was developed using a reversed-phase column (Waters 
Symmetry C18, 250 x 4.6 mm I.D., 5 mm). The binary gradient elution system 
consisted of water (A) and acetonitrile (B) and separation was achieved using the 
following gradient: 0–30 min, 20% B; 30–60 min, 20–45% B; 60–78 min, 45–75% B; 
78–80 min, 75–100% B. The flow-rate was 1 mL /min and the injection volume was 5 
mL. The UV detection wavelength was set at 203 nm and diode array scanning was 
from 190 to 400 nm. 
 
3.3.2.3 Separation of fractions 
The ethyl acetate and n-butanol fractions were subjected to normal phase 
open-column chromatography (Silica gel 60, 63-200 µm, 70-230 mesh). 6.5 g of ethyl 
acetate fraction and 4.5 g of n-butanol fraction were applied to the column and 
gradient elution using different compositions of dichloromethane and methanol (0 to 
100% methanol) was employed. The collected fractions were analysed by TLC using 
dichloromethane and methanol (9:1 to 1:1) as a mobile phase. The spots on the TLC 
were detected by spraying with 40% v/v sulphuric acid in ethanol and heating the 
plate at 100˚C for 5 min. `Similar fractions were combined, evaporated, reconstituted 
and analyzed using the same HPLC conditions as described earlier except for the 
shorter gradient: 0-10 min, 20-45% acetonitrile; 10-25 min, 45-75% acetonitrile; 25-
28 min, 75-100% acetonitrile; 28-35 min, 100% acetonitrile. From the HPLC 
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chromatograms, further combinations of similar fractions containing the peaks of 
interests were carried out. 
 
3.3.2.4 Purification and isolation of pure components 
Semi-preparative HPLC methods, using an Agilent 1100 liquid chromatograph 
equipped with quaternary gradient pump, autosampler and DAD, were carried out to 
isolate and purify the pure components. Separation was achieved using semi-
preparative reverse-phase column (Agilent Zorbax SB-C18, 250 x 9.4 mm I.D, 5 µm 
particle size). Isocratic elution using water and acetonitrile (A, B, C) with the flow 
rate of 4ml/min. was used (A. 35% acetonitrile; B. 455 acetonitrile and C. 55% 
acetonitrile) and the injection volume was 50 µl. The UV detection wavelengths were 
set at 203, 230, 254, 280 and DAD was scanned from 190 to 400 nm. The fractions 
were collected by monitoring retention times and the peak areas. The tailing portions 
of each peak were collected separately to prevent contamination with neighboring 
peaks. The HPLC runs were repeated until the total volume of the fractions were 
injected. The collected pure fractions were combined and evaporated to dryness under 
vacuum. The identity of the isolated ginsenosides is confirmed by comparing their 
high resolution LC-MS profiles with those of standards. 
 
3.3.2.5 High resolution liquid chromatography-mass spectrometry analysis 
An Agilent 1200 series HPLC chromatography coupled with an Agilent 6210 
Accurate-Mass Time-of-Flight (TOF) MS (Santa Clara, CA, US) with electrosray 
ionization (ESI) in negative ionization mode (LC-ESI-MS/TOF) was used to confirm 
the identity of isolated ginsenosides. The fragmentor was set to 225 V. Nebulizer 
pressure was set to 60 psi. Drying gas flow and temperature were set to 5 L/min and 
325 ˚C respectively. Scan range was m/z 100–1000. Isocratic elution with 1:1 ratio of 
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solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile) 
was performed for 15 min. with the flow rate of 0.4 mL/min. Hypersil™ ODS column 
(150 X 2.1 mm, 5 µm) from Thermo Fisher Scientific was used for the separation. 
The injection volume was 5 µl. Data acquisition was performed on Mass Hunter 
workstation software (Version A.02.02) from Agilent Technologies (Santa Clara, CA, 
US). 
 
3.3.2.6 Cell Culture 
The human liver cancer cell lines (SNU449, SNU182 and HepG2), breast 
cancer cell lines (MDA-MB-231), cervical cancer cell line (C33A), colon cancer cell 
line (HCT-116) and ovarian cancer cell line (PA1) were purchased from the American 
Type Culture Collection, ATCC (Manassas, VA, USA). RPMI 1640 media 
supplemented with 10% fetal bovine serum (FBS) was used for culturing SNU 449 
and SNU182 cells. For the HepG2 cells, DMEM media supplemented with 10% fetal 
bovine serum (FBS) was used. The seeding cell densities for 96 well plates for cell 
lines SNU449, SNU182 and HePG2 were 6000, 6000 and 11000 cells per well 
respectively.  The selectivity for anti-proliferative activity of selected ginsenosides 
(20(S)-Rg3, Rk1 and Rk3) was also determined by using normal liver cells THLE-2 
cells purchased from the ATCC. THLE-2 cells were grown in LHC-9 media 
supplemented with 10% fetal bovine serum. For the cell cycle analysis, propidium 
iodide, sodium citrate, triton-X-100 and ribonuclease A solution (10mg/mL) were 






3.3.2.6 Cell proliferation analysis using WST-1 assay: Screening for anti-
proliferative activity and selectivity 
Samples  
Extracts of raw and steamed P. notoginseng were prepared by ultrasonication 
using 95 % ethanol. 1 g of raw and steamed P. notoginseng root powder were 
extracted with 10 mL of 95 % ethanol each. The extraction was repeated for two more 
times and the extracts of the same sample were combined, filtered and dried under 
vacuum. These extracts were dissolved in 100 % DMSO for WST-1 assay (WST-1 
celll proliferation reagent, Roche, Singapore). Pure ginsenosides were dissolved in 
4% DMSO. Final concentration of DMSO for all samples screened was less than 
0.5 %. 
First Day 
Cells were suspended at optimized densities as mentioned above in their 
respective media. 100 µl of this suspension was dispensed into 96 well plates. The 
cells were then incubated for 24 hours at 37ºC with 5% CO2.   
Second Day 
The ginsenosides were dissolved in DMSO and diluted to a series of 
concentrations using media. Final concentration of DMSO for all samples screened 
was less than 0.5 %. The media was then discarded from the wells. 100 µl of diluted 
ginsenosides were then added except for the wells at the 4 edges.  0.4 % v/v DMSO 
was used as a control for the assay. The plates were then incubated for 72 hours at 
37ºC with 5% CO2.  
Fourth/Fifth Day 
The optimized drug treatment time for SNU 449 and HepG2 was 48 hours 
while that for SNU182 was 72 hours. After the desired period of exposure, the 
supernatant from all wells was discarded. Then 100 μl of 10% WST-1 solution in 
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media was added into each well excluding the wells at the 4 edges. The plates were 
then incubated for one hour at 37ºC with 5% CO2. After incubation, the absorbance 
was recorded at 440 nm with reference wavelength of 650 nm. 
Statistical Analysis 
Average percentage cell viability for a well was expressed as a percentage of 
the control wells by comparing the average absorbance of treated wells against 
average absorbance of control wells in triplicate manner. The results obtained were 
expressed as a mean for three cell line passages and the standard deviation (SD) were 
also calculated. Statistical analysis was performed according to student‟s t-test by one 
way analysis of variance. Significant difference was taken as p < 0.05. The IC50 
values were determined by Calcusyn 3.0 software. Each reported value is the mean ± 
SD from 3 independent experiments. The selectivity index was determined by taking 
the ratio of IC50 values against the cancer cells and the normal liver cells (THLE-2 
cells). 
 
3.3.2.7 Cell cycle analysis by propidium iodide (PI) staining and flow cytometry 
Samples 
Ginsenosides 20(S)-Rg3, Rg5, Rh4 and Rk3 were dissolved in 0.4 % DMSO. 
The final concentration of DMSO was less than 0.5% v/v. 0.5% v/v DMSO was used 
as a vehicle control. 
Preparation of hypotonic fluorochrome solution (for 40 mL) 
0.04 g of sodium citrate was weighed and dissolved in autoclaved water 
(filtered through 0.22 µm filter to get rid of particles which might interfere with the 
fluorescence) in a falcon tube. To this solution, 40 µL of triton-X-100 solution was 
added. This was followed by addition of 200 µL each of PI solution (10 mg/mL in 




SNU 449 cells were plated in 6 well plates in a density of 0.5 million cells/2 
mL of media per well. After 24 hours of incubation at 37ºC with 5% CO2, 
ginsenosides 20(S)-Rg3, Rg5 Rh4 at a concentration of 200 µg/mL and ginsenosides 
Rk3 at  concentrations of 50, 100 and 200 µg/mL were added to the cells.  After pre-
determined time points (12 hours and 24 hours), the drug solution was removed from 
the wells and washed with 1 mL cold phosphate buffer saline (PBS). After washing, 
the cells were trypsinized by addition of 200 µL of trypsin. After 5-7 min of 
incubation, the trypsin was neutralized by the addition of media containing 10% FBS. 
The media containing cells is transferred back into the falcon tube. The tubes were 
then centrifuged at 1200 rpm at 4˚C for 5 min.  
After centrifugation, the supernatant was drained and the cell pellet was 
washed with 1 mL of ice cold PBS. The tubes were again centrifuged at 1200 rpm at 
4˚C for 5 min. After centrifugation, the supernatant was drained and the cell pellet 
was re-suspended into 500 µL of hypotonic fluorochrome solution and stored in dark 
at 4˚C over night before it was analysed by flow cytometry. The cell suspension was 
passed through 40 µm filter to obtain a single cell suspension before it was analyzed 
by flow cytometry. Cell cycle distribution was analyzed by a CYAN-LX flow 
cytometer (DakoCytomation, Fort Collins, CO) equipped with Summit v4.3 software 
(DakoCytomation). Cells with sub-G1 DNA (as designated by R1 in the histogram) 







3.3.2.8  Measurement of cell viability, cytotoxicity and caspase-3/7 activation 
Chemicals 
ApoTox™ Triplex assay kit from Promega (Wisconsin, USA) was used for 
the simultaneous measurement of caspase-3/7 activation and cell viability in the same 
sample well.  The kit contains GF-AFC Substrate (for cell viability), bis-AAF-R110 
Substrate (for cytotoxicity) and luminogenic DEVD-peptide substrate for caspase-3/7 
and Ultra-Glo™ Recombinant Thermostable Luciferase (to measure caspase-3/7 
activation). 
Samples 
Ginsenosides Rk3 and 20(S)-Rg3 were dissolved in DMSO. Final 
concentration of DMSO was less than 0.5 % v/v. 
Procedure 
This assay was performed by using ApoTox™ Triplex assay kit from Promega 
(Madison, Wisconsin, USA). SNU 449 cells (10 x 10
3 
cells/well) were seeded into 96 
well plates with white background. The cells were then incubated for 24 hours at 37˚C 
with 5% CO2. After incubation ginsenosides dissolved in 0.4 % DMSO were then 
added at different concentrations in media to the well containing cells. The plate was 
then incubated for desired incubation period (6 hours and 12 hours). After incubation, 
20 μL of viability/cytotoxicity reagent (as supplied by the manufacturer) was added to 
all wells, and briefly mixed by orbital shaking (300–500 rpm for ~30 seconds). The 




30 min. Then the fluorescence was measured 
at following wavelengths: viability (Ex: 400/Em: 405), cytotoxicity: (Ex: 485/Em: 
520). To the same plate, 100 μL of Caspase-Glo® 3/7 reagent was added to all wells, 
and briefly mixed by orbital shaking (300–500 rpm for ~30 seconds). The plates were 
then incubated for 30 min at room temperature before measuring luminescence 
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(caspase activation, a hallmark of apoptosis). Average percentage cell viability, 
cytotoxicity and caspase-3/7 activation for a well was expressed as a percentage of the 
control wells by comparing the average fluorescence and luminescence of treated 
wells against that of control wells in a triplicate manner. The results obtained were 
expressed as a mean for three cell line passages and the standard deviation (SD) were 
also calculated.  
 
3.3.2.9 Combined effect of ginsenosides and currently used chemotherapeutic 
agents 
SNU 449 cells were plated in 96 well plates at a density of 6000 cells per well 
as described in Section 3.3.2.6. After 24 hours of incubation at 37ºC with 5% CO2, 
ginsenosides Rg5, Rh4, Rk1 and Rk3 with doxorubicin or paclitaxel were added in 
different molar ratios. Rk1 and Rk3 were combined with doxorubicin in fixed 
combination ratios of 1:5, 1:1 and 5:1 ratios while Rg5 and Rh4 were combined in 
fixed ratios of 1:10, 1:5 and 1:1. After 48 hours of exposure, the supernatant from all 
wells was discarded. Then 100 μl of 10% WST-1 solution in media was added into 
each well excluding the wells at the 4 edges. The plates were then incubated for one 
hour at 37ºC with 5% CO2. After incubation, the absorbance was recorded at 440 nm 
with reference wavelength of 650 nm. 
Data obtained from the above WST-1 assay were subjected to the median 
effect analysis using the CalcuSyn® software (version 2, Biosoft, Cambridge, UK) to 
determine the type and extent of the interactions of ginsenosides Rk1 and Rk3. The 
CalcuSyn® program determines if the combined agents act in additive, synergistic or 
antagonistic manner by using the average cell viability percentages from the WST-1 
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assay as a function of drug concentrations to generate a Combination Index (C.I.). C.I 
could be computed by the following equation: 
C.I. = [(D) 1 / (Dx) 1] + [(D) 2 / (Dx) 2], 
Where (D) 1 and (D) 2 represent doses of drug 1 and drug 2, respectively, used in the 
combination to induce a defined effect (e.g. 50% cell death), and (Dx) 1 and (Dx) 2 
represent the doses of drug 1 and drug 2 , respectively, required to have the same 
effect when the two drugs are administered as single agents. C.I. <0.9, 0.9-1.1 and 
>1.1 represent synergistic, additive and antagonistic effect for a drug combination, 
respectively. For ginsenosides Rg5 and Rh4, isobolograms were plotted to determine 
the type of interaction. An isobologram is a graph with equipotency sum of doses. It is 
plotted by using isoeffective points from extrapolation or interpolation of dose-effect 
curves. 
 
3.4 Results and discussion 
3.4.1 Isolation, purification and identification of ginsenosides 
The yield of the crude extract obtained by ultrasonication using 95% v/v 
ethanol was approximately 10.7% w/w of the quantity of powdered root used. Initial 
separation of the crude extract into hexane, ethyl acetate and butanol fractions gave 
yields of 0.36%, 5.5% and 4.3% w/w of the quantity of powdered root used 
respectively.  This may correspond to non-polar compounds (e.g lipids, fatty acids 
and polyacetylenes), mid polar and polar compounds. The HPLC chromatograms of 
crude extract, n-butanol fraction and ethyl acetate fractions are shown in Figure 3.1.  
Column chromatography using the silica gel was used to fractionate the ethyl 
acetate and butanol fractions into different fractions each containing several 
components. These fractions were further analyzed by HPLC. As the polarities of the 
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components in different fractions were similar, they eluted together. The separation of 
these compounds was not achieved by use of low resolution normal column 
chromatography. Therefore, semi-preparative HPLC methods were optimized to 
separate the components of different fractions to obtain pure ginsenosides.  
Seven pure ginsenosides 20(S)-Rg3, Rg5, 20(S)-Rh1, 20(R)-Rh1, Rh4, Rk1 
and Rk3 with yields of 0.5, 0.42, 0.91, 0.12, 1.28, 0.59 and 0.54 % w/w respectively 
were finally isolated from the ethyl acetate and n-butanol fractions (Figure 1.1).  
Their identities were confirmed by comparing their high resolution LC-MS 
profiles with those of standards as shown in Table 3.1. Total ion chromatogram (TIC) 
and high resolution mass spectrum of 20S-Rh1 is shown in Figure 3.2 and those of 
remaining ginsenosides are presented in Appendix 1.  
 
Table 3.1 Comparisons of LC-ESI-MS/TOF accurate masses of isolated ginsenosides 





















20S-Rg3 C42H72O13 829.4949 829.4984 829.4993 
Rg5 C42H70O12 811.4844 811.4954 811.4944 
20S-Rh1 C36H62O9 683.4370 683.4461 683.4443 
20R-Rh1 C36H62O9 683.4370 683.4443 683.4403 
Rh4 C36H60O8 665.4265 665.4346 665.4324 
Rk1 C42H70O12 811.4844 811.4967 811.4958 











 DAD1 E, Sig=203,16 Ref =360,100 (DHAVAL\11210G10.D)







 DAD1 E, Sig=203,16 Ref =360,10 (DHAVAL\DNP20003.D)







 DAD1 E, Sig=203,16 Ref =360,10 (DHAVAL\DNP20002.D)
 
 
Figure 3.1 HPLC chromatograms of (a) 95 % ethanol crude extract (b) ethyl acetate 
fraction, (c) n-butanol fraction of steamed (15 hours) P. notoginseng. The labeled 
peaks from 1 to 8 correspond to ginsenosides 1. 20(S)-Rh1, 2. 20(R)-Rh1, 3. Rk3, 4. 
Rh4, 5. 20(S)-Rg3, 6. 20(R)-Rg3, 7. Rk1 and 8. Rg5. 
 
Ginsenosides 20S-Rh1 and 20R-Rh1 were isolated from the ethyl acetate 
fraction and the ginsenoside 20S-Rg3 was isolated from the butanol fraction. 
However, ginsenosides Rg5, Rh4, Rk1 and Rk3 were isolated from both the ethyl 






























































in the ethyl acetate extract while ginsenosides Rg5 and Rk1 were predominant in the 
butanol extract.  
 
3.4.2 Anti-proliferative effects of P. notoginseng root extracts and ginsenosides 
on cancer cells 
The anti-proliferative activity of P. notoginseng root extracts and ginsenosides 
was determined using WST-1 cell viability assay. The WST-1 cell proliferation 
reagent is nonradioactive, ready to use reagent which measures the metabolic activity 
of viable cells spectrophotometrically. WST-1 is a tetrazolium salt that when in 
contact with metabolically active cells gets cleaved to formazan. The stable 
tetrazolium salt WST-1 is cleaved to a soluble formazan by a complex cellular 
mechanism that occurs primarily at the cell surface. This bioreduction is largely 
dependent on the glycolytic production of NAD(P)H in the viable cells. Therefore, the 
amount of formazan dye formed directly correlates to the number of metabolically 
active cells in the culture. Cells, grown in a 96-well tissue culture plate, are incubated 
with the ready-to-use WST-1 reagent for approximately 0.5 - 4 hours. After this 
incubation period, the formazan dye formed is quantitated with a scanning multi-well 
spectrophotometer. The measured absorbance directly correlates to the number of 
viable cells. Compared to traditional MTT assay, WST-1 is more sensitive, offers less 
variation in readings, requires less number steps by eliminating formazan dissolution 
and washing steps and therefore faster and is more convenient. WST-1 is also more 
stable than the MTT and XTT assays (also forms water soluble formazan)  and  it is 
stored in a ready-to-use solution, unlike the XTT reagent where mixing of two 
reagents is required before use. 
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Initially, the anti-proliferative effect of extracts of raw and steamed form of P. 
notoginseng was evaluated on SNU449 liver cancer cells. Compared with vehicle 
control (0.5% v/v DMSO), the extract of raw form showed no significant anti-
proliferative activity (cell viability: 89.2 ± 3.7%, p values > 0.05).  In comparison, 
95% ethanol extract of the steamed P. notoginseng significantly inhibited cell 
proliferation at the concentration of 0.15 and 0.25 mg/mL as reflected by the cell 
viability values of 0.38 ± 0.1% and 0.37 ± 0.1% respectively. This data is consistent 
with the previous studies by Sun et al., (2010) and Toh et al., (2010) where they 
reported that the steaming of P. notoginseng roots increases their anti-proliferative 
activity. This could be due to the formation of less polar ginsenosides upon steaming. 
Therefore, it is important to evaluate the anti-proliferative activity of ginsenosides 
formed upon steaming. 
All major ginsenosides formed upon steaming are therefore isolated and 
screened for their anti-proliferative activity against three liver cancer cell lines 
(SNU449, SNU 182 and HepG2). Seven isolated ginsenosides (20(S)-Rg3, Rg5, 
20(S)-Rh1, 20(R)-Rh1, Rh4, Rk1 and Rk3) and Rh2 (commercial standard) of 
steamed P. notoginseng are evaluated for their anti-proliferative activity against liver 
cancer cells. Figure 3.2 shows the cell viability of three liver cancer cell lines after 




Figure 3.2 In vitro anti-proliferative effects of ginsenosides on three liver cancer cell 
lines (SNU449, SNU182 and HepG2). Cells were exposed to saponins at 250 µg/mL 
(ginsenosides 20(S)-Rg3, Rg5, 20(S)-Rh1, 20(R)-Rh1, Rh4 and Rk3) and 150 µg/mL 
(ginsenosides Rh2 and Rk1) for 48 hours. Cell proliferation was measured by WST-1 
assay. Plot shows the average percentage cell viability ± standard deviation as 
compared to the vehicle control of three independent experiments conducted in six 
wells each. Statistical significance (*) was set at p < 0.05. 
 
Among the ginsenosides present in the steamed P. notoginseng, ginsenosides 
20(S)-Rg3, Rh2, Rk1 and Rk3 has significant anti-proliferative activities against all 
the three liver cancer cell lines as compared to vehicle control (p < 0.001). From the 
preliminary screening, the concentration of ginsenosides Rh2 and Rk1 was chosen as 
0.15 mg/mL while for the other six ginsenosides; 0.25 mg/mL concentration was 
chosen.  Ginsenoside Rg5 did not show any significant anti-proliferative activity 
against SNU449 and SNU 182 cells. However, it has significant anti-proliferative 
activity against HepG2 liver cancer cells. Ginsenoside 20(R)-Rh1 and Rh4 did not 
show significant anti-proliferative activity against all three liver cell lines. 
Ginsenoside Rh4 was not found to inhibit the cell proliferation at the 0.25 mg/mL 
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concentration. From these results, ginsenosides 20(S)-Rg3, Rh2, Rk1 and Rk3 were 
found to be most potent (all gave cell viability values less than 20% compared to 
control) among eight major ginsenosides of the steamed P. notoginseng.  
Ginsenoside 20(S)-Rh1 showed moderate inhibitory anti-proliferative activity 
(cell viability values in the range of 69.3 – 87.1 %). Ginsenoside Rg5 showed 
moderate activity only against HepG2 cells. Ginsenoside 20(R)-Rh1 showed some 
inhibitory activity but it was not significant then the control. However, ginsenosides 
Rh4 was found to be inactive at 0.25 mg/mL concentration. Ginsenoside Rg5 is 
reported to possess anti-cancer activity (Lee et al., 1997). Ginsenoside Rg5 is reported 
to possess anti-proliferative activity against SK-HEP-1 liver cancer cells (Lee et al., 
1997). These differences from the results of this study could be due to variability in 
activity of these ginsenosides against different cell lines. The liver cancer cell lines 
used in this study were different than those used (SK-HEP-1 liver cancer cells) in 
previous study by Lee et al., (1997).  
Ginsenosides 20(S)-Rg3, Rg5, Rh2, Rh4, Rk1 and Rk3 were also screened at 
selected concentrations against breast cancer cell lines (MDA-MB-231), cervical 
cancer cell line (C33A), colon cancer cell line (HCT-116) and ovarian cancer cell line 
(PA1) to investigate their effects against these cancer cells. Figure 3.3 (a) shows the 
effects of above ginsenosides against breast cancer cells while Figure 3.3 (b) shows 
the effects of these ginsenosides against cervical, colon and ovarian cancer cells. 
Ginsenosides Rh2, Rk1, Rk3 and 20(S)-Rg3 were also found to have significant anti-
proliferative activity against breast cancer, cervical cancer, colon cancer and ovarian 




Figure 3.3 In vitro anti-proliferative effects ginsenosides on (a) breast cancer cell 
lines (MDA-MB-231 and T47D) and (b) cervical cancer cells (C33A), colon cancer 
cells (HCT-116) and ovarian cancer cells (PA1). Cells were exposed to saponins at 
250 µg/mL (ginsenosides 20(S)-Rg3, Rg5, 20(S)-Rh1, 20(R)-Rh1, Rh4 and Rk3) and 
150 µg/mL (ginsenosides Rh2 and Rk1) for 48 hours. Cell proliferation was measured 
by WST-1 assay. Plot shows the average percentage cell viability ± standard deviation 
as compared to the vehicle control of three independent experiments conducted in six 





Interestingly, ginsenoside Rg5 was found to have significant anti-proliferative 
activity against the above mentioned five different types of cancer cells. This result 
suggests the selective action of ginsenosides Rg5 against this cancer cells compared to 
liver cancer cells on which it has weak anti-proliferative activity.  
Ginsenoside Rh4 was also found to have significant anti-proliferative activity 
against cervical, colon and ovarian cancer cells. Interestingly, ginsenosides Rh4 has 
stronger activity against cervical cancer cells compared to colon and ovarian cancer 
cells. However, it has no anti-proliferative activity against the breast cancer cells. 
From the above results, the four most potent ginsenosides 20(S)-Rg3, Rh2, 
Rk1 and Rk3 were selected to further investigate their dose-response effects to 
determine their IC50 values against three liver cancer cell lines. Ginsenosides 20(S)-
Rg3 and Rk3 were screened at concentrations of 0.04, 0.06, 0.08, 0.12, 0.2 and 0.25 
mg/mL. Ginsenoside Rh2 was screened at concentrations of 0.001, 0.01, 0.025, 0.05, 
0.06, 0.075, 0.1 and 0.125 mg/mL. Concentrations of ginsenoside Rk1 used for the 
determination of its IC50 value were 0.04, 0.06, 0.08, 0.12, 0.16 and 0.20 mg/mL. The 
IC50 values for ginsenosides 20(S)-Rg3, Rh2, Rk1 and Rk3 are shown in Table 1.2. 
From the results of IC50 values, it was evident that the ginsenosides Rh2 had the 
lowest IC50 values against all three liver cancer cell lines and hence was the most 
potent amongst the four ginsenosides. 
Ginsenosides Rk1 and Rk3 were more potent than the ginsenosides 20(S)-Rg3 
against all three cell lines used as indicated by their lower IC50 values than that of 
ginsenoside 20(S)-Rg3 which is currently marketed as an anti-cancer agent in China 
(Wang et al., 2007; Shibata, 2006). These results were consistent with the results of 
study conducted by Toh et al., (2010) on effect ginsenosides 20(S)-Rg3, Rh2, Rk1 
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and Rk3 on SNU 449 cells. In addition, in this study IC50 values of these ginsenosides 
were also determined on other two liver cancer cell lines (SNU182 and HepG2).  
 
Table 3.2 IC50 values of different ginsenosides against three liver cancer cell lines 





























Rh2 0.027 ± 
0.002 








Rk1 0.086 ± 
0.006 








Rk3 0.101 ± 
0.004 








20(S)-Rg3 0.140 ± 
0.004 








* Duration of treatment  
Note: Cells were exposed to saponins at different concentrations for 48 hours 
(SNU449 and HepG2) or 72 hours (SNU182). Cell proliferation was measured by 
WST-1 assay. Ginsenoside Rh2 showed the lowest IC50 values for all three cell lines 
followed by Rk1, Rk3 and 20(S)-Rg3. 
 
The anti-proliferative activity of ginsenoside Rh2 against liver cancer cells 
(SK-HEP-1 cells) was reported by Lee et al., (1996) which was consistent with the 
data reported in this study. In this study, IC50 value of ginsenoside Rh2 was 
determined against liver cancer cells SNU449, SNU182 and HepG2.   Ginsenoside 
Rk1 was also reported to exhibit anti-proliferative activity against HepG2 cells (Kim 
et al., 2008). Kim et al., (2008) reported that the IC50 value of ginsenoside Rk1 was in 
the range of 75-100 µM. This value is lower than the IC50 value found in this study 
(143.6 ± 2.6 µM). This could be due to the differences in number cells used for study 
and the volume of ginsenosides used for screening. Kim et al., (2008) used 10,000 
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cells per well (11,000 cells/well were used in this study). They have used 200 µL of 
drug treatment volume compared to 100µL used in this study.   
Ginsenosides 20(S)-Rg3, Rk1 and Rk3 were further evaluated for their 
selectivity against liver cancer cells by investigating their effects on normal liver 
cancer cells. Selectivity index was then determined by taking the ratio of IC50 value 
against cancer cells (SNU449 cells, most sensitive cell line) Vs the normal liver cells 
(THLE-2 cells). Table 3.3 shows the SI values of ginsenosides 20(S)-Rg3, Rk1 and 
Rk3.  
Table 3.3 IC50 and selectivity index (SI) values of ginsenosides 20(S)-Rg3, Rk1 and 
Rk3 
 
Ginsenoside IC50 value against SNU 
449 (mg/mL) 




20(S)-Rg3 0.140 ± 0.004 0.207 ± 0.006 1.5 
Rk1 0.086 ± 0.006 0.199 ± 0.010 2.3 
Rk3 0.101 ± 0.004 0.208 ± 0.012 2.1 
 
SI indicates differential activity of pure compound. SI values > 2 indicate 
selective activity (Koch et al., 2005; Badisa et al., 2009). However, SI values < 2 
indicate that the compound may have general toxicity (Koch et al., 2005; Badisa et al., 
2009). Based on this, as can be seen from the Table 3.3, the ginsenosides Rk1 and 
Rk3 displayed selective anti-proliferative activity against the liver cancer cells. 
Ginsenoside Rk1 displayed better potency and selectivity compared to that of Rk3 and 
20(S)-Rg3. Therefore, the above results suggest that ginsenosides Rk1 and Rk3 
possess better anti-proliferative activity and selectivity than 20(S)-Rg3. To the best 
our knowledge, this is the first report of cytotoxicity of ginsenosides Rk1 and Rk3 
against the normal hepatocytes. However, the selectivities of ginsenosides are not 
high. Therefore, they might have unwanted effects on normal cells. These results 
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suggest that in vivo toxicity of the ginsenosides using animal models should be 
evaluated before they are considered for clinical use in humans. 
 
3.4.2.1 Structure-activity relationship for anti-proliferative activity of 
ginsenosides 
The above data (Figure 3.3 and 3. 4 and Table 3.2) shows that the most of 
ginsenosides pre-dominantly present in steamed P. notoginseng possess anti-
proliferative activity. The formation of these ginsenosides upon steaming could be the 
reason for the increased anti-proliferative activity of steamed P. notoginseng 
compared to the raw form. In addition, the comparison of differential activities of the 
eight major ginsenosides formed upon steaming gave important insights into the 
structure-activity relationship of the ginsenosides of steamed P. notoginseng.  The 
relative order of anti-proliferative activity of the eight ginsenosides screened in this 
study in decreasing order is Rh2 > Rk1 > Rk3 > 20(S)-Rg3 > 20(S)-Rh1 > Rg5 > 
20(R)-Rh1 > Rh4.   
Ginsenosides possess a four trans-ring rigid steroid skeleton (Figure 1.1), with 
a modified side chain at C-20 and sugar residues attached to the –OH of the aglycone 
(Nag et al., 2012). In the case of PPD type ginsenosides (Figure 1.1), the sugar 
residues are attached to the β-OH at C-3 and another -OH at C-20 of the aglycone 
whereas in the case of PPT type ginsenosides (Figure 1.1), the sugar residues are 
attached to the α-OH at C-6 and another-OH at C-20 of the aglycone (Nag et al., 
2012).In general, protopanaxadiol (PPD) saponins such as ginsenosides Rh2, 20(S)-
Rg3 and Rk1 showed better activity with the exception of ginsenoside Rg5 (showed 
moderate activity against HepG2 cells). In comparison, the protopanaxatriol (PPT) 
saponins such as 20(S)-Rh1, 20(R)-Rh1 and Rh4 displayed less or no anti-
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proliferative activity with exception of ginsenoside RK3 which displayed significant 
anti-proliferative activity against all three cell lines.  These results are consistent with 
the previously reported study by Wang et al., (2007) in which they reported that PPD 
saponins had better anti-proliferative activity than those of PPT saponins. 
Ginsenosides interact with the β-OH group of cholesterol in the cell membrane which 
in turn affects the functions of cell membrane responsible for their cellular response. 
Therefore, the differences in the number and position of –OH groups influence the 
anti-cancer activity of ginsenosides (Nag et al., 2012). 
The exception of ginsenoside Rg5 from PPD and Rk3 from PPT are related to 
the position of double bond at the carbon 20(21) or carbon 20(22) as can be seen in 
Figure 1.1. Ginsenosides containing double bond at the carbon 20(21), ginsenosides 
Rk1 and Rk3 displayed significant anti-proliferative activity. However, their 
respective positional isomers ginsenosides Rg5 and Rh4 (double bond at the carbon 
20(22) displayed poor or no anti-proliferative activity. This important observation 
highlighted the importance of proper positioning of double bond at the carbon no. 20. 
Compared to ginsenoside Rk3, ginsenoside Rk1 displayed better anti-proliferative 
activity (Table 3.2). In ginsenosides having double bond at carbon 20(21), it can be 
further deduced that the glycosylation at the carbon no. 6 (ginsenoside Rk3) reduces 
the activity compared to glycosylation at the carbon no. 3 (ginsenoside Rk1). This 
observation is also true in the case of ginsenosides Rh1 and Rh4 which are having 
glycosylation at the carbon no. 6 compared to ginsenosides Rh2, 20(S)-Rg3 and Rk1 
which are having glycosylation at the carbon no. 3.  
Furthermore, the no. of sugar moieties involved in the glycosylation plays 
important role for the anti-proliferative activity of ginsenosides. For example, 
ginsenoside Rh2 has a monosaccharide moiety at the carbon no. 3 and is more active 
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than others having disaccharides such as ginsenosides 20(S)-Rg3 and Rk1 (Figure 
1.1). These findings concurred with those of previous study by Wang et al., (2007).  
This observation can also be deduced from the study of Toh et al., (2010), in which 
ginsenosides with four sugar moieties (e.g. ginsenoside Rb1) and three sugar moieties 
(e.g. ginsenoside Rd, notoginsenoside R1) exhibited weak anti-proliferative activity 
against the liver cancer cell lines. The presence of sugar moieties decreases the 
hydrophobicity of the ginsenosides and hence limits their cell permeability. Therefore 
the anti-proliferative activity is indirectly proportional to the number of sugar 
molecules (Nag et al., 2012).  
In summary, structural features such as PPD structure, double bond at the 
carbon 20(21), glycosylation at the carbon no. 3 with less no. of sugar moieties 
(preferably a monosaccharide) are required for the better anti-proliferative activity in 
the case of ginsenosides.  These SAR features would be helpful in the development of 
ginsenoside derivatives or semi-synthetic derivatives as anti-proliferative agents. 
 
3.4.2.2 Effects of ginsenosides on cell cycle  
The cell cycle is a series of events taking place in the cell which results in cell 
growth and division into two daughter cells. The various stages are G1, S, G2 and M 
phase (Cooper, 2000). Once the cell division is triggered, the cell enters G1 phase 
where certain proteins essential for DNA replication are made. When the cell begins 
to make new DNA, it enters the S phase of cell cycle where the DNA content of cell 
gets doubled. After this, the DNA synthesis stops which is called as the G2 phase 
(Ormerod, 2000). After this the cell will enter into M phase and returns to the G1 after 
dividing. If the DNA content of the cells (≥ 10,000) is measured and plotted against 
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the number of cells in a histogram, it will represent the state of the cell cycle 
(Ormerod, 2000).  
The most commonly used dye for DNA content/cell cycle analysis is 
propidium iodide. Propidium iodide intercalates into the major groove of double-
stranded DNA and produces a highly fluorescent adduct that can be excited at 488 nm 
with a broad emission centered around 600 nm. Propidium iodide binds 
stoichiometrically to nucleic acids so that fluorescence emission is proportional to the 
DNA content of a cell. When apoptotic cells are stained with propidium iodide and 
analyzed with a flow cytometer, they display a broad hypodiploid (sub-G1) peak, 
which can be easily discriminated from the narrow peak of cells with normal (diploid) 
DNA content. However, propidium iodide can also bind to double-stranded RNA. 
Therefore, it is necessary to treat the cells with RNAase for optimal DNA resolution. 
The excitation of propidium iodide at 488 nm can be measure by various flow-
cytometers.  
To determine if ginsenosides suppressed the cell proliferation of SNU449 liver 
cancer cells in through induction of apoptosis, ginsenosides treated cells were 
examined using staining with propidium iodide and analyzed for sub-G1 staining. For 
cells undergoing apoptosis, the DNA content is low due to loss of small fragmented 
DNA (Darzynkiewicz et al., 1992). By labeling DNA with propidium iodide, the low 
DNA content can be detected using flow cytometric analysis. Sub-G1 population 
represents cells with decreased propidium iodide staining and thus represents 
apoptotic cells.  Figure 3.5 (a) and (b) show the effects of ginsenosides Rg5, Rh4 and 
Rk3 on SNU cancer cells after 12 hours and 24 hours of treatment.  
Ginsenoside Rk3 was screened at three different concentrations, 50, 100 and 
200 µg/mL while ginsenosides Rg5 and Rh4 were screened at 200 µg/mL. These 
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concentrations were selected based on earlier screening of their anti-proliferative 
activity against SNU 449 cells (Figure 3.4 and Table 3.2). Figure 3.5 shows 
representative histograms of effect of ginsenoside Rk3 on cell cycle regulation after 
12 hours of treatment.  
 
  
Figure 3.4 Effect of ginsenosides Rg5, Rh4 and Rk3 on different stages of cell cycle 
regulation in SNU449 cells. Cells were exposed to ginsenosides Rg5 and Rh4 (200 
µg/mL) and ginsenoside Rk3 (50, 100 and 200 µg/mL) for (a). 12 hours and (b). 24 
hours. Plot shows the average percentage of cells ± SD in different stages of cell cycle 
from three independent experiments. Statistical significance (*) was set at p < 0.05 for 
the analyses of cell population Sub-G1 phase. Ginsenoside Rk3 at 200 µg/mL induced 
apoptosis by Sub-G1 arrest in SNU449 cells after 12 hours of treatment. For 24 hours 
of treatment, ginsenoside Rk3 at 200 µg/mL, killed almost all the cells and therefore 









Figure 3.5 Effects of ginsenoside Rk3 on cell cycle regulation of SNU 449 liver 
cancer cells. The cells were exposed to ginsenoside Rk3 at 50, 100 and 200 µg/mL 
concentrations for 12 hours and 24 hours. The cells after required treatment exposure 
were stained by PI and analyzed by flow-cytometry. Sub-G1 values in were 
represented by the percentage of cells in R1 region. Data is representative of a single 
experiment for 12 hours of treatment repeated on three different occasions with 
similar results. Ginsenoside Rk3 induced apoptosis at 200 µg/mL concentration is 
indicated by the increased percentage of cells in Sub-G1 phase. The data is 
representative of a single experiment for 12 hours of treatment repeated on three 
different occasions with similar results. 
 
 
As can be seen from the Figure 3.5 (a) and 3.6, the proportion of cells in Sub-
G1 phase was significantly increased (44.26 ± 4.69 %, p value < 0.001) in the case of 











of apoptosis by ginsenoside Rk3 at 200 µg/mL after 12 hours of treatment. However, 
no significant change in population of cells in Sub-G1 was observed for ginsenosides 
Rg5 and Rh4. This suggests that ginsenosides Rg5 and Rh4 has no apoptosis inducing 
effect after 12 hours of treatment.  Ginsenoside Rh4 did not show any effect even 
after 24 hours of treatment as well. Ginsenoside Rg5 showed significant apoptotic 
effect after 24 hours of treatment (2.59 ± 0.37 % cells in Sub-G1, p value < 0.05). 
However, effect of ginsenoside Rg5 is much lower than that of ginseoside Rk3.  
Ginsenoside Rk3 has significant anti-proliferative activity at 200 µg/mL after 
24 hours of treatment. It killed almost all the cells and therefore enough cells were not 
available for PI staining suggesting very strong anti-proliferative activity.  The above 
results show that ginsenoside Rk3 causes cell cycle arrest in sub-G1 phase which may 
trigger DNA repair mechanism, leading to apoptosis. These observations are in line 
with studies conducted on the other ginsenosides. For example, Popovich and Kitts 
(2002) reported that 20(S)-protopanaxadiol and 20(S)-protopanaxatriol reduces cell 
proliferation of leukemia cell line THP-1 by arresting cells in the sub-G1 phase.  
 
3.4.2.3 Measurement of cell viability, cytotoxicity and caspase-3/7 activation  
Apoptosis is characterized by the distinct morphological changes such as 
membrane blabbing, nuclear condensation, and fragmentation of genomic DNA 
(Hacker, 2000; Oh et al., 2005). Most of these morphological changes are conducted 
by caspases, a family of aspartate-specific cysteine proteases, which play essential 
roles in apoptotic cells (Hengartner, 2000). The apoptosis is mainly triggered by two 
pathways. One involves binding of transmembrane death receptors such as Fas and 
TNF-α receptors by their specific ligands which results in the recruitment and 
activation of caspase-8, which activates downstream effector caspases such as 
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caspases-3, -6 and -7. The other pathway depends on mitochondrial dysfunction (Oh 
et al., 2005; Salvesen and Dixit, 1991). 
The ApoTox-Glo™ Triplex Assay can be used to assess the cell viability, 
cytotoxicity and caspase activation within a single assay well. The first part of the 
assay simultaneously measures two protease activities; one is a marker of cell 
viability, and the other is a marker of cytotoxicity. The live-cell protease activity is 
restricted to intact viable cells and is measured using a fluorogenic, cell-permeant, 
peptide substrate (GF-AFC). The substrate enters intact cells where it is cleaved by 
the live-cell protease activity to generate a fluorescent signal which is proportional to 
the number of living cells. This live-cell protease becomes inactive upon loss of cell 
membrane integrity and leakage into the surrounding culture medium. A second, 
fluorogenic cell-impermeant peptide substrate (bis-AAF-R110) is used to measure 
dead-cell protease activity, which is released from cells that have lost membrane 
integrity. Because bis-AAF-R110 is not cell-permeant, essentially no signal from this 
substrate is generated by intact, viable cells. The live- and dead-cell proteases produce 
different products, AFC and R110, which have different excitation and emission 
spectra, allowing them to be detected simultaneously at different excitation and 
emission wavelengths. Since the ApoTox-Glo™ Triplex Assay meassures cell vibility 
by recording fluorescence, it is more sentitive than the WST-1cell proliferation 
reagent to measure the cell viability (Niles et al., 2007; 2008; O‟Brien et al., 2005). 
The second part of the assay uses a luminogenic caspase-3/7 substrate, which 
contains the tetrapeptide sequence DEVD, in a reagent optimized for caspase activity, 
luciferase activity and cell lysis. Adding the Caspase-Glo® 3/7 reagent in an “add-
mix-measure” format, results in cell lysis, followed by caspase-3 and caspase-7 
cleavage of the substrate and generation of a “glow-type” luminescent signal 
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produced by luciferase. Luminescence is proportional to the amount of caspase-3 and 
caspase-7 activities present. These members of the cysteine aspartic acid-specific 
protease (caspases) family play a key effectors role in causing the apoptosis in 
mammalian cells. ApoTox-Glo™ Triplex Assay have been ised in the literature to 
measure caspase-3/7 levels in the cellular systems (Duan et al., 2011; He et al., 2010; 
Mrakovcic et al., 2013) 
To investigate the involvement of caspases in ginsenoside Rk3 induced 
apoptosis, experiments were carried out to assess whether ginsenosides treatment 
could activate caspase-3 and 7. As shown in Figure 3.6, ginsenosides Rk3 and Rg3 
increased the levels of caspase-3/7 in SNU 449 cells in a concentration dependant 
manner upon treatment for 6 hours. The assay was performed by using ApoTox assay 
kit from Promega. This kit offers an advantage of simultaneous measurement of cell 
viability, cytotoxicity and caspase-3/7 levels within a same cellular system.  
Ginsenoside Rk3 dose dependently (25, 50, 100, 150 and 200 µg/mL) 
decreased the viability (cell proliferation) by increasing cytotoxicity. The cell viability 
was 42.59 ± 2.76 % compared to control upon treatment with Rk3 (200 µg/mL) after 
6 hours of treatment. At the same time, the caspase-3/7 levels were 3164.39 ± 300.30 
% of those of untreated vehicle control cells. The caspase-3/7 levels were increased 
upon increasing the concentration (Fig. 3.6).  The levels of caspase-3/7 increased from 
108.85 ± 7.62 % (for 25 µg/mL) to 3164.39 ± 300.30 % (for 200 µg/mL). 
Furthermore, as it can be seen from the Figure 3.7, Rk3 possessed stronger apoptosis 
inducing activity compared to 20(S)-Rg3.  After 6 hours of incubation, 20(S)-Rg3 
increased the levels of caspase-3/7 to 134 %, while Rk3 increased to 3164 %. 
Ginsenoside Rk3 displayed > 20 times higher apoptosis inducing activity compared to 






Figure 3.6 Effects of ginsenosides (a) Rk3 and (b) 20(S)-Rg3 on caspase-3/7 levels, 
cell viability and cytotoxicity in SNU 449 liver cancer cells. The plot shows the 
average percentage of cell viability/ cytotoxicity/ caspase-3/7 levels ± SD from three 
independent experiments. The cells were exposed to ginsenosides Rk3 and 20(S)-Rg3 
at 25, 50, 100 and 200 µg/mL concentrations for 6 hours.  
 
The above results further supports the findings of propidium iodide staining 





involvement of caspases in ginsenosides induced apoptosis have been reported (Lee et 
al., 2010; Nag et al., 2012; Park et al., 2010). In SK-HEP1 liver cancer cells, 
ginsenoside Rh2 activates caspase-3 to cause apoptosis (Park et al., 2010). 
Ginsenoside Rg3 also reported to activate caspase-3 and caspase-9 (Lee et al., 2010a). 
Similarly, Korean red ginseng causes activation of caspase-3 to induce apoptosis 
(Cheng et al., 2005).  The effects of ginsenoside Rk3 on cell cycle and caspase 
activation were studied for the first time in this study. Ginsenoside Rk3 was found to 
possess strong anti-proliferative activity accompanied by its strong apoptosis 
induction activity. 
 
3.4.3 Combined effect of ginsenosides and currently used chemotherapeutic 
agents 
Combination therapy is one of the most successful treatment regimens for 
cancer. Combination therapy is often more effective because of favorable additive or 
synergistic interactions of the drugs used in a combination. However, the success of 
this therapy is largely dependent on the selection of optimum combination of drugs. 
Initially, effects of ginsenosides Rg5, Rh4, Rk1 and Rk3 on the anti-proliferative 
activities of two chemotherapeutic agents, doxorubicin (5 µM) and paclitaxel (1 µM) 
were investigated. From results of this preliminary screening, it was found that all 
four ginsenosides were able to increase the anti-proliferative activity of doxorubicin. 
However, the anti-proliferative activity of paclitaxel was not affected by co-treatment 
with the ginsenosides. Figure 3.7 shows the representative plots of effect of 








Figure 3.7 Effects of ginsenoside Rk3 on anti-proliferative activities of doxorubicin 
and paclitaxel in SNU 449 liver cancer cells. The plot shows the average percentage 
cell viability ± SD from three independent experiments after 48 hours of treatment 
exposure. The cells were exposed to combination of (a). 5 µM of doxorubicin or (b). 1 
µM paclitaxel  and ginsenoside Rk3 at 8, 16, 40 and 80 µM (corresponding to 5, 10, 
25 and 50 µg/mL of Rk3) concentrations for 6 hours.  
 
As can be seen from Figure 3.7 (a), ginsenoside Rk3 enhanced the anti-
proliferative activity of doxorubicin at all tested concentrations. Conversely, 
ginsenoside Rk3 did not affect the activity of paclitaxel [Figure 3.7 (b)].  Similar 





Based on above preliminary results, further experiments were designed to 
investigate the type and extent of interactions of ginsenosides Rg5, Rh4, Rk1 and Rk3 
with doxorubicin. Fixed ratio combination was investigated by studying interaction of 
three different combinations for each ginsenosides. For ginsenosides Rk1 and Rk3, 
ratio of 1:5, 1: 1 and 5:1 (doxorubicin: ginsenosides Rk1/Rk3) were investigated 
while for ginsenosides Rg5 and Rh4 1:10, 1: 5 and 1:1 (doxorubicin: ginsenosides 
Rg5/Rh4) were chosen. Figures 3.8, 3.9, 3.10 and 3.11 show the effect of different 
fixed molar ratio combinations of doxorubicin and ginsenosides Rk1, Rk3, Rg5 and 
Rh4 respectively. However, the type and extent of interaction could not be deduced 
from such sigmoidal dose-response curve. Hence, the median-effect analysis method 
developed by Chou and Talalay (1984) to calculate combination index (C.I) using 
CalcuSyn software was adopted.   
The plot of C.I. versus fraction affected (different levels) for the various fixed 
molar ratio combination of ginsenosides and doxorubicin are plotted. Figure 3.12 and 
3.13 shows the plot of C.I. versus fraction affected for ginsenosides Rk3 and Rk1 
respectively.  The data displayed in Figure 3.12 and 3.13 provide overall information 
about the ability of the various Rk1/Rk3-doxorubicin combinations to produce cancer 
cell killing effect at different levels (fractions affected). The synergistic drug 
combination at the 50% (EC50), 75% (EC75) and 90% (EC90) for ginsenosides Rk3 and 









Figure 3.8 Effects of ginsenoside Rk3 and doxorubicin as combination on the SNU 
449 liver cancer cells. The plot shows the average percentage of cell ± SD from three 






Figure 3.9 Effects of ginsenoside Rk1 and doxorubicin as combination on the SNU 
449 liver cancer cells. The plot shows the average percentage cell viability ± SD from 








Figure 3.10 Effects of ginsenoside Rg5 and doxorubicin as combination on the SNU 
449 liver cancer cells. The plot shows the average percentage cell viability ± SD from 







Figure 3.11 Effects of ginsenoside Rh4 and doxorubicin as combination on the SNU 
449 liver cancer cells. The plot shows the average percentage cell viability ± SD from 







Figure 3.12 Plot of estimated C.I. values of ginsenoside Rk3 and doxorubicin as 
combination on the SNU 449 liver cancer cells. Data points represents the C.I. values 
estimated from data pooled from three independent sets of WST-1 assays, each with 
quadruple determinations. C.I. values of < 0.9, 0.9-1.1, > 1.1 indicates synergism, 







Figure 3.13 Plot of estimated C.I. values of ginsenoside Rk1 and doxorubicin as 
combination on the SNU 449 liver cancer cells. Data points represents the C.I. values 
estimated from data pooled from three independent sets of WST-1 assays, each with 
quadruple determinations. C.I. values of < 0.9, 0.9-1.1, > 1.1 indicates synergism, 














































Table 3.4 Combination indices (C.I) of ginsenosides Rk3 and Rk1/doxorubicin 
combinations in different fixed molar ratios in SNU 449 liver cancer cells. C.I. values 
were estimated from the data pooled from three independent sets of WST-1 assays, 
each with quadruple determinations. C.I values of < 1, 0.9-1.1, >1.1 indicates 
synergism, additivity and antagonism respectively.  
 
 










EC50 EC75 EC90 
1 DOX:Rk3 (1:5) 0.5367 0.5685 0.6660 4.6 0.9906  
 DOX:Rk3 (1:1) 0.9920 0.7438 0.5839 10.8 0.9527  
 DOX:Rk3 (5:1) 0.8203 0.8710 0.9354 9.5 0.9924  
2 DOX:Rk1 (1:5) 0.6613 0.7307 0.9247 5.4 0.9937  
 DOX:Rk1 (1:1) 0.9159 0.8850 0.9196 9.9 0.9888  
 DOX:Rk1 (5:1) 1.0107 0.8944 0.8069 11.6 0.9848  
3. DOX  (single drug) N.A N.A N.A 11.7 0.9906  
 
 
It is important to evaluate the type of interaction of combinations of 
ginsenosides Rk1 and Rk3 with doxorubicin at the maximum cell killing effect i.e. 
EC90. As can be seen from Table 3.4, C.I. values at EC90 for doxorubicin: ginsenoside 
Rk3 in fixed molar ratios were synergistic for 1:5 and 1:1 ratios with C.I values of 
0.67 and 0.58 respectively. However, the 5:1 ratio was found to be additive (C.I: 
0.94). Comparatively, the combination of doxorubicin and ginsenoside Rk1 at all 
three ratios was found to have additive effect with C.I values of 0.93, 0.92 and 0.81 
for 1:5, 1:1 and 5:1 molar ratios respectively. Figure 3.14 shows the estimated dose 
reduction of doxorubicin that could be achieved by utilizing various fixed molar ratios 
for ginsenosides Rk3 and Rk1. These two ginsenosides were found to offer 3.5 and 
3.1 fold dose reduction of doxorubicin, to kill 90% of SNU 449 cancer cells at molar 
ratio of 1:5 (Doxorubicin:Rk1/Rk1). Therefore, doxorubicin: Rk1/Rk1 at molar ratio 
of 1:5 appears to be most promising. These results suggested that these two 
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Figure 3.14 Dose reduction indices of ginsenosides Rk1 and Rk3 to reduce the dose 
of doxorubicin when used in combination on the SNU 449 liver cancer cells. The plot 
shows the concentration required to kill 90% of cells by doxorubicin alone or in 
combination with ginsenosides Rk1 and Rk3. 
 
 The isobolograms of combination regimens of ginsenosides Rg5 and Rh4 at 
different molar ratios with doxorubicin are shown in Figure 3.15 and 3.16. These two 
ginsenosides were found to have synergistic interaction with doxorubicin at molar 






Figure 3.15 Schematic representation of isobologram for the indicated molar ratio 





Figure 3.16 Schematic representation of isobologram for the indicated molar ratio 




 For ginsenosides Rg5 and Rh4, the median effect principle method cannot 
be used since these two ginsenosides have no anti-proliferative activity at even at the 
concentrations of 320 µM and 400 µM respectively. Therefore, their IC50 could not be 
determined and hence, CalcuSyn software could not be utilized to determine the type 
and extent of their interaction with doxorubicin. However, by taking the qualitative 
IC50 values of > 320 µM for ginsenoside Rg5 and > 400 µM for ginsenoside Rh4, 
their interaction was predicted by using isobolograms.  
 From the above results it appears that ginsenosides Rk3. Rk1, Rg5 and Rh4 
have the potential to enhance the anti-proliferative activity of doxorubicin. These 
ginsenosides were successfully demonstrated to possess beneficial interaction with 





 Seven major marker ginsenosides were successfully isolated from steamed 
P. notoginseng and evaluated for their anti-proliferative activity. Ginsenoside Rk3 
was found to induce apoptosis by arresting cells in sub-G1 phase and activation of 
caspase-3/7. Four ginsenosides Rk3, Rk1, Rg5 and Rh4 were found to have beneficial 
interaction with doxorubicin and could help to reduce the side effects of doxorubicin 





















Pharmacokinetic evaluation of drug molecules is an essential component of 
drug discovery and development.  After characterization of the target receptor or 
enzyme, medicinal chemists generate libraries of many compounds by modifying the 
structure of compound to maximize its in vitro activity (Lin and Lu, 1997). However, 
the observed in vitro activity cannot be extrapolated to in vivo activity without various 
data of pharmacokinetics parameters (Lin and Lu, 1997). Therefore, evaluation of 
pharmacokinetics is very important for any drug molecule for its development as a 
medicinal agent. 
Ginsenosides, a group of triterpenoid saponins are generally believed to be the 
main active components responsible for the claimed efficacy of herbs in the genus 
Panax e.g. Panax ginseng (Asian or Korean ginseng), Panax quinquefolius (American 
ginseng) and Panax notoginseng (Tienchi or Sanchi) (Jia and Zhao, 2009a; 2009b; 
Christensen, 2009; Lu et al., 2009). So far, more than 150 ginsenosides have been 
isolated from different forms of Panax herbs” (Christensen, 2009). Many of them 
were reported to possess various beneficial health effects such as anticancer, 
immunomodulatory, prevention and treatment of cardiovascular diseases, anti-
hyperglycemic, neuropharmacological, anti-stress, and anti-inflammatory and other 
effects (Jia and Zhao, 2009a; 2009b; Christensen, 2009; Lu et al., 2009).
 
Although 
there are many reports of pharmacological investigations on these ginsenosides, the 
pharmacokinetic profiles are not well studied (Qi et al., 2011; Yu et al., 2012a).  
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Ginsenoside Rh4 (Rh4) and ginsenoside Rk3 (Rk3) have been reported to be 
present in the processed Panax herbs (Toh et al., 2011; Liao et al., 2008; Baek et al., 
1996; Yang et al., 2007a; Lee et al., 2010b; Lee et al., 2011). These two ginsenosides 
are positional isomers of the double bond at carbon-20(21) or carbon-20(22). Rh4 
displayed anti-complementary, anti-platelet aggregating, immunomodulatory, 
immunological-adjuvant and haemolytic activities; while Rk3 possessed anti-
complementary, anti-platelet aggregating and anti-proliferative activity (Toh et al., 
2011; Lee et al., 2010b; Lee et al., 2011) . Moreover, Rk3 was found to have stronger 
anti-proliferative activities against liver cancer cells than ginsenoside 20(S)-Rg3 (Toh 
et al., 2011). Ginsenoside Rg3 has been approved in China and Taiwan for its use as 
an innovative anti-cancer agent (Yue et al., 2007; Barthomeuf et al., 2004). As shown 
in Chapter 3, ginsenoside Rk3 was more active than 20(S)-Rg3 against three cancer 
cell lines, SNU449, SNU182 and HepG2. Furthermore, as presented in Chapter 3, 
these two ginsenosides were also found to enhance the anti-proliferative activity of 
doxorubicin. Therefore, these ginsenosides have great potential to become medicinal 
agents. However, to explore the potential medicinal application of ginsenosides Rh4 
and Rk3, a study of their pharmacokinetics is crucial. 
 
4.2 Objective 
The objective of this study is to develop, validate and apply an LC-MS/MS 








4.3.1 Materials and reagents 
Ginsenoside 20(S)-Rg3 (Rg3, internal standard) and sodium salt of 
carboxymethyl cellulose (CMC) were purchased from ChromaDex, Inc (USA) and 
Hopkins and Williams (Chadwell Health, UK), respectively. Ginsenosides Rh4 and 
Rk3 were isolated in-house (purity >95% by HPLC). High performance liquid 
chromatography grade methanol and acetonitrile were purchased from Tedia 
Company (Fairfield, OH). Formic acid was purchased from Sigma-Aldrich (USA). 
 
4.3.2 Methods 
4.3.2.1 Sample preparation 
Stock solutions of Rh4, Rk3 and the internal standard 20(S)-Rg3 were 
prepared in methanol and stored at 4
°
C in the dark. The final concentrations of 
calibration standards for Rh4 and Rk3 were 10, 15, 25, 50, 100, 500, 1000 and 1500 
ng mL
-1
. They were freshly prepared by spiking 2.5 µL each of appropriate 
concentrations of ginsenosides and internal standard (final concentration: 100 ng mL
-1
) 
into 35 µL of pooled rat plasma in clean 1.5 mL microcentrifuge tubes. After one-min 
vortex, 100 µL of ice-cold methanol was added for protein precipitation. The samples 
were then centrifuged at 10000 g for 5 min and supernatant was collected. During 
analysis, 20 µL of the each supernatant was injected into the LC-MS/MS system. 
Quality control (QC) samples (20, 125 and 1200 ng mL
-1
) were prepared 






4.3.2.2 LC-ESI-MS/MS method 
An Agilent 1200 chromatograph (Palo Alto, CA, USA) equipped with 
quaternary gradient pump, and autosampler coupled to a 3200 QTRAP hybrid triple 
quadrupole linear ion trap mass spectrometer (Applied Biosystems, Foster city, Ca, 
USA) equipped with a Turbo Ion Spray electrospray ionization (ESI) source were 
used. Multiple ion monitoring (MIM) and multiple reaction monitoring (MRM) 
experiments were performed using negative ESI mode. The dwell time used for all 
MIM and MRM experiments was 250 ms. The source dependant mass spectrometer 
parameters such as curtain gas, ion spray voltage and temperature were set at 12 psi, -
4500 V and 500˚C respectively. The Nebulizer gas 1 and 2 were maintained at 40 and 
45 PSI respectively. The compound dependant parameters such as declustering 
potential (DP), entrance potential (EP), collision energy (CE), collision cell exit 
potential (CXP) for ginsenosides Rh4 and Rk3 (MIM of (m/z): 665.3 in Q1 and Q3) 
were -50, -7, -20 and -4 respectively. For the MRM transition (m/z) 665.0→619.0, 
which was used as a qualifier, values of parameters DP, EP, CE and CXP were 50, -7, 
-24 and -4 respectively. The compound dependant parameters, DP, EP, CE and CXP 
for ginsenoside 20(s)-Rg3 (MIM of (m/z): 829.2 in Q1 and Q3) were -35, -9, -15 and 
-4 respectively. To avoid contamination of the ion and to maximize the ion signal, the 
interface heater was kept on.  
The chromatographic separation was achieved on a Poroshell 120 EC-C18 
(2.7 µm, 50 × 4.6 mm i.d) column (Agilent, Palo Alto, CA, USA). The optimized 
mobile phase consisted of solvent A (0.1 % formic acid in water) and solvent B (0.1% 
formic acid in acetonitrile) in isocratic elution in the ratio of 56:44 (A:B) for 12 min. 
The flow rate of mobile phase was 0.4 mL/min. Data acquisition and processing was 
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performed using the Analyst software version 1.4.2 (Applied Biosystems, Foster city, 
CA, USA). 
 
4.3.3.3 Method validation 
The method was validated for selectivity, sensitivity, matrix effect, linearity, 
accuracy, precision and extraction efficiency were investigated. The stability profiles 
of ginsenosides Rh4 and Rk3 were also evaluated under different conditions. 
Selectivity of the developed LC-MS/MS method was investigated by comparing the 
chromatograms of blank plasma (pooled from eight rats) to the same pooled plasma 
spiked with ginsenosides 20(S)-Rg3 (internal standard), Rh4 and Rk3. Selectivity was 
further confirmed from the analysis of pre-dosing samples from the 12 individual rats 
used in this study. The lower limit of quantification (LOQ) was determined by using a 
signal to noise ratio of 10. The matrix effect was evaluated by determining matrix 
factor from the comparison of peak areas of spiked ginsenosides in the blank plasma 
obtained from the six individual rats to that obtained from the ginsenosides in neat 
solvent. The intraday (n=6)   and inter-day (n=3) analyses were evaluated of QC 
samples in rat plasma on five consecutive days. The relative standard deviation (RSD) 
of intra- and inter-day analyses was used to assess the precision of the assay.  
To evaluate the accuracy of this assay, the analytical recoveries of the QC 
samples (both intra- and inter-day) were calculated by comparing the amounts of 
ginsenosides detected to that spiked into plasma. Comparison of the peak areas of QC 
samples with the peak areas of ginsenosides with the same concentration in a neat 
solvent was used to calculate the absolute recovery. Absolute recovery was used as an 
indicator of extraction efficiency. The stability profiles of ginsenosides Rh4 and Rk3 
solutions (n=3) were investigated by keeping sample solutions of standards at 24˚C 
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for three weeks. Autosampler stability or post-preparative stability was also evaluated 
by re-injecting the processed samples (n=3) kept at 24˚C for 24 hours. Samples were 
also subjected to three freeze (-80˚C) –thaw (24˚C) cycles to assess their freeze-thaw 
stability. For the long-term stability evaluation, the QC samples were stored at -80˚C 
for a one month. Short term stability of Rh4 and Rk3 was evaluated by keeping QC 
samples at 4˚C for 24 hours. 
 
4.3.3.4  In vivo pharmacokinetics study 
This pharmacokinetic study was carried out with compliance with the 
“Guidelines on the Care and Use of Animals for Scientific Purposes” (National 
Advisory Committee for Laboratory Animal Research, Singapore, 2004). The study 
design and animal handling procedures were reviewed and approved by the 
Institutional Animal Care and Use Committee of the National University of Singapore 
(NUS).  
Twelve Sprague-Dawley rats (Male, ~ 320 g) were purchased through 
Comparative Medicine, NUS. The animals were maintained in a specific pathogen 
free animal facility (24°C, 60% relative humidity) at Comparative Medicine and kept 
on a 12-h light/dark cycle with free access to food and water. On the day before the 
pharmacokinetic study, surgery was performed and a polyethylene tube (I.D. 0.58 mm, 
O.D. 0.965 mm, Becton Dickinson, Sparks, MD 21152, USA) was implanted into the 
right jugular vein under isoflurane anesthesia. This catheter was used for intravenous 
drug administration as well as for blood sampling. The rats were divided into four 
groups. Group 1 (n = 3) received a single intravenous administration of Rh4 at the 
dose of 5 mg/kg while Group 2 (n = 3) received a single oral gavage of Rh4 
suspended in 0.5 % (w/w) of sodium carboxymethyl cellulose at the dose of 20 mg/kg. 
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Similarly, Group 3 (n = 3) received a single intravenous administration of Rk3 (5 
mg/kg) while Group 4 (n = 3) received a single oral dose of RK3 suspended in 0.5 % 
(w/w) of sodium carboxymethyl cellulose (20 mg/kg). Serial blood samples were 
collected before dosing and at 5, 15, 30, 60, 90, 120, 180, 300, 420, and 600 min after 
intravenous administration and at 15, 30, 45, 60, 90, 120, 180, 300, 420, and 600 min 
after oral gavage. After each intravenous dosing or blood sampling, the catheter was 
flushed with 0.2 mL heparin-saline (10 I.U./mL). The blood samples were 
centrifuged; the plasma was collected and stored at -80 °C. The study design of this 
pharmacokinetic study was a slight modification of our recent study. 
 
Pharmacokinetic calculation 
The pharmacokinetic parameters were calculated using the non-compartmental 
model with the software WinNolin standard version 1.0 (Scientific Consulting Inc., 
Apex, NC). The area under the plasma concentration of ginsenosides Vs time curve 
(AUC0→t) for rats who received the ginsenosides intravenously was calculated using 
the linear trapezoidal rule with the time points 0 to the last point with a logarithmic 
scale. Clearance (CI) values of ginsenosides were calculated using non-
compartmental methods as CI= dose/ AUC0→t. Statistical analyses were performed 
using GraphPad Prism Version 3.03. All experimental values were reported as mean ± 
SD. 
 
4.4 Results and discussion 
4.4.1 LC method development  
During preliminary HPLC-ESI-MS/MS method development, different 
combinations of 0.1% formic acid in water and 0.1% formic acid in acetonitrile were 
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attempted.  Mobile phase comprising 0.1% formic acid in water and 0.1% formic acid 
in acetonitrile were reported to give better separation and ionization of ginsenosides.
 
Based on peak shape and resolution of ginsenosides Rh4, Rk3 and 20(S)-Rg3 (IS), it 
was confirmed that mobile phase comprising 0.1% formic acid in water and 0.1% 
formic acid in acetonitrile yielded the required separation with good resolution among 
the three ginsenosides in less than 10 min. 
This was achieved by the enhanced separation using a 2.7 µm particle size and 
with a shorter length (50 mm). Isocratic elution with 0.1 % formic acid in water and 
0.1% formic acid in acetonitrile in the ratio of 56:44 (A:B) for 12 min with the flow 
rate of 0.4 mL/min was optimized for the analyses. Gradient elution gave similar 
separation and resolution to that given by isocratic elution. However, gradient elution 
required more analysis time as it required extra equilibration time between two runs. 
Therefore, isocratic elution with blank runs after every five samples (to eliminate any 
carry over) was employed. Although ginsenosides Rh4 and Rk3 were structural 
isomers, they were well separated and eluted at 7.39 and 6.51 min respectively. The 





                                                                                                                                                  
Figure 4.1 LC-ESI-MS/MS chromatograms for (A) A blank plasma, (B) A blank 
plasma spiked with internal standard 20(S)-Rg3, (C) A blank pooled plasma spiked 
with 10 ng/ mL of ginsenosides  Rh4 (RT: 6.51 min) and Rk3 (RT: 7.29 min) 
 
 
4.4.2 ESI-MS/MS method development  
Both positive and negative ionization mode were tested.  It was found that the 
ES- mode of ginsenosides afforded the higher sensitivity. Our data concurred with the 
previous studies (Toh et al., 2010; Chan et al., 2007; Cui et al., 2001; Miao et al., 
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2002; Liu et al., 2004) that negative ESI mode provided greater ionization for the 
ginsenosides but positive ionization offered more structural information.
 
In negative 
ionization mode, 665.6 [M+HCOO]
¯





were most prevalent for ginsenosides Rh4 and Rk3 because of the use of formic 
acid (Figure 4.2). Comparatively, positive ionization gave 643.7 [M+Na]
+ 
 adduct ion 







 that arose from fragmentation (Figure 4.2).  




in negative mode was much more than 
that of 643.7 [M+Na]
+  
from the positive mode. Therefore, negative ionization mode 
was chosen for further optimization. Auto product ion scan by syringe infusion for 
quantitative analysis gave m/z of 665.3 as base peak ion with product ions of m/z of 
45.0, 619.3, 58.9, 101.0 and 160.9 in descending order of ion intensity. Based on 
these product ions, 665.3→619.3, 665.3→101.0, 665.3→58.9, 665.3→45.0 
transitions were tested to determine the selectivity and sensitivity. However, from 
these transitions, desired sensitivity (LOQ~ 10ng/mL) could not be achieved. All of 
these transitions gave LOQ ~ 50 ng/mL. Although, the transition 665.3→45.0, yielded 
higher sensitivity (LOQ ~ 5 ng/mL), it was not suitable as the m/z ratio of 45.0 is too 
low and there could be interferences from the mobile phase or other components of 





Figure 4.2 Mass spectrum of ginsenoside Rk3 in full scan mode (100-1000 amu) (A) 
positive ESI mode, (B) negative ESI mode 
 
 
Furthermore, additional attempts to perform manual variation of different 
parameters such as collision energy (CE) did not give any MRM transition for higher 
sensitivity. Therefore, MIM of m/z of 665.3 in Q1 and Q3 was attempted at lower CE 
(15-20). The MIM of 665.3 was found to possess good sensitivity (LOQ ~ 10 ng/mL). 
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In addition, no interference from the plasma was observed at the retention times of the 
three ginsenosides.  Therefore, the MIM of 665.3 in Q1 and Q3 was chosen for the 
quantification of ginsenosides in PK samples whereas the MRM transition of 665.0 
[M+HCOO]
 ¯→619.0 [M-H] ¯ was used as a qualifier. Similarly, for ginsenoside 
20(S)-Rg3, MIM of 829.2 in Q1 and Q3 and MRM transition 829.0→783.0 were 





respectively for ginsenoside 20(S)-Rg3. 
 
4.4.3 Method validation  
The high selectivity of the assay was demonstrated by absence of interfering 
peaks in the blank pooled plasma samples, pre-dosing samples or in post-dosing 
samples at the retention times of ginsenosides and the internal standard. The average 
matrix factor near LOQ obtained by evaluating the matrix effect near LOQ in seven 
individual rats for ginsenoside Rh4 (20 ng/mL) and Rk3 (20 ng/mL) were 0.92 ± 0.03 
(RSD= 3.8%) and 0.93 ± 0.02 (RSD= 2.6%) respectively, implying minimal ion 
suppression. The calibration curves for ginsenosides Rh4 and Rk3 were obtained on 
five consecutive days by spiking their standard solutions. Table 4.1 summarizes the 
data for the linearity and LLOQ. The RSDs of intra- and inter-day precision of all QC 
samples were ≤ 8.2 for ginsenoside Rh4 and ≤ 10.1 for ginsenoside Rk3 (Table 4.2 
and 4.3).     
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The accuracy of the developed method was found to be satisfactory as the 
percentage deviations of the QC samples from the nominal concentration were all 
within the acceptable limit of ± 10% for the two ginsenosides (Table 4.2 and 4.3). The 
absolute recoveries or extraction efficiency of the two ginsenosides were consistent 
(RSD values: 1.6-10.1%) and were more than 80% (Table 4.2 and 4.3).The results of 
stability studies under different conditions have shown that the two ginsenosides are 
stable at all tested storage and handling conditions (Table 4.4). 
 
Table 4.4 Stability of Rk3 and Rh4
a 
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4.8 
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4.4.4 Pharmacokinetic profiles of ginsenosides Rh4 and Rk3 
The above validated LC- MS/MS method was used to determine the 
pharmacokinetic profiles of ginsenosides Rh4 and Rk3 in Sprague-Dawley rats. 
Figure 4.3 shows the LC-MS/MS chromatograms of plasma analysed from rats after 
five hours of intravenous administration of ginsenosides Rh4 and Rk3. The 
intravenous pharmacokinetic profiles of ginsenosides Rh4 and Rk3 are shown in 
Figure 4.4.  
 
Figure 4.3 LC-ESI-MS/MS chromatograms (A) Ginsenoside Rh4 in a plasma sample 
taken from rat after 5 hours of being dosed intravenously with 5 mg kg
-1 
(B)  
Ginsenoside Rk3 in a plasma sample taken from rat after 5 hours of being dosed 




































































Figure 4.4 Plasma concentration versus time profiles of ginsenosides in rats after 
receiving a single intravenous administration of 5 mg/kg of (A) ginsenoside Rh4 (n=3) 
and (B) ginsenoside Rk3 (n=3) 
 
Plasma concentration of ginsenosides Rh4 and Rk3 declined rapidly over first 
30 min. and detectable concentrations were measured until 5 hours after the single 
intravenous injection (5 mg/kg). Both of them had abundant plasma exposure. For the 
ginsenoside Rh4, moderate apparent volume of distribution (V = 1223.8 ± 785.1 
mL.kg
-1
) was found. Comparatively, low apparent volume of distribution ((V = 236.4 
± 88.6 mL.kg
-1









 was observed for ginsenosides Rh4 
and Rk3 respectively. Likewise, moderate terminal half-lives of 157.2 ± 65.2 min and 
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99.5 ± 37.8 min were also observed for ginsenosides Rh4 and Rk3 respectively. The 
major pharmacokinetic parameters after single intravenous injection are shown in 
Table 4.5.  








) 5 5 
A (µg·mL
-1
) 5.7 ± 4.8 2.3 ± 0.7 
B (ng·mL
-1
) 199.1 ± 184.0 294.6 ± 96.8 
 (10-1min-1) 1.0 ± 0.5 1.7 ± 0.4 
 (10-3min-1) 7.6 ± 4.3 8.8 ± 2.5 
Vc (mL·kg
-1
) 1223.8 ± 785.1 236.4 ± 88.6 
AUC0→last (10





) 50.2 ± 7.7 23.8 ± 1.4 
t1/2 Z (min) 157.2 ± 65.2 99.5 ± 37.8 
MTT0→last (min) 32.6 ± 5.7 19.1 ± 2.6 
a 
Results are presented as mean ± SD, n = 3 
 
However, no detectable concentrations were observed after single oral gavage 
(20 mg/kg) for both ginsenosides. This indicated a poor bioavailability of Rh4 and 
Rk3. Similarly, low bioavailability (< 5%) has been reported with other ginsenosides. 
(Qi et al., 2011; Yu et al., 2012a; Li et al., 2007; Xie et al., 2005; Qian et al., 2005; 
Sun et al., 2005; Lai et al., 2009; Liu et al., 2009). The oral bioavailability (the F 
values of ginsenosides) Ra3, Rb1, and Rd ranged from 0.1 to 0.2%, whereas those of 
ginsenosides Re, Rg1, and notoginsenoside R1 were 0.2–0.6% after oral 
administration of P. notoginseng extract to rats (Liu et al., 2009). Extensive 
metabolism in the gastrointestinal tract, poor membrane permeability and low 
solubility limit the oral bioavailability of ginsenosides. (Tawab et al., 2003; Cai et al., 
2003; Liu et al., 2009; Gu et al., 2009).  
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The ginsenosides are reported to be extensively metabolised by intestinal 
bacteria (Qi et al., 2011; Yu et al., 2012a). Deglycosylation reactions by intestinal 
bacteria in the form of stepwise cleavage of sugar moieties is proposed as the major 
metabolic pathway (Tawab et al., 2003; Liu et al., 2009; Hasegawa et al., 2004). 
Ginsenosides Rb1 and Rd are reported to be metabolized into compound K whereas 
ginsenosides Rg3 and Rg5 are reported to be converted to ginsenosides Rh2 and Rh3 
respectively (Qiang et al., 2006; Yang et al., 2007b; Bae et al., 2002; Shin et al., 
2006). Furthermore, it is also reported that in rat stomach, ginsenoside Rg1 gets 
hydrolysed into 20(R/S)-ginsenosides Rh1 and 20(R/S)-25,26-hydrated ginsenosides 
(Odani et al., 1983). However, the intestinal absorption of the major ginsenosides 
from the orally administered P. notoginseng extract was poor, mainly because of low 
membrane permeability rather than the aqueous solubility or transporter-mediated 
intestinal efflux (Liu et al., 2009). 
Poor membrane permeability of ginsenosides is attributed to their 
physicochemical properties (Yu et al., 2012a) which include high molecular weight (> 
500 Da), higher capacity for hydrogen-binding (> 12) and higher molecular flexibility 
(> 10). Optimum balance of the above mentioned properties are required to increase 
the membrane permeability. In the case of ginsenosides Rh1, Rh2, F1, compound K, 
20(S)-protopanaxadiol and 20(S)-protopanaxatriol, reduction in number of sugar 
moieties will reduce the hydrogen binding capacity and molecular flexibility. 
However, it will also reduce their aqueous solubility (Yu et al., 2012a). In this study, 
due to the limited supplies of Rh4 and Rk3, we only orally administered the 
ginsenosides at 20 mg/kg. Higher dose of Rh4 and Rk3 could lead to greater systemic 
exposure. In a previous study, after oral administration of  total Panax notoginseng 
saponins (TPNS) at the dose of 300.0 mg/kg, the absolute bioavailabilities of 
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notoginsenosides R1, Rg1, Rd, Re and Rb1 were 9.29%, 6.06%, 2.36%, 7.06% and 
1.18%, respectively (Li et al., 2007).  
High oral doses might saturate the metabolism and hence might increase the 
bioavailability (Qi et al., 2011). However, even at such high doses, the bioavailability 
was less than 10 % (Li et al., 2007). Modulating the solubility and/or dissolution of 
ginsenosides might be a strategy to improve the oral bioavailability. Micronization of 
ginsenoside Rh2 doubled its bioavailability (Gu et al., 2009).
 
Therefore, innovative 
dosage form might improve the bioavailability of Rh4 and Rk4. The results of this 
study also indicated that although Rh4 and Rk3 possessed moderate clearances and 
terminal elimination half-lives, it may not be possible to achieve the desired effective 
concentration in vivo. Higher dose might be required to achieve effective in vivo 
concentrations even after I.V. administration. This presents additional challenge for 
their clinical use. Nevertheless, the data on their synergistic actions on the 
doxorubicin are promising. Ginsenosides (particularly Rk1 and Rk3) were found to 
increase the anti-proliferative activity of doxorubicin at lower concentrations (Section 
3.4.3, Chapter 3). Therefore, the effectiveness of ginsenosides in combination 
treatment for future clinical use should be further investigated.  
 
4.5 Conclusion 
A reliable LC/MS/MS method was developed and validated for the 
quantification of Rh4 and Rk3 in rat plasma to study their pharmacokinetic profiles in 
Sprague-Dawley rats. The findings of this study provided important information for 







Analysis of adverse events reports 
associated with the use of complementary 
medicine and health supplements  
 
5.1 Introduction 
As discussed in the Section 1.1, with increased usage of complementary and 
alternative medicine (CAM), in particular herbal medicine and health supplements, 
there are growing concerns regarding their safety. Many factors such as the inherent 
toxicity, misidentification, contamination, adulteration, herb-drug interactions, herb-
herb interactions, abuse and over-use of herbal supplements can affect the safety of 
herbal medicines and hence may result in adverse events (Mosihuzzaman and 
Choudhary, 2008; Woolf, 2006; Van Breemen et al., 2008; Stickel et al., 2005).  
Some of these factors have been previously discussed in the Section 1.2. Toxicities 
such as hepatic toxicity, cardiac toxicity, nephrotoxicity, carcinogenicity, hematologic 
toxicity, idiosyncratic reactions and severe allergic reactions of some plants used in 
herbal medicine have been reported (Tovar and Petzel, 2009; Willet et al., 2004). 
Moreover, CAM and health supplements are not as stringently regulated as western 
pharmaceuticals and sometimes adverse events and product recalls related to such 
products are encountered.  
According to the WHO-Uppsala Monitoring Centre (Glossary of terms, WHO-
UMC), an adverse event is “any untoward medical occurrence that may present during 
treatment with a pharmaceutical product but which does not necessarily have a causal 
relationship with this treatment.” In the EU Directive 2010/84, which will become 
applicable in July 2012, an adverse reaction is defined as “a response to a medicinal 
103 
 
product which is noxious and unintended (Glossary of terms, WHO-UMC). An 
adverse drug reaction (ADR), contrary to an adverse event (AE), is characterized by 
the suspicion of a causal relationship between the drug and the occurrence (Glossary 
of terms, WHO-UMC). The science and activities relating to the detection, 
assessment, understanding and prevention of adverse effects or any other drug related 
problem is called as pharmacovigilance (Glossary of terms, WHO-UMC). 
The main objective of pharmacovigilance is the detection of adverse events 
related to the use of medicines that are unknown or new in terms of their clinical 
nature, severity or frequency. This requires the search for preliminary signals of 
adverse events. The WHO-UMC defines a signal as „reported information on a 
possible causal relationship between an adverse event and a drug, the relationship 
being unknown or incompletely documented previously (Glossary of terms, WHO-
UMC). Usually more than a single report is required to detect a signal, depending on 
the seriousness of the event and the quality of the information. It has been reported 
that surveillance systems used to detect adverse events due to herbs are often 
inadequate, detecting less than 1% of all events, thus adverse events due to herbs are 
still vastly under-reported (Walker, 2000).  
Various methods used for the pharmacovigilance of medicine include 
spontaneous reporting of adverse events, data from the pre-clinical and clinical studies, 
prescription event monitoring, large automated data resources on morbidity and drug 
use, observational epidemiological studies such as case-control surveillance and 
follow-up studies (Meyboom et al., 1997; Kaufman et al., 2001; Lindquist et al., 
2001; Waller and Lee, 1999; Hartmann et al., 1999). Among these methods, 
spontaneous reporting of adverse events is the most frequently used and efficient 
method to identify various signals for the monitoring of drug safety (Meyboom et al., 
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1997; Kaufman et al., 2001; Lindquist et al., 2001; Waller and Lee, 1999; Hartmann 
et al., 1999). 
Using an international or national database of reported adverse events is an 
effective tool for the surveillance of adverse events associated with the use of herbal 
medicine (Saokaew et al., 2011). Therefore, national databases such as the Singapore 
pharmacovigilance database of adverse events can be used to identify signals and 
trends of adverse events associated with the use of herbal products. 
 
5.2 Objective 
The objective of this study is to collate and analyze adverse events reports 
associated with the use of complementary medicine and health supplements submitted 
to the Health Sciences Authority of Singapore for the period 1998-2009 to identify 
various trends and signals for pharmacovigilance purposes. 
 
5.3 Methods 
5.3.1 Source of data 
The Vigilance Branch of HSA in Singapore uses a number of post-marketing 
risk assessment approaches to ensure the continued safe use of health products 
(Health Products Regulation, HSA). These include mandatory reporting from 
pharmaceutical manufacturers, spontaneous reporting from health professionals, 
literature reviews and the exchange of regulatory information with other national drug 
regulatory bodies. Reports of adverse events are submitted to the Vigilance Branch of 
the Health Sciences Authority (HSA) in Singapore using the form shown in Fig. 5.1. 
It contains fields for information such as patient‟s details, reporter‟s details, and 
details of adverse event, suspected health product and other relevant information 




              Figure 5.1 Suspected adverse event reporting form used in Singapore 
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The reports can also be submitted by email, fax or mail or electronically 
through the Critical Medical Information Store component of Electronic Medical 
Record Exchange. The Critical Medical Information Store serves as an online 
database of medical alerts, adverse drug reactions and drug allergy data. At present, 
the Electronic Medical Record Exchange is only confined to individual hospitals. 
However, the Ministry of Health is developing the Electronic Health Record which 
will enable sharing of vital medical information among hospitals and government 
clinics across Singapore. All the submitted forms are reviewed by trained regulatory 
specialists of the Vigilance Branch who are pharmacists by training (Health Products 
Regulation, HSA).  
The submitted reports are individually reviewed with particular attention paid 
to the serious cases that resulted in death, require inpatient hospitalization, or 
prolongation of existing hospitalization, result in persistent or significant 
disability/incapacity or are life-threatening according to WHO definition. The 
information is then entered into the national database for use in aggregate analysis. As 
a member of the WHO International Drug Monitoring Programme, these reports are 
submitted to the Uppsala Monitoring Centre in Sweden for collation into the World 
Bank of Adverse Drug Reactions.  
 
5.3.2 Data collection and analyses 
 The adverse event reports reviewed by the Vigilance Branch at HSA for the 
period 1998 – 2009 involving complementary medicine and health supplements were 
collated and analyzed. For the purpose of this study, such products will be referred to 
as CAM products and are further divided into three groups, namely CPM, other 
complementary medicine (traditional medicines other than CPM, e.g., Malay 
traditional medicine, Indonesian traditional medicine or Jamu, Indian traditional 
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medicine or Ayurvedic medicine, homeopathic medicine etc.) and health supplements. 
The World Health Organisation-Uppsala Monitoring Centre organization system for 
standardized case causality assessment is used. Only reports with causality terms 
“certain”, “probable” and “possible” were included in our analysis. 
 From these reports, the following information was extracted and collated on 
Microsoft ® Excel files: age, gender and ethnicity of patient, type and indication of 
CAM products, organ system affected, seriousness of the adverse event, route of 
administration, hospitalization status and outcome of adverse event, concomitant use 
of conventional drugs, testing for adulteration, and profession of the reporter. Adverse 
reaction terminology developed by World Health Organization (WHO-ART) is used 
to categorize reported adverse events into different system-organ classes (SOC) (The 
WHO Adverse Reaction Terminology). More than one adverse reaction terms may be 
described in an adverse event report. 
Hospitalization due to adverse event was categorized into hospitalized, not 
hospitalized, and already hospitalized. The term “Already hospitalized” describes the 
group of patients who were admitted for other co-morbidities when the adverse event 
was detected. The outcomes of the adverse events associated with the use of CAM 
products were also analyzed by categorizing them into four categories as patients who 
recovered, not yet recovered at the point of reporting, had uncertain outcome, and 
died. Other drugs consumed by patient at the same time and/or 3 months before at the 
time report were made were also extracted and considered as concomitant medication. 
To determine the likely cause of the adverse event, some of the products 
implicated were sent to the Pharmaceutical Division of HSA to test for the presence of 
drug adulterants and toxic heavy metals. Results of all the products which were sent 
for testing during the study period were also collated. From the products which were 
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found to contain adulterants, information on the type and frequency of adulterants was 
extracted and complied. All of the above variables were analyzed using descriptive 
statistics. No patient identifiers were available on the extracted information supplied 
to the researchers. 
 
5.4 Results and discussion 
A total of 16 696 adverse event reports (inclusive of all conventional 
medicines, complementary medicines and cosmetics) were received by HSA in the 
period 1998 – 2009 (Table 5.1). Of these, 627 (3.8%) reports involved CAM products 
(Table 5.1).  
 
Table 5.1 Type and number of cases of adverse events involving CAM products 
(CPM, other complementary medicines and health supplements) and the total number 
of cases of adverse events (involving conventional medicine, CAM products and 
cosmetics) for the period 1998-2009 


















1998 4 1 0 5 319 
1999 3 0 0 3 497 
2000 2 0 0 2 439 
2001 4 0 0 4 627 
2002 23 3 10 36 850 
2003 16 3 15 34 1115 
2004 21 10 23 54 1152 
2005 25 11 16 52 1185 
2006 18 4 7 29 1923 
2007 9 3 7 19 1719 
2008 37 222 12 271 3155 
2009 26 80 12 118 3715 




Most of these 627 cases (80.2%) were found to be serious according to the 
assessment of the Vigilance branch (Fig. 5.2). Further grouping of CAM products into 
three categories as CPMs, other complementary medicines, and health supplements 
(Table 5.1) showed that CPMs alone were implicated in 30% of the cases while other 
types of complementary medicines were implicated in 53.5% of the cases. Table 5.2 
shows the patient demographics (gender, age group, and ethnicity) and profession of 
the reporters.  
 
Figure 5.2 Total number of adverse event reports due to CAM products for the period 
1998 – 2009. The secondary axis shows the percentage (%) of these cases which were 
considered serious. 
 
The majority of patients were Chinese, followed by Malays, and Indians. Most 
of the reports were made by doctors and pharmacists. From the analysis of 
information on concomitant medication, it was found that there were only 85 (13.6%) 
patients who took both CAM products and concomitant conventional drugs during the 
study period. The remaining 542 (86.4%) patients were not reported to consume any 
conventional medicine concomitantly. 
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Table 5.2 Patient demographics and profession of reporters 
 
Characteristics No. of cases (n=627) 
from 1998 to 2009 
Percentage (%) 
Gender   
Female 213 34 
Male 414 66 
Age   
< 1 7 1.1 
1-20 27 4.3 
21-40 172 27.4 
41-60 235 37.5 





Ethnicity   
Chinese 443 70.7 
Malay 86 13.7 
Indian 49 7.8 





Profession of reporter   
Doctor 582 92.8 
Pharmacist 40 6.4 
Manufacturer 4 0.7 











5.4.1 Indications and routes of administration 
The indications of the CAM products implicated in the adverse event are 
shown in Table 5.3.  
Table 5.3 Indications of CAM products implicated in adverse events 
Indications of CAM and health supplements Number of cases Percentage (%) 
Sexual performance enhancement 291 46.4 
Pain 36 5.7 
Skin problem 4 0.6 
Gastrointestinal problem 10 1.6 
Respiratory problem 6 1.0 
Endocrine disorders like diabetes and menstrual 
disorder 
4 0.6 
Urinary problem 5 0.8 
Heart and circulatory problem 5 0.8 
Cerebral disorder 1 0.2 
Liver and bile system problem 1 0.2 
Others for example, alopecia, antioxidant etc. 34 5.4 
Slimming 27 4.3 
Information not available 203 32.4 
Total 627 100 
 
 
Of the 627 cases of adverse events, most of the patients used CAM products 
for sexual performance enhancement (291, 46.4%), to relieve pain such as joint and 
neck pain (36, 5.9%), and for slimming purposes (27, 4.3%). The indications of 203 
(32.4%) CAM products implicated were not available. A total of 314 products 
(50.1%) were taken orally as powders, capsules, or tablets while two (0.3%) products 
were topically administered. However, in 311 (49.6%) cases, information on the route 




5.4.2 Adverse events grouped according to system organ class classification 
Table 5.4 shows the classification of the adverse events into different system 
organ class (SOC) involved according to the WHO-ART classification. This Table 
also shows the most commonly reported ADR term in each SOC group. From the 627 
reports, there were 1456 different adverse events reported. Endocrine disorders 
(22.5%) and central and peripheral nervous system disorders (20.6) were the most 
commonly reported adverse events.  
In 47.5% of the cases of endocrine disorders (156 out of 328 cases), patients 
suffered from severe hypoglycemia along with central and peripheral nervous system 
disorders and/or psychiatric disorders such as drowsiness, confusion, abnormal mental 
state, loss of consciousness, and coma. They were associated with the use of CAM 
products claimed to enhance the sexual performance in men. Serious adverse events 
during the study period included severe hypoglycemia with coma (16 cases), hepatic 
failure (15 cases), Stevens-Johnson syndrome (10 cases), shock (four cases), acute 
renal failure (three cases), and one case each of anaphylaxis, exfoliative dermatitis, 











Table 5.4 Adverse events associated with the use of CAM products classified by 
System Organ Class (SOC) according to WHO Adverse Reaction Terminology 
(WHO-ART) 
 
No. SOC involved n Most frequently reported adverse reaction 
terms (n) 
1. Endocrine disorders 328 Hypoglycemia (288), Cushing‟s syndrome 
(17), adrenal insufficiency (6) 
 
2. Central and peripheral nervous 
system disorders 
300 Unconsciousness (98), drowsiness (80), 
giddiness (36), Coma (16) 
 
3. Body as a whole - general 
disorders 
175 Lethargy (23), fever (19), diaphoresis (17) 
 
4. Liver and biliary system 
disorders 
155 Jaundice (38), hepatitis (34), increased liver 
enzymes (27), Hepatic failure (15) 
 
5. Skin and appendages disorders 132 Rash (26), urticaria (15), maculopapular rash 
(12), Stevens-Johnson syndrome (10) 
 
6. Gastro-intestinal system 
disorders 
99 Vomiting (20), Nausea (14),  Abdominal pain 
(13) 
 
7. Psychiatric disorders 89 Confusion (23), abnormal mental state (20), 
Insomnia (8) 
 
8. Urinary system disorders 40 Acute renal failure (11), urine discolouration 
(11), urine incontinence (6) 
 
9. Respiratory system disorders 25 Shortness of breath (6), wheeze (5), 
Respiratory failure (3) 
 
10. Metabolic and nutritional 
disorders 
22 Hypokalaemia (6), hyponatraemia (4), 
Diabetes mellitus (2) 
 
11. Heart rate and rhythm 
disorders 
19 Palpitations (14), tachycardia (5) 
12. Cardiovascular disorders, 
general 
17 Hypotension (5), hypertension (4), Septic 
shock (4) 
 
13. Platelet, bleeding and clotting 
disorders 
13 Coagulation disorder (5), Thrombocytopenia 
(4), Increased prothombin time (2) 
 
14. White cell and 
reticuloendothelial system 
disorders 
11 Eosinophilia (3), Leucopenia (2), 
Pancytopenia (2)  
 
15. Musculo-skeletal system 
disorders 





No. System Organ Class (SOC) 
involved in adverse event 
n Most frequently reported adverse reaction 
terms (n) 
16. Red blood cells disorders 6 Anaemia (4), Haemolysis (1), 
Methamoglobinemia (1) 
17. Reproductive disorders, female 4 Hypo menorrhea (1), hyper menorrhea (1), 
postmenopausal bleeding (1) 
18. Vascular (extracardiac) 
disorders 
4 Vasculitis (2), stroke (1), subdural 
haemorrhage (1) 
19. Myo-, endo-, peripheral and 
valve disorders 
3 Myocardial infarction (1), myocarditis (1), 
endocarditis (1) 
20. Vision disorders 3 Blurred vision (2),  Blindness (1) 
21. Collagen disorder 1 Systemic lupus erythematosus (1) 
22. Hearing and vestibular 
disorders 
1 Tinnitus (1) 
23. Neoplasms 1 Hepatocellular carcinoma (1) 
 Total 1456  
 
 
5.4.3 Hospitalization and outcomes of the adverse events 
Among a total of 627 cases, 450 (71.8%) patients were hospitalized due to the 
adverse events. 118 (18.8%) patients were not hospitalized and 34 (5.4%) patients 
were already hospitalized at the point of reporting. However, in 25 (4.0%) cases, 
information on hospitalization was not available. Analysis of the outcomes of the 
adverse events associated with the use of CAM products showed that 359 (57.3%) 
patients had recovered at the time the reports were made while 246 (39.2%) patients 
were either not yet recovered (170, 27.1%) or had uncertain outcome (76, 12.1%). 
The treatment provided to the patients may not have been revealed to HSA in the 




Hepatotoxicity was responsible for the deaths of 10 patients. In 2008 alone, 
there were 12 cases of death where 9 cases were due to unknown illegal sexual 
performance enhancement products, and the patients encountered severe 
hypoglycaemia before they died. 
 
5.4.4 Adulterations 
For the period 2002 – 2009, 160 (25.5%) products out of the 627 CAM 
products were sent for testing (Table 5.5).  
Table 5.5 Number and percentage of implicated CAM products sent for testing for 
adulterations 
Year Number of AE cases 
involving 
complementary 
medicine and Health 
supplements 
Number and 
percentage (%) of 
AE products that 
were sent for 
testing 
Number and 
percentage (%) of 
those sent for testing 
and found to contain 
adulterants 
1998 5 - - 
1999 3 - - 
2000 2 - - 
2001 4 - - 
2002 36 17 (47.2) 15 (88.2) 
2003 34 10 (29.4) 5 (50) 
2004 54 7( 12.9) 2 (28.6) 
2005 52 26 (50) 12 (46.2) 
2006 29 18 (62.1) 4 (22.2) 
2007 19 9 (47.4) 2 (22.2) 
2008 271 43 (15.9) 20 (46.5) 
2009 118 30 (25.4) 12 (40.0) 




Of these, 72 (45%) products were found to be adulterated with drug 
adulterants while in 88 (55%) products, common adulterants were not detected. For 
the period 1998 – 2001, no products were sent for testing. The remaining 467 (74.5%) 
products were not sent for testing and hence it was not known whether they were 
adulterated or not. Table 5.6 shows the different types of adulterants found in tested 
products. It also shows the frequency of each adulterant in products tested. The top 10 
drug adulterants found, in decreasing order of frequency, include sildenafil and 
analogues, dexamethasone, N-nitrosofenfluramine, chlorpheniramine, 
phenylbutazone, glibenclamide, paracetamol, sibutramine, indomethacin, and 
prednisolone. Out of 72 products found to be adulterated, 44 products were 
adulterated with more than one adulterant, 17 products had 2 adulterants each, 20 
products had 3 adulterants each, while 6 products had 4 adulterants each. Two 
products, namely Pil Setelan (a Jamu) and Hu Luo Jing Dan (a CPM) were found to 
contain five adulterants (amidopyrone, chlorpheniramine, dipyrone, paracetamol, and 
phenylbutazone) and three adulterants (dexamethasone, indomethacin, and 
prednisolone), respectively.  
In 2002, 13 cases involved an adulterated slimming product named “Slim 10”. 
Those 13 patients had symptoms of hyperthyroidism like palpitations, sweating, or 
signs of hepatotoxicity such as raised liver enzymes and jaundice. One patient 
eventually died because of liver failure. This product was found to be adulterated with 
fenfluramine, N-nitrosofenfluramine and thyroid gland preparations (HSA, 2002; Lau 
et al., 2004). The number of adverse events surged in 2008 and 2009 due to the cases 
involving adulterated sexual performance enhancement products, for example, “ 
Power 1 Walnut ” (41 cases), “ Santi Bovine Penis Erecting Capsule ” (three cases), “ 
117 
 
Zhong Hua Niu Bian ” (eight cases) and other unknown illegal sexual enhancement 
products (158 cases).  
Table 5.6 List of different adulterants found to be present in implicated CAM and 
health supplements products 
Adulterants detected Number of cases 





















Tetracyclines antibiotic 1 
 
The known products were found to contain sildenafil as well as glibenclamide, 
the latter at concentrations of up to five times the maximum dose taken by diabetics. 
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This caused the consumers to experience symptoms of hypoglycemia such as 
giddiness, weakness and unconsciousness and in some cases death.  
The majority of cases in 2008 (158 from total of 271) and 2009 (66 from total 
of 118) involved unknown sexual performance enhancement products without 
complete information such as type of product, indication, and route of administration. 
These patients denied that they took any supplement but glibenclamide of unknown 
origin was found in their blood. As the occurrence and clinical presentations were 
similar to other patients who took adulterated sexual performance enhancement 
products, therefore, in this study, these cases were grouped into other types of 
complementary medicines as unknown illegal sexual performance enhancement 
products. These were the suspected cases whereby traces of glibenclamide were 
detected in the blood/urine.  
In this study, two of the implicated products were also found to contain toxic 
heavy metals (mercury and lead) above the Singapore legal permissible limits. In 
2006, one of the products implicated was “Endopile” which was a traditional Indian 
medicine for the treatment of hemorrhoids. This product was found to contain lead at 
more than 100 times the permissible limits (limit is 20 ppm) and mercury at 8 times 
the permissible limits (limit is 0.5 ppm). A press release was issued to alert the public 
to this harmful product (HSA, 2006). 
This study presents the analyses and describes the pattern of adverse event 
reports associated with the use of CAM products during a 12-year period. There was 
an upward trend in the number of adverse event reports in Singapore. This may be 
attributed in part to the increasing popularity of CAM and apparent increase in 
adulteration with undeclared drugs. Other reasons include efforts by HSA to promote 
greater public awareness and adverse event reporting. Although cases due to CAM 
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products only comprised 3.8% of the total number of cases, this is higher than the 
corresponding number (Jacobsson et al., 2009; Farah et al., 2000) in Sweden (1.2%) 
and WHO database of adverse drug reactions (0.5%, during 1968 – 1997). However, 
in China (Zhang et al., 2012b), 13.8% of the total reports were associated with use of 
TCM. Furthermore, a majority of the cases reported in this study were serious and 
3.5% of suspected cases had a fatal outcome. Therefore, adverse events due to CAM 
products should not be taken lightly because with their increased use, the number of 
adverse events may also increase. It was also seen that CPMs and Chinese patients 
were more commonly implicated in adverse events than other CAM products and 
ethnic groups. This may be due to higher usage of CPM by the Chinese population 
which comprised about 77% of the total population of Singapore. 
 According to the National Centre of Complementary and Alternative 
Medicine (NCCAM, 2008), 28.2% of the population in the United States used 
complementary medicine for the purpose of controlling back, joint, and neck pain. In 
our study, most of these implicated products were used for sexual performance 
enhancement (46.4%) and only 5.9% were used to alleviate pain. However, a direct 
comparison cannot be made because the Singapore data is gathered only from the 
adverse event reports and the indications of many products (32.4%) were unknown. In 
contrast to previously reported studies where more reports involved women 
(Jacobsson et al., 2009; Farah et al., 2000; Saokaew et al., 2011), in this study, more 
men than women were involved. This could be attributed to higher consumption of 
illegal sexual performance enhance products by men in Singapore during the study 
period. 
In the WHO adverse drug reaction database (Farah et al., 2000), skin reactions 
were the most frequently reported adverse events associated with the use of herbal 
120 
 
medicines. In Sweden over a 20-year period, skin and hypersensitivity reactions (e.g., 
urticaria, exanthema and contact dermatitis) were the most prevalent CAM-related 
adverse events (Jacobsson et al., 2009). Likewise in Italy (Menniti-Ippolito et al., 
2008), between 2002 and 2007, skin disorders, gastrointestinal disorders, and 
psychiatric disorders were the most frequently reported. In Thailand (Saokaew et al., 
2011), gastro-intestinal problems were the most common adverse event reported in a 
total of 593 adverse events related to herbal products. In comparison to the above 
studies, because of the higher consumption of adulterated unknown illegal sexual 
performance enhancement products (particularly in year 2008 and 2009), the majority 
of adverse events in this study involved endocrine disorders and central and peripheral 
nervous system disorders.  
Increasing numbers of reports of adulteration with undeclared drugs and/or 
their synthetic analogues and contaminants such as heavy metals, pesticides, 
microorganisms, and microbial toxins products had been reported and was of serious 
concern for the regulatory authorities (Koh and Woo, 2000; Chan, 2003; Li et al., 
2009b; Low et al., 2009). In this study, the adulteration of CAM with conventional 
medicine appears to be one of the causes of the associated adverse events. Common 
adulterants were found to be drugs associated with the specific indications of the 
products. For example, products used for pain and inflammation management were 
usually adulterated with non-steroidal anti- inflammatory drugs and steroids. This is 
very dangerous as long term usage of non-steroidal anti-inflammatory drugs may be 
associated with an increased risk of cardiovascular side effects such as myocardial 
infarction and stroke while long term usage of steroids can lead to Cushing‟s 
syndrome such as thinning of skin, muscle wasting, easy bruising, and osteoporosis.  
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Products used for slimming such as “Slim10” were adulterated with 
fenfluramine, N-nitrosofenfluramine, and thyroid gland preparations. Drug 
preparations containing fenfluramine and dexfenfluramine were withdrawn from the 
Singapore market in response to reports of heart valve problems from the US Food 
and Drug Administration (US FDA) in 1997 (Ministry of Health, 1997). 
Nitrosofenfluramine, which is an analogue of fenfluramine, can cause serious 
hepatotoxicity (Nakagawa et al., 2006; Satoh et al., 2006). From the year 2000 to 
2002, more than 800 clinical cases of serious hepatic injury with necrosis were 
reported in Japan in patients taking Chinese dietary supplements adulterated with N-
nitrosofenfluramine for weight loss (Nakagawa et al., 2006; Satoh et al., 2006). Most, 
except for the few patients who died, recovered after the consumption of the 
supplements was stopped.  
Products used for sexual performance enhancement were found to be 
adulterated with sildenafil and glibenclamide. Both are prescription drugs and should 
only be taken under the supervision of a doctor. Undeclared sildenafil may interact 
with some prescription drugs (e.g., nitrates) and may lower blood pressure to 
dangerous levels. Interestingly, the presence of glibenclamide, an anti-diabetic drug, 
in the sexual performance enhancement products remains unexplained. The possible 
reasons could be contamination or mixing up of ingredients during manufacturing. 
This posed a challenge for authorities to take appropriate action to alert the public 
about unsafe products which they should avoid and to ban the implicated products in 
the market. The surge in cases of adverse events associated with the use of adulterated 
sexual performance enhancement products led HSA to conduct a study to evaluate the 
extent of adulteration of health products seized from red-light districts in Singapore 
(Low et al., 2009). Of the 175 products seized and evaluated in seven raids, 134 
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(77%) were found to be adulterated with drugs or their analogues (Low et al., 2009). 
Hence, consumers taking adulterated illegal sexual performance enhancement 
products and slimming products may be at higher risks compared to those taking other 
kinds of CAM products. This further highlights the importance of greater public 
awareness of the danger of consuming such products.  
In view that not all of these products were sent for testing as not all the 
products were available, the number of cases involving drug adulterants could have 
been higher than expected if screening was conducted. For the products which were 
sent for testing but not found to be adulterated, the exact causes of the adverse events 
are not known. Patients might have experienced adverse reactions due to allergies or 
improper usage of products. However, one of the most serious safety concerns for 
botanicals and their derived products is the potential intrinsic toxicity.  
In this study, liver was the main organ affected by the adverse events. In 
previously reported analysis of 31 patients with drug induced liver injury in 
Singapore, CAM was the most common medication implicated in 22 (71%) patients 
(Wai et al., 2007; Wai, 2006). Nine of 31 products analyzed from 17 of these patients 
were found to contain adulterants (Wai et al., 2007). Causative agents for the 
remaining products were largely unknown (Wai et al., 2007).  One possible reason for 
the liver toxicity was that most of the products were orally ingested and liver is the 
major organ for drug metabolism. Thus the liver is at a high risk for drug-induced 
hepatotoxicity. Several reports and reviews on the involvement of botanicals and 
botanical health products in drug induced liver injury had been published. Botanicals 
containing pyrrolizidine alkaloids, Germander (Teucrium chamaedrys), Piper 
methysticum (Kava), pennyroyal oil, Rhubarb, and Senna were reported to be 
involved in hepatotoxicity (Ernst, 1998; Chitturi and Farrell, 2008; Stickel et al., 
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2005; Pittler and Ernst, 2003). Therefore, besides screening for adulterants, other 
measures to assess toxicity are also necessary.  
Concomitant drug administration often makes the causality assessment for 
adverse events more complicated because it is difficult to distinguish the actual 
causative agent. In a study conducted on 316 cancer patients in Singapore, 25% of 
patients reported concurrent use of oral CAM products with chemotherapy (Chow et 
al., 2010). However, oncologists were unaware of the use of CAM in 86% of cases 
(Chow et al., 2010). It was also possible that sometimes, health care providers were 
not aware that herbal products could cause adverse events (Meyboom et al., 2002; 
Egberts, 2007). In the current study, 13.6% patients reported concomitant 
consumption of both conventional drugs and CAM products. Concurrent use of CAM 
products with conventional medicine could result in herb – drug interactions which 
may cause potentially dangerous adverse events (Hu et al., 2005). Therefore, open 
and effective communication between patients and their doctors should be established 
to avoid such situations. 
In this study, reports of adverse events were examined retrospectively. 
Information on indications of CAM products, route of administration, hospitalization, 
types of treatment provided, and other relevant information regarding the patients ‟ 
medical condition were often not included by the reporter in the report. This may 
happen if the reporters or patients were reluctant to divulge sensitive medical 
information. Also, in many cases, the exact herbal ingredients were not described or a 
sample of the CAM product was not available for testing. As such, it was not possible 
to determine whether the product may contain ingredients that were intrinsically toxic, 
without carrying out toxicity tests. The adverse events might also be due to the 
concomitant drugs taken or due to the adulterants in the products. Therefore, a causal 
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relationship cannot be confidently drawn. Moreover, under reporting might be 
possible because many patients did not inform their healthcare providers that they 
were using herbal medicine.  
Under-reporting is an unavoidable limitation of spontaneous reporting 
especially in the case of herbal medicine since patients usually do not inform their 
doctors about adverse events and do not seek professional advice before using them 
(Barnes, 2003). In a study conducted in the United States, 72% had not informed their 
healthcare providers about their CAM use (Eisenberg et al., 1993). Nevertheless, 
spontaneous reporting of adverse event is an important tool because resources to 
conduct large scale post-marketing surveillance studies of herbal medicine may be 
limited (Barnes, 2003).   
Regulatory authorities should also encourage healthcare professionals to report 
adverse events by implementing user-friendly reporting systems. Any safety signals 
arising from clustering of adverse events related to specific products should also be 
disseminated effectively to healthcare professionals and the public using mass media 
such as television, newspaper, and internet. These actions help to raise the awareness 
of potential safety issues and also promote the reporting of similar cases to aid further 
investigations by regulatory authorities. Health authorities should also step up 
enforcement by taking legal punitive actions against offenders found guilty of selling 
illegal and adulterated products. Healthcare professionals should encourage patients to 
disclose the use of CAM, allowing the detection of potential drug- herb interactions, 
or source of adverse events. They should also follow-up on the adverse events 
reported and be more vigilant in detecting them. Most importantly, the perception that 
natural is equivalent to risk free should be corrected and a qualified practitioner 




In conclusion, 627 adverse event reports associated with CAM products had 
been successfully analyzed and described. They constituted 3.8% of the total number 
of adverse events reported from 1998 to 2009. Outbreaks of severe hypoglycaemia in 
2008 and 2009 were associated with the use of adulterated and illegal sexual 
performance enhancement products. The liver was the main organ affected in serious 
adverse events. Further work to confirm the hepatotoxicity of implicated CAM 
products is warranted. Reporting of suspected adverse events is strongly encouraged 
even if the causality is not confirmed because any signs of clustering will allow rapid 
regulatory actions to be taken. The analysis of spontaneously reported adverse events 
is an important surveillance system in monitoring the safety of CAM products and 





























Chemical analyses of the botanical health 




As discussed in the Chapter 1, there are reports of botanical health products 
implicated in adverse events such as DILI. In some cases, this has been attributed to 
poor quality control measures and adulteration or contamination. Hence, it is very 
important to monitor the chemical composition of botanicals and botanical health 
products to safeguard the patient safety. Additional problems with these products 
include botanical misidentification, product contamination or deliberate adulteration, 
mislabeling and variability in the collection and extraction processes adopted, and 
lack of active compound stability. This complicates our understanding of many 
aspects of botanical health products usage, from the basic understanding of what 
exactly is being ingested, to the interpretation of clinical efficacy, to the monitoring of 
adverse events (Willett et al., 2004). Therefore it is very important have various 
chemical analysis methods which could help to ensure the safety of botanicals and 
their derived products.  
 
6.2 Objective 
The objective of this study is to perform chemical analyses of 15 botanical 
health products implicated in DILI to identify potential toxic components using 









6.3.1.1 Materials and reagents  
15 products implicated in DILI were obtained from the Vigilance branch of 
HSA. The complete list is shown below: 
1. Slim10 
2. Merit 
3. Anti-constipation Capsules 
4. Intra 
5. Hydroxycut 
6. Control Plus 
7. TCM pill-5 
8. TCM pill-3 
9. SCM powder 
10. Unlabelled powder 
11. Andrographis Antiphlogistic Capsules 
12. Bo Ying Compound 
13. Vitiligo Tabs 
14. Lipid Health Tablets 
15. Houzao Zhenzhu Babao Jingfengsan 
 
 The solvents used for fractionation of extracts were of analytical grades, while 
the solvents used for the HPLC were of HPLC grade. HPLC grade methanol and 
acetonitrile were purchased from Tedia Company (Fairfield, OH, USA). The water 
was treated with Milli-Q water purification system (Millipore, Bedford, USA). The 
analytical grade (ACS) hexane, dichloromethane and methanol were purchased from 
the Tedia Company (Fairfield, OH, USA). Silica gel 60 (63-200 µm, 70-230 mesh) 
for column chromatography, and TLC aluminum sheets precoated with silica gel 60 
(layer thickness 0.2 mm, 20 x 20 cm) were purchased from Merck KGaA (Darmstadt, 
Germany). Reference standards psoralen, α-asarone, chrysophanol, emodin, 
paracetamol, caffeine and hydroxymethyl furfural were obtained from Sigma-Aldrich, 
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Singapore. β-asarone was obtained from Karl-Roth, Germany. Rheine, aloe-emodin 
and physcion were purchased from Nature Standards, Shanghai, China. 
 
6.3.1.2 Methods 




Figure 6.1 Schematic diagram of overall methodology 
 
 
6.3.1.2.1 Sample preparation for screening for toxic components 
For capsules, tablets, pills or powder: 20 mL of methanol was added to 1 g of finely 
ground botanical health product samples. These mixtures were then subjected to 
ultrasonication (230 V, Branson model 5510, Danbury, CT, USA) for 20 min. This 
was repeated 3 times. The filtrates were combined and evaporated to dryness by a 
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rotary evaporator. The residue was dissolved in 4-6 mL of methanol and filtered with 
a 0.45 µm membrane filter for HPLC and GC–MS analysis. For syrup and liquid: 20 
mL of methanol was added to 1 g of samples. It was then subjected to ultrasonication 
for 20 min. This was repeated 3 times. The filtrates were combined and centrifuged 
(4000 rpm, 5 min). After centrifugation, the supernatants were decanted and 
evaporated to dryness by a rotary evaporator. The residue was dissolved in 5 mL of 
methanol and filtered with a 0.45 µm membrane filter for HPLC and GC–MS 
analysis. 
 
6.3.1.2.2 Chemical analyses by high performance liquid chromatography 
An Agilent 1100 liquid chromatograph equipped with quaternary gradient 
pump, autosampler and DAD was used. System control, data acquisition and process, 
and auto-library search were performed using software of Agilent ChemStation for 
LC 3D. A HP Lichrosorb reversed phase (RP C18, 200 x 4.6 mm
2
), 10 µm (particle 
size) column was used. Gradient elution (acetonitrile: phosphate buffer) was 
performed as follows: Solvent A, sodium dihydrogen phosphate buffer (25 mM, pH-
3.2); solvent B, acetonitrile; step gradient was from 10% to 30% of B over 10 min, 
then to 50% of B over another 10 min, and finally to 70% of B over 10 min and 
maintained for another 5 min. Total chromatography duration was 35 min. The 
equilibration time between two consecutive injections was set at 5 min (total cycle 
time 40 min). The flow-rate of mobile phase was 1 mL/min. Injection volume was 10 
mL. The detection wavelengths were set at 203, 210, 220, 254 and 280 nm. The 
ultraviolet (UV) spectra from 190 to 400 nm were recorded on-line during the 
chromatographic run. Unknown UV data were compared with those in the in house 
library. Library match factors of UV spectra were automatically calculated for each 
peak and a score of 1000 represents a perfect match.  
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In house library of the UV spectra of 266 standard drugs was used to identify 
the presence of undeclared conventional drugs (if any) in the implicated botanical 
health products. Only those compounds, which have been identified by library search 
(UV spectra comparison) and with less than 15% difference in their RT compared to 
that of corresponding library data, are considered. The UV library match indicated 
how closely the unknown spectrum matched the library data. Match of 1000 indicated 
identical spectra and those below 900 indicated a different one. A peak identification 
result with a library match above 950 could be considered as identification with good 
certainty.  
 
6.3.1.2.3 Chemical analyses by gas chromatography-mass spectrometry 
Shimadzu gas chromatography-mass spectrometry (GC-MS) (Shimadzu, 
gc2010 and qp2010 MS, Japan) and/or Agilent gas chromatography-mass 
spectrometry (Agilent 7980 GC-MS) was used. A DB-5MS column of film thickness 
0.25 μm, length 30.0 m and diameter 0.25 mm was used with the carrier gas (helium) 
set at 1 mL/min. A 1.0 µl volume of the sample was injected using the splitless mode. 
The data acquisition system was controlled by MS ChemStation. Full scan mass 
spectra were collected between 50 and 550 amu at 1.53 scan s
-1
. The MS was operated 
in the electrospray ionization mode. The initial oven temperature was set at 80°C. It 
was then increased to 300°C at 10°C/min. The final temperature of 300°C was held 
for 10 min. The total running time was 32 min. The injection volume was 1 µl. The 
Wiley standard chemical MS library, NIST library and spectra of reference standards 





6.3.1.2.4 Chemical analyses by liquid chromatography-mass spectrometry 
analysis of product “Merit” 
An Agilent 1200 series HPLC chromatography coupled with an Agilent 6210 
Accurate-Mass Time-of-Flight (TOF) MS (Santa Clara, CA, US) with electrosray 
ionization (ESI) in negative ionization mode (LC-ESI-MS/TOF) was used to identify 
anthraquinone glycosides in “Merit”. The fragmentor was set to 225 V. Nebulizer 
pressure was set to 60 psi. Drying gas flow and temperature were set to 5 L/min and 
325 ˚C respectively. Scan range was m/z 50–1000. Hypersil™ ODS column (150 X 
2.1 mm, 5 µm) from Thermo Fisher Scientific was used for the separation. The 
injection volume was 5 µl. Data acquisition was performed on MassHunter 
workstation software (Version A.02.02) from Agilent Technologies (Santa Clara, CA, 
US). Gradient elution was performed as follows: Solvent A, water with 0.1 % formic 
acid; solvent B, acetonitrile with 0.1 % formic acid; step gradient was from 12 % to 
40% of B over 23 min, 60% of B over next 3 min, then to 75 % of B for next 4 min 
and finally to 90 % of B over 3 min and maintained for another 7 min. Total 
chromatography duration was 40 min. The equilibration time between two 
consecutive injections was set at 5 min (total cycle time 45 min). The flow-rate of 
mobile phase was 0.4 mL/min.  
 
6.3.1.2.5 Hydrolysis of methanol extracts of products suspected to contain 
anthraquinone glycosides 
40 mg of methanol extract was hydrolysed using 35 mL of 6N hydrochloric 
acid under reflux at 80
0 
C for two hours. Then the reaction mixture was extracted 
using ethyl acetate (3 X 50 mL). The ethyl acetate fractions wee combined and 
washed with 150 of water and then dried under vacuum. The residues were 
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reconstituted in 10 mL of HPLC methanol. The sample was finally filtered through 
0.45 µm filter before being analyzed by HPLC. 
 
6.3.1.2.6 Fractionation of methanol extract of Control Plus 
The methanol extract of Control Plus was subjected to normal phase open-
column chromatography (Silica gel 60, 63-200 µm, 70-230 mesh). 270 mg of extracts 
was applied to column and gradient elution using different compositions of hexane, 
dichloromethane (DCM) and methanol was employed. The separation was carried out 
using 300 mL of hexane, followed by 500 mL of dichloromethane, then 300 mL of 
1 % methanol in DCM, followed by 500 mL of 10 % methanol in DCM and 300 mL 
of 20% methanol in DCM. Finally the column was washed with 300 mL of 50 % 
methanol in DCM, followed by 100 % methanol. Each time 20 mL of eluent was 
collected in a test tube. The collected fractions were analyzed using the same HPLC 
conditions as described earlier From the HPLC chromatograms, further combinations 
of similar fractions containing the peaks of interests were carried out. 
 
6.3.1.2.7 Fractionation of methanol extract of Merit 
The methanol extract of Merit was subjected to normal phase open-column 
chromatography (Silica gel 60, 63-200 µm, 70-230 mesh). 350 mg of extracts was 
applied to column and gradient elution using different compositions of hexane, 
dichloromethane (DCM) and methanol was employed. The separation was carried out 
using 300 mL of hexane, followed by 500 mL of dichloromethane, then 300 mL of 
1 % methanol in DCM, followed by 300 mL of 4 % methanol in DCM and 300 mL of 
20% methanol in DCM. Finally, the column was washed with 200 mL of 100 % 
methanol. Each time 20 mL of eluent was collected in a test tube. The collected 
fractions were analyzed using the same HPLC conditions as described earlier From 
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the HPLC chromatograms, further combinations of similar fractions containing the 
peaks of interests were carried out. 
 
6.3.1.2.8 Analysis of fractions of methanol extracts of Merit and Control Plus 
using High performance liquid chromatography 
An Agilent 1100 liquid chromatograph equipped with quaternary gradient 
pump, autosampler and DAD was used. A Phenomenex Luna C18(2) (150 x 2.0 mm), 
5 µm (particle size) column was used. Gradient elution was performed as follows: 
Solvent A, water with 0.1 % formic acid; solvent B, acetonitrile with 0.1 % formic 
acid; step gradient was from 12 % to 40% of B over 23 min, 60% of B over next 3 
min, then to 75 % of B for next 4 min and finally to 90 % of B over 3 min and 
maintained for another 7 min. Total chromatography duration was 40 min. The 
equilibration time between two consecutive injections was set at 5 min (total cycle 
time 45 min). The flow-rate of mobile phase was 0.4 mL/min. Injection volume was 5 
µl. The detection wavelengths were set at 220, 254 and 280 nm. 
 
6.3.1.2.9 Synthesis of N-nitrosofenfluramine 
The synthesis was performed in the Carcinogen Laboratory of Health Sciences 
Authority, Singapore. The following procedure was used for the synthesis: 0.6 g of 
fenfluramine and 2.5 g sodium nitrite were dissolved in 50ml of distilled water 
separately. The two solutions were cooled at 4
˚
C for 30 mins.  After which the two 
solutions were mixed and acidified with dilute hydrochloric acid.   The mixture was 
allowed to stand at 4
˚
C for 20 hours. The mixture was then extracted with chloroform 




6.3.2 Results and discussion 
The main compounds detected by chemical analysis using GC-MS and HPLC analysis of methanol extracts of implicated botanical health 
products are summarized in Table 6.1 
 
Table 6.1 List of compounds detected by chemical analysis and the details of adverse event 
No. Sample Intended Use Compounds identified by HPLC and GC-MS Details of adverse events 
 
1. Slim10 Slimming N-nitrosofenfluramine, Fenfluramine, Niacinamide 13 cases, one death due to liver 
failure 
2. Merit Slimming Chrysophanol, Physcion , Aloe-emodin, Emodin, 
Rhein 





Reinforce energy and 
maintain strength 
Chrysophanol, Physcion, Emodin, Aloe-emodin, 
Rhein, 5-Hydroxymethylfurfural, 
Liver injury marked by raised liver 
enzymes 
4. Intra Balance and 
strengthen the body 
5-Hydroxymethylfurfural  hepatitis,  required liver transplant 
5. Hydroxycut Slimming Caffeine, unidentified pyrogallol like compound No adverse event in Singapore, 
voluntarily recalled by distributor 
6. Control Plus Slimming (-)Spathulenol, sesamine,  isosesamine,(-)asarinin Jaundice with liver dysfunction, 
coagulopathy 
7. TCM pill-5 Not stated - Hepatotoxic effect, jaundice 
8. TCM pill-3 Not stated 5-Hydroxymethylfurfural, unidentified pyrogallol 
like compound 
Hepatotoxic effect, jaundice 
135 
 
9. SCM powder Not stated α- asarone, β- asarone, 5-Hydroxymethylfurfural Hepatotoxic effect, jaundice 
10. Unlabelled 
Powder 
Not stated 5-Hydroxymethylfurfural, unidentified pyrogallol 
like compund, Coumarin 






Quinic acid, (-)-Loliolide Raised liver enzymes and worsening 
renal function 
12. Bo Ying 
Compound 
Common cold and 
fever 
α- asarone, β- asarone, 5-Hydroxymethylfurfural 3 month old baby, worsening acute 
liver failure 
13. Vitiligo Tabs Vitiligo Psoralene, Isopsoralene Hepatitis, jaundice 
Product purchased from internet 
14. Lipid Health 
Tablets 
Improve blood 
circulation and reduce 
blood lipids 
Chrysophanol, Physcion, Emodin, Aloe-emodin, 
Rhein, 5-Hydroxymethylfurfural  




Reduce fright, fever 
and vomiting 
Hesperidin , Borneol, Tangeretin (flavanoid 
compound) 
4 month old baby, Acute liver 
failure, required liver transplant 
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From the chemical analyses of implicated products by HPLC and GC-MS, 
potentially toxic components such as emodin, rhein, aloe-emodin, chrysophanol, 
physcion, hydroxymethylfurfural, cis-asarone (β-asarone), trans-asarone (α-asarone), 
psoralen, isopsoralen, were identified. The structures of potential toxic compounds 
identified are shown in Figure 6.2.  
 
 









Most of these compounds were confirmed to be present by concurrent 
analyses using the chemical standards. Product “Houzao Zhenzhu Babao Jingfengsan” 
was found to contain high concentrations of hesperidin and borneol. Similarly, 
product “Hydroxycut” was also found to contain high concentration of caffeine. All 
implicated were not found to be adulterated with conventional drugs. Therefore, 
detailed investigations to identify different components of the implicated products 
were performed. 
 
6.3.2.1 N-nitrosofenfluramine in Slim10 
The “Slim10” sample was reported to contain the hepatotoxin N-
nitrosofenfluramine previously (Lau et al., 2004) and therefore the product was 
withdrawn from the market. In order to confirm the presence of N-
nitrosofenfluramine in “Slim10” sample, N-nitrofenfluramine was synthesized and 
subsequently characterized by GC-MS. The mass spectrum of synthesized N-
nitrosofenfluramine is shown in Figure 6.3.  
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The GC-MS profile of synthesized N-nitrosofenfluramine was then compared 




Figure 6.4 Comparisons of gas chromatography chromatograms of (a) N-
nitrosofenfluramine in methanol and that of (b) methanol extract of “Slim10”. 
 
The results of GC-MS comparison confirmed that the “Slim10” sample used 
in this study contained N-nitrosofenfluramine. The Slim10 containing N-
nitrosofenfluramine was used as a positive control to evaluate hepatotoxic effects of 
implicated samples.  Exposure of hepatocytes to N-nitrosofenfluramine caused a 
concentration and time-dependent decrease in cell viability, accompanied by losses of 
intracellular ATP, adenine nucleotides, GSH, and protein thiols, and an increase in 





















6.3.2.2 5-Hydroxymethylfurfural and caffeine 
GC-MS analyses suggested the presence of 5-hydroxymethylfurfural in 
methanol extracts of products: Intra, Anti-constipation, TCM pill-3.  Of these samples, 
GC-MS and HPLC chromatograms of the sample “Intra” were indicating high 
concentration of 5-hydroxymethylfurfural. The presence of 5-hydroxymethylfurfural 
in these samples was subsequently confirmed by using the chemical standard 
purchased from Sigma Aldrich. The confirmation was based on the GC-MS and 
HPLC analysis of the samples along with the standard. Figure 6.5 shows the HPLC 
chromatograms of 5-hydroxymethylfurfural standard and implicated sample “Intra”. 
 











































Figure 6.5 Comparisons of HPLC chromatograms of (a) 5-hydroxymethylfurfural 
standard in methanol and (b) methanol extract of “Intra”. The inserts show the UV 
profiles of the labeled peaks (5-hydroxymethylfurfural). 
 
The amount of 5-hydroxymethylfurfural was quantified by HPLC method (as 
described in the Section 6.3.3.2). The same method was also used to quantify caffeine 
























*DAD1, 4.782 (230 mAU,Apx) Ref =2.975 of  15OCT003.D
 















results of method validation are presented in the tables 6.2 and 6.3. The results of 
validation suggest that this method is simple and reliable for the quantification of 
caffeine and 5-hydroxymethylfurfural in botanical health products. Upon 
quantification by the validated HPLC method, Intra was found to contain 0.10 ± 0.001 
mg of 5-hydroxymethylfurfural per mL.  
 
Table 6.2 Linear regression data for validation of HPLC method for quantification of 
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95.7 ± 2.31 
100.5 ± 1.23 

















92.3 ±  1.48 
100.7 ± 0.79 
100.1 ±  0.02 
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5-hydroxymethylfurfural is a common Maillard reaction product formed 
through the reactions between reducing sugars and amino acids during the heating of 
food (Janzowski et al., 2000). In an analytical screening of nearly 500 food samples, 
fairly high 5-hydroxymethylfurfural concentrations, exceeding 1 g/kg, have been 
found in products such as juice, dried fruits or caramel (Janzowski et al., 2000). It is 
not clear whether human exposure to 5-hydroxymethylfurfural present a potential 
health risk, since in vitro studies on genotoxicity/mutagenicity have given 
controversial results.  
Experiences in rats at high 5-hydroxymethylfurfural concentrations have 
shown cytotoxic effects, causing irritation to eyes, respiratory tract, skin and mucosa 
with an oral LD50 of 3.1 g/kg of rat body weight (Janzowski et al., 2000). 5-
hydroxymethylfurfural also depleted protective glutathione enzyme in primary rat 
hepatocyes (Janzowski et al., 2000).  Tumorigenic activities have also been associated 
with this compound, which acts as an initiator and a promoter of preneoplasic lesions, 
such as the colonic aberrant crypt or skin papillomas. It has been proposed that it is 
metabolically activated through the sulfonation of its allylic hydroxyl functional 
group, which can take place in the liver by hepatic sulfotransferase. The electrophilic 
intermediate obtained, 5-sulfooxymethylfurfural (SMF), can interact with critical 
cellular nucleophiles (e.g. DNA, RNA and proteins) resulting in structural damage 
which can lead to toxicity and mutagenicity (Janzowski et al., 2000; Monien et al., 
2009). 
However, the long term toxicity studies (National Toxicology Programme 
USA, 2008) showed weak indication of carcinogenicity except for the liver adenomas 
in female B6C3F1 mice. The relevance of such effects must be viewed as doubtful 
(Abraham et al., 2011). Therefore, the toxic potential of HMF is remains unclear. 
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A high concentration of caffeine in Hydroxycut
®
 was detected during the GC-
MS analysis. Therefore, caffeine was quantified by the validated HPLC method and 
found to be 93.3 ± 4.3 mg per tablet. While caffeine may not be a potential toxicant, it 
is a moderate CYP1A2 and CYP3A4 inhibitor and may trigger drug-drug interactions 
by interfering in the metabolism of another drug (Charles F. Lacy, 2009-2010). As 
there is no information on the label claim for this product, therefore it is difficult to 




6.3.2.3 Psoralen in methanol extract of Vitiligo Tabs  
Chemical analysis of product “Vitiligo Tabs” showed presence of 
furanocoumarin compounds, Psoralen and Isopsoralene. The presence of psoralen in 
“Vitiligo Tabs” was subsequently confirmed by using chemical standard of psoralen 
by GC-MS analysis. Figure 6.6 shows the comparison of GC-MS chromatograms of 
psoralen standard and methanol extract of product “Vitiligo Tabs”.  
Psoralens (or linear furanocoumarins) are photosensitising substances which 
acts through covalent interaction with DNA at specific wavelength (320-410 nm) to 
enhance skin sensibility by enhancing melanin production in the case of vitiligo (da 
Silva et al., 2009). However, there are reports of teratogenicity and carcinogenicity 
associated with use of furanocoumarins. Psoralens are also reported to cause hepatitis 
when taken orally (Bhargava and Bhargava, 1996; da Silva et al., 2009). Case reports 
of hepatotoxicity associated with the consumption of herbs containing 
furanocoumarins such as Psoraleae corylifolia can be found in literature (Cheung et 
al., 2009; Nam et al., 2005). Hepatotoxicity of furanocoumarins could results from 3-
hydroxylated derivatives and metabolites formed by furan ring rupture (da Silva et al., 
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2009). Upon oral administration, furanocoumarins undergo metabolization via 
CYP2A6 enzymes to give hydroxylation at position 3, 7 and 8 (Hadidi et al., 1997).  
 
 
Figure 6.6 Comparisons of GC-MS chromatograms of (a) Psoralen standard in 
methanol and (b) methanol extract of “Vitiligo Tabs”. 
 
These hydroxylated derivatives are proposed as the hepatotoxic metabolites of 






































product from the internet. Many of such products are offered on-line without 
providing sufficient information and advice for consumers on their safety and 
direction for appropriate use. Therefore, unsupervised consumption of this product 
containing potentially hepatotoxic components could be one of the reasons for the 
observed hepatitis. 
 
6.3.2.4  Hesperidin and borneol  
Chemical analyses of implicated baby product “Houzao Zhenzhu Babao 
Jingfengsan” suggested the presence of high concentrations of hesperidin and borneol. 
The presence of hesperidin in high concentration was further confirmed by concurrent 
analysis with the chemical standard of hesperidin in HPLC analysis. HPLC analysis 


















Figure 6.7 Comparisons of HPLC chromatograms of (a) hesperidin standard in 
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Hesperidin standard 





The presence of borneol was confirmed by GC-MS analysis using chemical 
standard of borneol. Borneol‟s peak could be observed during HPLC analysis as it 
lacks essential chromophore for UV absorption. In addition to hesperidin, GC-MS 
analysis also indicated the presence of flavanoid type compounds such as Tangeretin. 
Hesperidin and tangeretin, like most of the flavanoids, have not been associated with 
toxicity in literature. 
While most flavonoids/phenolics are considered safe, flavonoid/phenolic 
therapy or chemo preventive use needs to be assessed, as there have been reports of 
toxic flavonoid–drug interactions, liver failure, contact dermatitis, hemolytic anemia 
etc. associated with dietary flavonoid/phenolic consumption or exposure. Moreover, 
the patient in the relevant adverse event case is a baby who is only a few months old. 
The young liver may be too immature and therefore these compounds might have 
accumulated and resulted in liver toxicity. In addition, a study shows that borneol at 
higher concentrations could cause DNA damage to rat primary hepatocytes 
(Horvathova et al., 2009).   
 
6.3.2.5 Anthraquinones 
Chemical analysis by GC-MS and HPLC indicated presence of anthraquinones 
such as aloe-emodin, chrysophanol, emodin, rhein and physcion in three implicated 
samples (Merit, Anti-constipation capsules and Lipid Health Tabs). Figure 6.8 shows 
the GC-MS chromatograms anthraquinone standards and methanol extract of “Merit”. 
Analysis of UV profiles of different peaks during HPLC analysis of products Merit 
and Anti-constipation capsules indicated the possibility of presence of anthraquinone 
glycosides. Figure 6.9 shows the LC-MS-TOF chromatograms of methanol extract of 





Figure 6.8 GC-MS chromatograms of (a) methanol extract of “Merit” (b) aloe-






Figure 6.9 LC-MS/TOF chromatograms of (a) methanol extract of “Merit” (b) peaks 
corresponding to m/z of 431 (Emodin-8-glucoside) (c) peaks corresponding to m/z of 
445 (Rhein-8-glucoside) (d) peaks corresponding to m/z of 415 (Chrysophanol-8-
glucoside). Initially peaks were identified by screening for corresponding m/z ratios 
of glycosides. Peak at individual m/z ratios were then analyzed for the presence of 
distinct aglycone fragment ion, [M-H-Glc]
 ¯ 
and accurate mass to assign the glycoside 
peak. 
 
Anthraquinones occur in two different forms as anthraquinone aglycones and 
anthraquinone glycosides. Most commonly found anthraquinones in plants and their 
derived products are aloe-emodin, emodin, rhein, Chrysophanol, physcion and their 
glycosides. Anthraquinone glycosides Emodin-8 glucoside, chrysophanol-8-glucoside 
and rhein-8-glucosides were tentatively identified by LC-MS/TOF analysis. These 








Accurate mass: 445.0857 [M-H]
- 
Chrysophanol-8-glucoside 
Accurate mass: 415.1086 [M-H]
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of their corresponding aglycone moieties in the mass spectrum at 10.8, 12.2 and 19.5 
min respectively (Table 6.4).  
 




























C21H20O10 431.0978 10.8 431.1049 269.0488 
Rhein-8-
glucoside 
C21H18O11 445.0771 12.2 445.0857 283.0289 
Chrysophanol-8-
glucoside 
C21H20O9 415.1029 19.0 415.1086 253.0522 
 
To further confirm the presence of above anthraquinone glycosides, extracts of 
these two products were also hydrolyzed using 6N hydrochloric acid before HPLC 
analysis. Hydrolyzed extracts showed increase in the concentration of five 
anthraquinones, particularly in Merit. Similarly, hydrolyzed extract of rhubarb also 
showed increase in the concentration of five anthraquinones.  
This increased concentration of anthraquinones in hydrolyzed extracts is 
attributed to the loss of sugar moieties from anthraquinone glycosides upon 
hydrolysis. Upon hydrolysis, glycosides are converted to their respective aglycones 
and thereby increasing the concentration of five anthraquinones. Five anthraquinones, 
aloe-emodin, chrysophanol, emodin, physcion and rhein were quantified by HPLC 
(discussed in the Section 6.4). Methanol extract of product “Merit” was fractionated 




6.3.2.6 Fractionation of Methanol extract of Merit  
Figure 6.10 shows the representative chromatograms of the three main fractions of 




Figure 6.10 Comparison of HPLC chromatograms of three fractions of Merit: (a) 
fraction 1 (b) fraction 3 (c) fraction 2 and (d) its methanol extract. Fraction 1 is 
anthraquinone rich fraction. 
 
The methanol extract of Merit was further fractionated and pooled into three 
different fractions, which were labeled as fraction 1, 2 and 3. These pooled fractions 
were analyzed by HPLC to identify anthraquinone rich fraction. Fraction 1 of Merit 
was identified as the anthraquinones rich fraction. HPLC analysis of fraction-2 and 3 
suggested that these fractions were rich in anthraquinone glycosides. These fractions 
were screened for their cytotoxic effects against liver cells to identify potential toxic 
fractions and subsequently potentially toxic compounds. This is discussed in the 
Chapter 7.  
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(a). Fraction 1 
(b). Fraction 3 
(c). Fraction 2 
(d). MeOH 


















6.3.2.7 Fractionation of methanol extract of Control Plus 
The methanol extract of Control Plus was further fractionated and pooled into three 
different fractions, which were labeled as fraction 1, 2 and 3. These pooled fractions 
were analyzed by HPLC and GC-MS to identify potential toxic components. Figure 






Figure 6.11 Comparison of HPLC chromatograms of different fractions, (a) fraction 2, 
(b) fraction 1 and (c) methanol extract of Control plus (d) fraction 3 
 
The compounds present in these fractions could not be identified. Fractions 1 
and 2 are greenish oily liquid whereas the fraction-3 is light brown colour powder. 
These fractions were screened for their cytotoxic effects against liver cells in order to 
further identify potential toxic fractions and toxic compounds. This is discussed in 
Chapter 7.  
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(a). Fraction 2 
(b). Fraction 1 
(c). Methanol extract of Control Plus 
















6.3.2.8  α and β-asarones  
The GC-MS analysis of adverse event samples suggested the presence of α 
and β-asarone in two adverse event samples and one samples which was not 
implicated in adverse event, supplied by HSA, Bo Ying compound (implicated in 
adverse event in infant, not actual patient sample, but a product from a different 
batch), Pak Po Chen Chin Hong (not an adverse event sample) and SCM powder 
(adverse event sample). The presence of asarones was later confirmed by using 




Figure 6.12 GC-MS chromatograms of methanol extract of “Bo Ying Compound” in 
Selection ion monitoring mode (SIM). The methanol extract was found to contain β 
and α asarone 
 
Asarones are potentially toxic components. Hence, quantification of α and β-
asarone in implicated samples was carried out using new and validated GC-Ms 























6.4 Quantification of anthraquinones in selected samples implicated in adverse 
events using High Performance Liquid Chromatography 
6.4.1 Materials  
6.4.1.1 Samples 
Three botanical health products (Merit, Anti-constipation Capsules and Lipid 
Health Tabs) implicated in DILI were obtained from HSA. Sample of “Merit” from 
the non-implicated batch was also obtained from the Malaysia for comparison with 
the implicated batch of “Merit”. Similarly, sample of Anti-constipation Capsules was 
also obtained from the local market in Singapore. In addition, authentic herb Rhubarb 
(Rheum palmatum L.) was obtained from the National Institute for the Control of 
Pharmaceutical and Biological Products (NICPBP), China. 
 
6.4.1.2 Standard Preparation 
Stock solutions of aloe-emodin, chrysophanol, emodin, physcion and rhein 
were prepared at the concentrations of 0.4, 0.25, 0.5, 0.2, 0.25 mg/mL respectively in 
HPLC methanol. Stock solutions were stored at 24˚C in dark. Working solutions were 
diluted from the stock solutions with methanol. A structurally similar anthraquinone, 
1,8-dihydroxyanthraquinone was used as an internal standard. Stock solution of 
1mg/mL of internal standard was also prepared and stored in dark at 24˚C. 
 
6.4.1.3 Sample preparation 
100 mg of product or powdered plant material was extracted using 5 mL of 
HPLC methanol by ultrasonication for 15 min. This cycle was repeated for two more 
time. The extracts were filtered, combined and the final volume is adjusted to 15 mL. 




For comparison of extraction solvents, three different concentrations of 
methanol were used for extraction by ultrasonication. 70% methanol, 90% methanol 
and 100% methanol were used for extraction of rhubarb powder using method 
described above. For comparison of extraction time, the concentration which gave 
better extraction of anthraquinones was further compared with extraction method 
involving single extraction with same solvent for 30 min. Total peak area for all five 
anthraquinones was calculated for three different concentrations of methanol to find 
out best concentration for extraction.  
 
6.4.2 Methods 
6.4.2.1. HPLC method for quantitative analysis 
An Agilent 1200 liquid chromatograph equipped with quaternary gradient 
pump, autosampler and DAD was used. A Hypersil ODS (RP C18, 200 x 4.6 mm), 5 
µm (particle size) column was used. Gradient elution was performed as follows: 
Solvent A, water with 0.1 % formic acid; solvent B, acetonitrile with 0.1 % formic 
acid; step gradient was from 25 % to 50% of B over 8 min, 60% of B over next 2 min, 
then to 75 % of B for another 2 min and finally to 80% of B over 2 min and 
maintained for next 3 min. Total chromatography duration was 17 min. The 
equilibration time between two consecutive injections was set at 5 min (total cycle 
time 22 min). The flow-rate of mobile phase was 1.5 mL/min. Injection volume was 
10 µl. The detection wavelengths were set at, 254, 280 and 450 nm. 1,8-






6.4.2.2 Hydrolysis of anthraquinone glycosides 
Extract obtained from 100 mg of product was hydrolyzed using 30 mL of 6N 
hydrochloric acid under reflux at 80
0 
C for two hours. Then the reaction mixture was 
extracted using ethyl acetate (3 X 50 mL). The ethyl acetate fractions were combined 
and washed with 150 mL of water and then dried under vacuum. The residues were 
reconstituted in 10 mL of HPLC methanol. The sample was finally filtered through 
0.45 µm filter before being analyzed by HPLC. 
 
6.4.2.3 Method validation 
The mixed standard working solutions at each concentration were injected in 
triplicate. The calibration curves were constructed by plotting the ratio of peak areas 
of the anthraquinone standards to the peak area of internal standard against the 
corresponding concentration. The LOD and LOQ of HPLC-DAD detection were 
determined and calculated as the analyte concentrations with signal/noise ratios of 3 
and 10, respectively. Accuracy and precision of method were determined by analysing 
quality control (QC) samples at three concentrations (low, mid and high), representing 
the entire calibration range for each of the five anthraquinones. The intra-day (n = 6) 
and inter-day (n = 3) variations (intermediate precision) were evaluated by three 
replicate measurements of the QC samples of five studied compounds in a single day 
and on three different days, respectively. The recoveries of anthraquinones were 
determined by the standard addition method. Mixed standard solutions of aloe-emodin, 
chrysophanol, emodin, physcion and rhein at three different concentrations were 
added into a powder of rhubarb herb before extraction and were then analyzed in 
triplicate. Similarly, recoveries of anthraquinones were also studied by standard 
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addition method before extraction in “Merit” from non-implicated batch on single day 
and on three different days. The unspiked sample solution was concurrently analyzed.   
Stability of the stock solution after one week was also evaluated by comparing 
the peak area of QC samples prepared from the aged stock solution to that of a freshly 
prepared stock solution. Post preparative stability or auto-sampler stability of 
prepared QC samples was also evaluated by storing them for 48 hours at 24˚C in dark. 
 
6.4.3 Results and discussion 
6.4.3.1 Method development 
Ultrasonication is very powerful technique for extraction of plant material. 
Other methods such as refluxing and soxhlet were not used because of their own 
limitations. For example, refluxing required longer extraction time of at least 10 hours 
(Koyama et al., 2007). Soxhlet method may cause thermal degradation of components 
(He et al., 2009) and also requires longer extraction time. Therefore, ultrasonication is 
used for the extraction of anthraquinones. 
Choice of proper extraction solvent is a critical factor affecting the extraction 
efficiency. Previous studies (He et al., 2009; Koyama et al., 2007) have reported that 
aqueous methanol is better extraction solvents for extraction of anthraquinones. 
Therefore, different concentrations of aqueous methanol (70%, 90% and 100% 
methanol) were investigated for extraction. Furthermore, the solvent which gave 
better extraction was also compared for different volumes of solvents (30 mL and 40 
mL) in single extraction for 30 min. The effects of different solvents and extraction 





Table 6.5 Effects of different extraction solvents and extraction cycles on extraction 
of anthraquiones from rhubarb 
 
Solvent Extraction cycle Total peak area of 
anthraquinones ± S.D, n = 3 
 
70%  v/v Methanol 5 mL, three cycles each for 15 min 63.96 ± 0.01 
90%  v/v Methanol 5 mL, three cycles each for 15 min                 71.14 ± 0.92 
100%  Methanol 5 mL, three cycles each for 15 min 70.97 ± 0.62 
100%  Methanol 30 mL, single extraction for 30 min 52.93 ± 0.26 
100%  Methanol 40 mL, single extraction for 30 min 53.32 ± 0.38 
 
As can be seen from Table 6.5, 90% methanol and 100% methanol gave 
highest yield of anthraquinones when extracted with 5 mL of solvent for 15 min in 
three cycles. However, so significant difference could be found between these two 
solvents. Therefore, 100 % methanol was chosen as extraction solvent as it does not 
require any preparation and can directly used for analysis by GC-MS as well. 
Different composition of mobile phases such as acetonitrile and phosphate 
buffer (pH 3.2), acetonitrile and 0.1% acetic acid, acetonitrile and 0.1% formic acid, 
methanol and 0.1% formic acid, methanol and 0.1% phosphoric acid were compared 
for the separation of five anthraquinones and internal standard. Optimum mobile 
phase was selected based on resolution critical band pair of aloe-emodin and rhein and 
peak shape of anthraquinones.  
Different flow rates of 1 mL/min, 1.2 mL/min and 1.5 mL/min were also 
compared to have fast separation with sharp peaks of five anthraquinones. Gradient 
elution using 0.1% formic acid in water and acetonitrile with 0.1% formic acid with 
the flow rate of 1.5 mL/min was chosen as it was able to give good separation of all 
five anthraquinones and internal standard with sharp peaks. All five anthraquinones 
and an internal standard were separated in less than 16 min run time (Figure 6.13). 
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High flow rate of 1.5 mL/min was used instead of commonly used flow rate of 1 
mL/min to achieve fast separation and sharp peaks.  
This developed method has an advantage of faster separation with sharp peaks 
compared to previously reported HPLC methods (Liu et al., 1999; Qu et al., 2007; 
Koyma et al., 2007; Wang et al., 2008) which require longer analysis time (at least 25 
min). The problem of peak tailing during analysis of anthraquinones was resolved by 
the addition of formic acid into the mobile phase. If the pH of the eluent is not acidic, 
as is the case when pure water is used, these compounds will be ionized and elute near 
the dead time with broad peaks.  
 
 
Figure 6.13 HPLC chromatograms showing separation of mixed standards of aloe-
emodin (1), rhein (2), emodin (3), internal standard, 1,8-dihydroyanthraquinone (4), 
chrysophanol (5) and physcion (6) in methanol. All anthraquinones eluted between 
9.5 – 15.3 min with a very good resolution and symmetrical peak shapes without 
tailing.  
 
Furthermore, since all five anthraquinones are eluted after 9.5 min, this 
proposed method is more suitable for the analysis of multi-component herbal products 
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compared to previously reported methods (Liu et al., 1999; Qu et al., 2007; Koyma et 
al., 2007; Wang J et al., 2008) where anthraquinones eluted earlier. Multi-component 
herbal products often contain many polar compounds, which elute in early part of 
chromatogram and may interfere with the analysis of anthraquinones by HPLC. 
Therefore, delayed elution of anthraquinones is important to reduce the interference 
from other components present in the product. 
 
6.4.3.2 Method validation 
The developed HPLC method has been validated. The linearity data, 
concentration range, LOD and LOQ of five anthraquinones are presented in Table 6.6 
Analytical recoveries of QC samples for five anthraquinones are shown in Table 6.7 
Absolute recovery of analyzed anthraquinones (Table 6.8 and 6.9) was studied from 
the rhubarb herb as well from the product “Meritl” from the non-implicated batch. 
Because of limited availability of product “Merit” from the implicated batch, product 
from non-implicated batch was used for recovery or extraction efficiency studies. 
Table 6.10 shows the data for the stability of anthraquinones. 
 
Table 6.6 Linearity, concentration range, LOD and LOQ of aloe-emodin, 

















y = 0.0349x + 
0.0316 
0.9991 2.05-80 0.25 0.83 
2 Rhein 
y = 0.0198x + 
0.0117 
0.9994 1.28-50 0.12 0.40 
3 Emodin 
y = 0.0334x + 
0.0288 
0.9991 2.56-100 0.37 1.25 
4 Chrysophanol 
y = 0.0419x + 
0.0206 
0.9992 1.28-50 0.04 0.13 
5 Physcion 
y = 0.0206x + 
0.0044 
0.9990 1.02-40 0.08 0.27 
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Mean analytical recovery 
Intra-day (n=3) Inter-day (n=6) 









4.0 90.6 ± 0.7 0.74 93.9 ± 1.0 1.11 
16.4 107.9 ± 3.7 3.46 107.6 ± 3.8 3.47 
64.0 107.2 ± 1.2 1.12 108.5 ± 1.6 1.48 
2 Rhein 
2.6 90.6 ± 1.0 1.04 96.1 ± 1.6 1.64 
10.2 105.1 ± 2.3 2.28 105.2 ± 3.5 3.28 
40.0 107.2 ± 1.2 1.23 107.4 ± 5.1 4.79 
3 Emodin 
5.1 90.5 ± 0.1 0.12 90.8 ± 1.8 1.98 
20.5 106.6 ± 2.8 2.67 105.8 ± 3.5 3.32 
80.0 106.8 ± 1.3 1.24 105.6 ± 4.0 3.77 
4 Chrysophanol 
2.6 93.5 ± 0.1 0.08 99.3 ± 6.7 6.70 
10.2 107.2 ± 3.1 2.85 106.3 ± 3.6 3.38 
40.0 107.1 ± 1.3 1.21 109.8 ± 3.2 2.90 
5 Physcion 
2.0 95.1 ± 4.6 4.86 94.6 ± 6.9 6.86 
8.2 106.7 ± 2.6 2.47 105.1 ± 8.4 7.95 








Table 6.8 Absolute recoveries of aloe-emodin, chrysophanol, emodin, physcion and 





Mean recovery (n=3) 
% recovery ± SD RSD (%) 
1 Aloe-emodin 
0.165 97.6 ± 6.1 6.22 
0.410 106.3 ± 4.8 4.52 
0.640 101.2 ± 0.1 0.07 
2 Rhein 
0.105 107.6 ± 3.1 2.82 
0.256 104.8 ± 1.6 1.53 
0.400 104.4 ± 3.8 3.66 
3 Emodin 
0.150 92.3 ±  6.9 7.43 
0.500 92.0 ± 3.2 3.42 
0.800 108.9 ± 0.7 0.69 
4 Chrysophanol 
0.105 106.3 ± 4.1 3.90 
0.256 100.9 ± 2.4 2.43 
0.400 102.7 ± 7.3 7.07 
5 Physcion 
0.082 107.2 ± 4.5 4.16 
0.205 103.4 ± 8.1 7.83 









Table 6.9 Absolute recoveries of aloe-emodin, chrysophanol, emodin, physcion and 
















0.165 98.9 ± 4.8 4.88 96.4 ± 6.4 6.67 
0.410 108.7 ± 1.5 1.41 107.3 ± 3.2 2.94 
0.640 101.2 ± 0.2 0.19 101.2 ± 0.2 0.23 
2 Rhein 
0.105 107.8 ± 2.2 2.03 109.7 ± 4.2 3.80 
0.256 107.1 ± 0.7 0.61 105.8 ± 2.8 2.66 
0.400 107.1 ± 0.7 0.61 105.8 ±  2.8 2.66 
3 Emodin 
0.150 93.3 ± 6.0 4.66 89.8 ± 4.9 5.41 
0.500 92.4 ± 1.7 1.79 91.0 ± 2.7 2.96 
0.800 109.6 ±1.8 1.63 110.1 ± 1.9 1.75 
4 Chrysophanol 
0.105 107.3 ± 3.3 3.12 103.3 ± 8.2 7.92 
0.256 101.2 ± 1.8 1.82 99.0 ± 3.5 3.58 
0.400 103.7 ± 4.3 4.23 105.9 ± 6.4 6.03 
5 Physcion 
0.082 110.2 ± 1.4 1.03 110.0 ± 4.2 3.90 
0.205 93.1 ± 4.1 4.38 97.1 ± 8.6 8.92 












Stability of stock 




(% remained ± SD), 
 n = 3 
Post preparation 
stability after 48 
hours at 24 C
o  
(% remained ± SD),  
n = 3 
1 Aloe-emodin 
4.0 105.8 ± 0.6 91.0 ± 0.1 
16.4 102.1 ± 5.2 106.3 ± 3.6 
64.0 97.5 ± 7.1 106.5 ± 0.6 
2 Rhein 
2.6 95.0 ± 3.4 93.7 ± 1.4 
10.2 100.8 ± 7.9 103.9 ± 1.7 
40.0 98.7 ± 4.2 106.5 ± 0.7 
3 Emodin 
5.1 99.5 ± 4.7 90.5 ± 0.1 
20.5 99.7 ± 6.9 105.8 ± 3.5 
80.0 95.3 ± 6.8 107.5 ± 1.1 
4 Chrysophanol 
2.6 98.1 ± 7.2 93.5 ± 0.1 
10.2 99.9 ± 7.1 105.9 ± 2.9 
40.0 100.1 ± 3.1 106.4 ± 0.7 
5 Physcion 
2.0 96.9 ± 5.6 93.5 ± 5.3 
8.2 102.5 ± 6.5 105.7 ± 2.7 
32.0 99.6 ± 4.2 105.7 ± 0.7 
 
The calibration curves were found to have good linearity (R
2
 > 0.999). The 
RSDs of intra- and inter-day precision for five anthraquinone were 0.74 – 4.86 and 
1.11 – 7.95 respectively.  The accuracy of the developed method was found to be 
satisfactory as the percentage deviations of the QC samples from the nominal 
concentration were all within the acceptable limit of ± 10% for the all five 
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anthraquinones for recovery of anthraquinones from the rhubarb herb as well as 
product “Merit”. The absolute recoveries or extraction efficiency of all five 
anthraquinones from the herb as well the product “Merit” were all above 90%. The 
results of stability studies under different conditions have shown that the 
anthraquinones are stable at tested storage and handling conditions. 
The above optimization and method validation results show that the developed 
HPLC method is simple, sensitive, and reliable method with a high degree of 
specificity to simultaneously quantify five anthraquinones. In this method, 1, 8-
dihydroxy anthraquinone, a structurally similar compound was used as an internal 
standard, making this method more reliable for quantification purposes. This validated 
method was subsequently applied to quantify aloe-emodin, chrysophanol, emodin, 
physcion and rhein in botanical health products implicated in DILI and herb, R. 
Palmatum L. 
 
6.4.3.3 Quantification of anthraquinones 
Five anthraquinones were subsequently quantified in three implicated samples 
by the validated HPLC method. Since these products are labeled to contain herb Rhei 
Radix or rhubarb, quantification was also carried out in a rhubarb extract. Figure 6.14 
shows a chromatogram of methanol extract of “Merit” obtained using the optimized 
HPLC method for simultaneous quantification of five anthraquinones at a wavelength 





Figure 6.14 HPLC chromatograms of methanol extract of Merit (a) before and (b) 
after hydrolysis. 1. Aloe-emodin, 2. Rhein, 3. Emodin, 4. 1,8-dihydroxy 
anthraquinone (internal standard), 5.Chrysophanol  and 6. Physcion 
 
 
Anthraquinones are potentially genotoxic and mutagenic (Mueller et al., 
1998a; 1998b). In addition, in the literature, there are reports of hepatotoxic effects as 
well as hepatoprotective effects of anthraquinones and plants containing 
anthraquinones in in vitro and in vivo studies. There are reports of involvement of 
herbs containing anthraquinones in hepatotoxicity in humans (Ernst, 1998; Nadir et 
al., 2000; Pittler et al., 2003; Tian et al., 2008; Wang et al., 2009; 2011; Xu et al., 
2005; Zhang et al., 2004). For example, Rhubarb (Rheum palmatum L.) is reported to 
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have heptotoxic effects (Zhang et al., 2004; Xu et al., 2005; Tian et al., 2008; Wang 
et al., 2011; Wang et al., 2009 ). Furthermore, herbs, Radix Polygoni multiflori 
(Heshouwu in Chinese) and Radix Polygoni multiflori preparata (Zhiheshouwu in 
Chinese) were also reported to be implicated in adverse hepatic events in China and 
other countries (But et al., 1996; Park et al., 2001; Min et al., 2008; Cho et al., 2009).  
The most commonly reported adverse event was acute toxic hepatitis (Navarro and 
Senior, 2006; Murray et al., 2008). The consumption of herb Polygonum multiflorum 
was supervised by various drug regulatory authorities of countries such as Canada 
(Canadian Adverse Reaction Newsletter, 2003), Britain (Medicines and Healthcare 
Products Regulatory Agency, 2006a; b) and Australia (Therapeutic Goods 
Administration, 2008). These agencies have released press warnings to alert public 
regarding the hepatotoxic potential of this herb. In Australia, a requirement for a 
warning label “Warning: Polygonum multiflorum may harm the liver in some people” 
has been implemented on all the products containing this herb (Therapeutic Goods 
Administration, Australia, 2008). 
Continuous reports of adverse hepatic events related to Radix Polygoni 
multiflori  have led to the reduction (from 6-12 g to 3-6 g) of its daily recommended 
dose in latest edition of Chinese Pharmacopoeia (Commission of Chinese 
Pharmacopoeia, 2005b; 2010). Anthraquinones are believed to be responsible 
constituents for the hepatotoxicity of this herb. Recent studies reported that emodin 
and physcion could be responsible for the hepatoxicity of a herb Radix Polygoni 
multiflori (Yu J et al., 2011; Zhang et al., 2010). 
On the contrary, there are some reports where anthraquinones are reported to 
have liver protective effects in both in vitro and in vivo investigations (Ding et al., 
2008; Zhao et al., 2009). In animal studies, aloe-emodin pretreatment reduced the 
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acute liver injury induced by carbon tetrachloride in rats (Ding et al., 2008). 
Anthraquinones from rhubarb, including rhein, aloe-emodin and physcion, exhibited 
protective effects against alpha-naphthylisocyate induced damage in hepatocytes and 
cholangiocytes (Zhao et al., 2009). In the two years long term study in National 
Toxicology Programme, USA, emodin was not found to any have significant 
hepatotoxic effcts in mice and rats (National Toxicology Programme, 2001). In a 
recent study (Wang et al., 2011), dose-dependent alterations of liver fibrosis 
associated with increases in the fibrosis factor were clearly observed in the rats in the 
normal groups. Furthermore, at lower dosages (2.00 g/kg and 5.40 g/kg), rhubarb 
demonstrated some ameliorative effects on liver injury by decreasing the fibrosis 
caused by carbon tetrachloride. However, the fibrosis was aggravated rather than 
alleviated when the dosage was increased further (14.69 g/kg and 40.00 g/kg). This 
suggests that in addition to its hepatotoxic effects on control rats, its hepatoprotective 
effects in carbon tetrachloride treated rats diminish at higher dosage. The authors 
believed that the hepatotoxic potential of rhubarb is strongly related to liver fibrosis 
and warrants further investigation.  Hence, it is possible that herbs or compounds may 
exhibit both hepatotoxic or hepatoprotective effects. The exact determinant factors 
(e.g. dose, disease condition) need further investigations. 
Rhubarb contains a complex mixture of different hydroxyanthracene 
derivatives. The amount is 3 to 12 % depending on the method of determination. 
These hydroxyanthracene derivatives mainly (60 – 80 %) consist of mono- and 
diglycosides of 1,8-dihydroxyanthraquinones:  aloe emodin, chrysophanol, emodin, 
physcion and rhein, and only small amounts of the respective aglycones (European 
Medicines Agency, 2008). Table 6.11 shows the data of quantification of five 
anthraquinones in three implicated samples and rhubarb 
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According to the European Medicines Agency (EMEA) monograph, the 
recommended highest dose of anthraquinone (hydroxyanthracene glycosides and 
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aglycones) is 30 mg/day and any use for more than 1-2 weeks requires medical 
supervision. Side effects could also occur within the therapeutic dose (European 
Medicines Agency, 2008).  
Analysis of three products revealed that these products contain high contents 
of anthraquinones. In particular, the product Merit (patient sample) is found to contain 
29.5 mg per daily dose, which is close to the maximum allowable safe dose of 
anthraquinones. Therefore its long term usage could lead to unwanted adverse events.
 
Notably, comparison of two different batches of Merit also suggested that the product 
implicated (HSA ADR report reference no. 2006M0391) was found to contain > 50 
times higher than that of product from other batch (Batch no. 12180701 72), product 
was brought from Malaysia in 2009). In addition, the results also indicate that the 
amount of rhubarb in Merit (patient sample) is also more than 7 times than the labeled 
amount. 
These variations could be attributed to poor quality control measures such as 
substitution and/or adulteration with other herbs, non-uniform addition of herbs and 
variation in raw materials used. Quality, safety and efficacy are three inter-linked 
factors for all kinds of medicine. Therefore, quality control is very important for the 
regulation of herbal medicine and their products. From the analyses of Anti-
constipation Capsules batch-I (implicated) and batch-II (non-implicated), it was found 
that these products contain 13.3 and 10.3 mg/daily dose of anthraquinones 
respectively. Product Lipid Health Tablet was found to contain 0.74 mg/daily dose of 
anthraquinones. Therefore, in addition to anthraquinones, there could be other toxic 
components in products Anti-constipation Capsules and Lipid Health Tablets. Further 
work is required to identify other toxic components (if any) in these products.   
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 The developed method may also be used for the quality control of herbs and 
herbal products containing anthraquinones. The presence of high concentrations of 
anthraquinones coupled with poor quality control of botanical health products such as 
Merit warrant additional control measures to ensure patients‟ safety. 
 
6.5 Quantification of asarones in baby products using gas 
chromatography–mass spectrometry 
 
6.5.1 Materials  
6.5.1.1 Samples 
Authentic herb Rhizoma Acori tatarinowii was obtained from National 
Institute for the Control of Pharmaceutical and Biological Products (NICPBP), China. 
Seventeen botanical health supplements were purchased from local market (Appendix 
2). Three samples were supplied by HSA. The complete list of products analyzed is 
shown below: 
1 Mild Hot Cough San She Dan Chun Bei Mo 
2 Mild Cold Cough San She Dan Chen Pi Mo 
3 Zhen Zhu Chuan Bei Jing Feng San 
4 Cordyceps & Fritillaria Powder 
5 Babao Zhupo Wao San 
6 Zhupo Chuanbei Hou Zao San 
7 Fu Fang Chen Chu Ho Chou San 
8 Xiaoer Qingfeihuatan Keli 
9 She Tan Chuan Pei Chen Pi Mo 
10 Ban Kah Chai Hou Tsao San 
11 Mee Tao Chin Hong San 
12 Ban Kah Chai Serbuk Batuk 
13 Jing Feng powder 
14 Pai Pau Choo Pau Ying Tang 
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15 Zhenzu Pai Pao Chin Feng San 
16 Pearl & Amber Powder for Infantile 
17 Children Calming Granules 
18 Pak Po Chen Chu Chin Hong 
19 Houzao Zhenzhu Babao Jingfengsan 
20 Bo Ying Compound 
 
6.5.1.2 Preparation of standards 
Stock solutions of α and β-asarone were prepared at the concentrations of 1 
mg/mL respectively in HPLC grade methanol. Stock solutions were stored at 24˚C in 
dark. Working solutions were diluted from the stock solutions with methanol. A 
structurally similar compound, eugenol was used as an internal standard. Stock 
solution of 1mg/mL of internal standard was also prepared and stored in dark at 24˚C. 
 
6.5.1.3 Sample preparation 
100 mg of product or powdered plant material was extracted using 15 mL of 
HPLC grade methanol by ultrasonication for 15 min. The extracts were filtered and 
the final volume is adjusted to 15 mL. 1 mL of this extract was then filtered with a 
0.45 µm membrane filter for GC–MS analysis.  
For comparison of extraction solvents, three different concentrations of 
methanol 970% methanol, 90% methanol and 100% methanol) and ethanol (70% 
ethanol, 90% ethanol and 100% ethanol) were used for extraction by ultrasonication 
for extraction of A. tatarinowii powder using method described above. For 
comparison of optimum solvent required for extraction, the solvent which gave better 
extraction of asarones was further compared with extraction method involving 25 mL 
of same solvent. Total peak area of two asarones was calculated for different solvents 




6.5.2.1 GC-MS method for quantitative analysis 
Agilent gas chromatography-mass spectrometry (Agilent 7980 GC-MS) was 
used. A DB-5MS column of film thickness 0.25 μm, length 30.0 m and diameter 0.25 
mm was used with the carrier gas (helium) set at 1 mL/min. A 1.0 µl volume of the 
sample was injected using the splitless mode. The data acquisition system was 
controlled by MS ChemStation. Full scan mass spectra were collected between 50 and 
550 amu at 1.53 scan s
-1
. For SIM mode, ions with m/z of 208.1 were monitored for 
the quantification of asarones. Ions with m/z of 193.1 and 165.1 were used as qualifier 
ions for asarones. For the internal standard, eugenol, ion 164.1 was monitored. The 
MS was operated in the electron impact (EI) mode.  
The initial oven temperature was set at 80°C. It was then increased to 280°C at 
10°C/min. The final temperature of 280°C was held for 8 min. The total running time 
was 16 min. The injection volume was 1 µl. The Wiley standard chemical MS library, 
NIST library and spectra of reference standards were used in the identification when 
scan mode used for analysis. 
6.5.2.2 Method validation 
The mixed standard working solutions at each concentration were injected in 
triplicate. The calibration curves were constructed by plotting the ratio of peak areas 
of the asarone standards to the peak area of internal standard against the 
corresponding concentration. The LOD and LOQ of GC-MS method were determined 
and calculated as the analyte concentrations with signal/noise ratios of 3 and 10, 
respectively. Accuracy and precision of method were determined by analysing quality 
control (QC) samples at three concentrations (low, mid and high), representing the 
entire calibration range for α and β-asarone. The intra-day (n = 6) and inter-day (n = 3) 
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variations (intermediate precision) were evaluated by three replicate measurements of 
the QC samples in a single day and on three consecutive days, respectively.  
The recoveries of asarones were determined by the standard addition method. 
Mixed standard solutions of α and β-asarone at three different concentrations were 
added into a powder of A. tatarinowii herb before extraction and were then analyzed 
in triplicate. Similarly recoveries of asarone were also studied by standard addition 
method before extraction in one of the product “Zhupo Chuanbei Hou Zao San” on 
single day and on three different days. The unspiked sample solution was 
concurrently analyzed.   
Stability of the stock solution after one week was also evaluated by comparing 
the peak area of QC samples prepared from the aged stock solution to that of a freshly 
prepared stock solution. Post preparative stability or auto-sampler stability of 
prepared QC samples was also evaluated by storing them for 48 hours at 24˚C in dark. 
 
6.5.3 Results and discussion 
6.5.3.1 Method development 
Ultrasonication is very powerful and efficient method for the extraction of 
plant material. Therefore, ultrasonication method was chosen instead of other methods 
such as soxhlet extraction, maceration and steam distillation as these methods require 
long time for extraction. Steam distillation and /or hydrodistillation are more 
frequently used methods for determination of β-asarone in plant materials (Oprean et 
al. 1998; Kumari et al., 2009). However, such distillation methods require long 
extraction time and have more processing steps. Therefore, in this study 
ultrasonication method was optimized for the extraction of asarones from botanical 
health products.  Six different composition of solvent were compared for extraction of 
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asarones by ultrasonication method. Furthermore, the solvent which gave better 
extraction was also compared for different volumes of solvent (25 mL). The effects of 
different solvents are shown in Table 6.12. The results were analyzed by one way 
ANOVA to find significant differences. 
Table 6.12 Effects of different extraction solvents on ultrasonic extraction (for 15 min) 
of asarones  
 
Solvent Volume of 
solvent (mL) 
Total peak area of  
asarones ± S.D, n = 3 
70%  v/v Ethanol 15 190950 ± 503 
90%  v/v Ethanol 15 33895 ± 1843 
100%  Ethanol 15 385338 ± 2551 
70%  v/v Methanol 15 143338 ± 7707 
90%  v/v Methanol 15 362202 ± 4733 
100%  Methanol 15 456867 ± 13163 
100%  Methanol 25 452213 ± 6582 
 
As can be seen from Table 6.11, 100% methanol gave highest yield of 
asarones when extracted with 15 mL of solvent for 15 min. Furthermore, no 
significant improvement in the extraction efficiency could be found when the volume 
of solvent is increased to 25 mL for extraction. Therefore, optimised extraction 
conditions are ultrasonication using 15 mL of 100 % methanol for 15 min. 
The GC-MS method was optimized from initial screening method of 30 min to 
12 min for rapid quantification of asarones. This was achieved by optimization of 
temperature ramp to separate α-asarone, β-asarone and internal standard eugenol. The 
selectivity of method is documented. Although α and β-asarones are structural 
isomers, they were well separated at 6.3 and 6.6 min respectively (Figure 6.15). The 
internal standard, eugenol elutes at 5.1 min (Figure 6.15). Mass spectrum of β-asarone, 
α-asarone and eugenol were initially obtained by running in scan mode. From their 
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mass spectrum, ions 208.1 and 164.1 were selected in SIM mode for asarones and 
eugenol respectively for quantification purposes. 
β-asarone has been studied previously by TLC, HPLC, HPTLC and GC-MS, 
capillary electrophoresis methods (Oprean et al. 1998; Kumari et al., 2009; Widmer 
et al., 2005; Hanson et al., 2005; Chen et al., 2009). From above methods, GC-MS is 
widely used method for the analysis of β-asarone because of its volatility. Previously 
reported GC-MS methods require longer analysis time (at least 18 min) for the 
determination of asarones (Oprean et al. 1998; Kumari et al., 2009; Chen et al., 2009; 
Björnstad et al., 2009).  
 
 
Figure 6.15. GC-MS chromatograms of product “Pak Po Chen Chu Chin Hong”. The 
internal standard eugenol, β-asarone and α-asarone were well separated at 5.1, 6.3 and 
6.6 min respectively. 
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Furthermore, previously reported GC-MS methods were not fully validated for 
the quantification of α and β-asarones in herbal materials. Only partial validation 
without analysing quality control samples was carried out in the case of previously 
reported GC-MS methods. The method developed in this study only requires only 12 
min for simultaneous determination of asarones. This newly developed method was 
further subjected to full validation to determine its suitability for the quantification 
purposes. 
 
6.5.3.2 Method validation 
The developed GC-MS method has been validated. The linearity data, 
concentration range, LOD and LOQ are presented in Table 6.13. Analytical recoveries 
of QC samples for asarones are shown in Table 6.14. Absolute recovery of asarones 
(Table 6.15 and 6.16) was studied at three different concentrations from the A. 
tatarinowii herb as well from the product “Zhupo Chuanbei Hou Zao San”. Table 
6.17 shows the data for the stability of asarones at the tested conditions 
 
Table 6.13 Linear regression data for method validation of the GC-MS method for 
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2 α-asarone 
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Table 6.15 Absolute recoveries or extraction efficiency of asarones from the herb A. 
tatarinowii 
Asarone Concentration 















β-asarone 400 94.65 ± 4.67 4.94 95.75 ± 5.33 5.57 
1000 92.84 ± 5.89 6.34 93.79 ± 7.21 7.69 
4000 96.02 ± 4.15 4.32 96.59 ± 4.87 5.50 
α-asarone 400 96.61 ± 6.02 6.23 94.45 ±6.24 6.61 
1000 91.46 ± 3.15 3.44 90.61 ± 2.35 2.59 
4000 102.36 ± 4.22 4.12 101.03 ± 4.56 4.51 
 
Table 6.16 Absolute recoveries or extraction efficiency of asarones from the product 










No. Asarone Concentration 
Spiked (mg/g) 
Mean recovery (n=3) 
% recovery ± SD % RSD 
1 β-asarone 0.060 96.40 ± 4.94 5.13 
0.150 99.58 ± 2.83 2.84 
0.600 96.33 ± 6.50 6.74 
2 α-asarone 0.060 100.08 ± 2.74 2.73 
0.150 101.74 ± 5.48 5.38 
0.600 97.83 ± 3.61 3.69 
No. Asarones Concentration 
Spiked (mg/g) 
Mean recovery (n=4) 
% recovery ± 
SD 
% RSD 
1 β-asarone 0.060 98.27 ± 2.11 2.15 
0.150 99.53 ± 3.24 3.25 
0.600 96.60 ± 1.37 1.42 
2 α-asarone 0.060 103.23 ± 4.16 4.02 
0.150 93.85 ± 5.26 5.60 
0.600 95.11 ± 3.49 3.66 
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Stability of stock 
solution after one 
week  at 24 
o
C (% 
remained ± SD), n = 3 
Post preparation 




remained ± SD), 
n = 3 
1 β-asarone 400 95.20 ± 2.63 95.80 ± 4.09 
1000 96.13 ± 7.13 100.13 ± 1.33 
4000 99.41 ± 1.69 99.20 ± 3.41 
2 α-asarone 400 95.51 ± 2.78 91.50 ± 1.73 
1000 93.53 ± 6.83 93.60 ± 4.38 
4000 100.88 ± 1.48 101.74 ± 5.48 
 
 
The calibration curves were found to have good linearity (R
2
 > 0.999). The 
RSDs of intra- and inter-day precision for α and β-asarones were 4.31 – 7.69 and 2.59 
– 6.61 respectively.  The accuracy of the developed method was found to be 
satisfactory as the percentage deviations of the QC samples from the nominal 
concentration were all within the acceptable limit of ± 10% for the recovery of 
asarones. The absolute recoveries or extraction efficiency of asarones were all above 
90%. The results of stability studies under different conditions have shown that the 
asarones are stable at tested storage and handling conditions. 
α and β asarones are toxic compounds but their hepatotoxic effects in animal 
or humans have not been reported. α-asarone and β-asarone are reported as genotoxic 
and hepatocarcinogenic in rodents. There are also reports of their mammalian toxicity 
and carcinogenicity (European Medicines Agency, 2005; Hasheminejad and Caldwell, 
1994). It is also reported that β-asarone is more toxic than α-asarone (European 
Medicines Agency, 2005). In human studies, exposure to asarones from the herb 
Acorus calamus, which contains high concentrations of asarones, caused prolonged 
vomiting in 7 consumers (Bjornstad et al., 2009). In a recent study, cytotoxic and 
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genotoxic effects of asarones against HepG2 cells were reported (Unger and Melzig, 
2012). The authors have demonstrated that after metabolic activation, β asarone at 
concentrations higher than 50 µg/mL was genotoxic as indicated by the positive Ames 
test and sister chromatid exchange test (Unger and Melzig, 2012). Due to potential 
toxic effects of asarone, in particular, β-asarone,  the European council have limited 
the presence of β-asarone to a maximum of 1 mg/kg in alcoholic beverages and 
seasoning for snack food and 0.1 mg/kg in other food stuffs and beverages (European 
Medicine Agency, 2002).  In analogy with the food regulation (limitation of the intake 
of β-asarone from food and alcoholic beverages), a limit of exposure from herbal 
medicinal products of approximately 115 μg/day, i.e. about 2 μg/kg bw/day has been 
set temporarily until a full benefit/risk assessment has been carried out (European 
Medicines Agency, 2005).  
On the contrary, asarones are reported to possess nematicidal activity, 
insecticidal activity, anticoagulant activity, sedative effects and larvicidal activity 
against Aedes aegypti (EMEA, 2005). In addition, radioprotection and prevention of 
genotoxicity and hematopoetic injury by α-asarone is also reported (Sandeep and Nair, 
2011). Furthermore, anti-oxidant and liver protective effects of methanol extract of A. 
calamus are also reported (Ilaiyaraja and Khanum, 2011). Based on above reported 
studies, the hepatotoxicity of asarones remains unclear. However, in view of their 
other toxic effects, it is important to monitor the concentrations of toxic asarones in 
botanical health products. 
β-asarone is a natural constituent of some aromatic plants and their essential 
oil fractions, especially of species of the genus Acorus. Several other plants contain 
varying amounts of asarones mainly as a major component of their essential oil 
(European Medicines Agency, 2005). In traditional Chinese medicine (TCM), the 
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herbal drug Acori rhizoma (shi chang pu) consists of the dried rhizome, cut in slices, 
of Acorus tatarinowii Schott or Acorus gramineus Soland (Chinese Pharmacopoeia 
Commission, 2005a). Acori tatarinowii contains 1.0-3.4 % of essential oil, with 
asarone as the main constituent. Chemical analysis has demonstrated the presence of 
two geometrical isomers of asarone: α-asarone and, predominantly, β-asarone (Chu et 
al., 2009). 
 
6.5.3.3 Quantification of asarones 
As discussed in the Secttion 6.5.3.2, asarones are toxic compounds and 
therefore thier concentration in herbal medicinal products particularly products used 
for infants and children who are more prone to adverse drug of drugs should be 
monitored. Hence, we conducted a study to explore the prevalence of asarones in baby 
products marketed in Singapore. Table 6.18 shows the analysis of 20 products of 
which 3 were supplied by HSA and 17 were purchased from the local market. 
Of the 20 samples analysed, α and β asarones were found to be present in 10 
products (50 %). In six of 10 samples, the presence of asarone could be attributed to 
the labeled ingredient Rhizoma Acori tatarinowii. However, in four products, the 
presence of asarones could not be explained by any of the ingredients as labeled. 
Subsequently, asarones were quantified in 10 products, which were found to contain 
asarones by validated GC-MS method. Table 6.19 shows concentrations of α and β 







Table 6.18 Chemical analyses of baby products for the presence of β-asarone and α 
asarone by GC-MS. 
No. Name Presence of α 
and β asarones 
Remarks/Source 
1 Mild Hot Cough San She Dan Chun Bei 
Mo (轻微热咳蛇胆川贝末) 
Not detected - 
2 Mild Cold Cough San She Dan Chen Pi 
Mo (轻微寒咳蛇胆陈皮末) 
Not detected - 
3 Zhen Zhu Chuan Bei Jing Feng San  
(珍珠川贝惊风散) 
Yes Rhizoma Acori 
tatarinowii 
4 Cordyceps & Fritillaria Powder 
(虫草桔红川贝末) 
Not detected - 
5 Babao Zhupo Wao San  
(八宝珠珀惊风散) 
Yes Rhizoma Acori 
tatarinowii 
6 Zhupo Chuanbei Hou Zao San 
(珠珀川贝猴枣散) 
Yes Rhizoma Acori 
tatarinowii 
7 Fu Fang Chen Chu Ho Chou San 
(复方八宝珍珠猴枣散) 
Yes Rhizoma Acori 
graminei 
8 Xiaoer Qingfeihuatan Keli 
(小儿清肺化痰颗粒) 
Not detected - 
9 She Tan Chuan Pei Chen Pi Mo 
(蛇胆川贝陈皮末) 
Not detected - 
10 Ban Kah Chai Hou Tsao San 
(萬家濟猴枣散) 
Not detected - 
11 Mee Tao Chin Hong San 
(密桃牌珠珀八宝惊风散) 
Yes unknown source 
12 Ban Kah Chai Serbuk Batuk 
(川贝虫草化痰丹) 
Yes unknown source 
13 Jing Feng powder 
 (琥珀八宝惊风散) 
Yes Radix Et Rhizoma 
asari 
14 Pai Pau Chin Choo Pau Ying Tang  
(双料八宝珍珠保婴丹) 
Yes unknown source 
15 Zhenzu Pai Pao Chin Feng San (珍珠八宝
惊风散) 
Not detected - 
16 Pearl & Amber Powder for Infantile 
(猴枣惊风散) 
Not detected - 
17 Children Calming Granules  
(小儿安宁颗粒) 
Not detected - 
18 Pak Po Chen Chu Chin Hong 
(珍珠八宝惊风散) 
Yes unknown source 
19 Houzao Zhenzhu Babao Jingfengsan 
(珍珠猴枣八宝惊风散) 
Not detected - 
20 Bo Ying Compound 
(保婴丹) 





Table 6.19 Quantification of asarones in baby products found to contain asarones by 
validated GC-MS method 
 






1 Zhen Zhu Chuan Bei Jing Feng San 273.6 ± 21.6 40 ± 1.2 
2 Babao Zhupo Wao San 230.9 ± 21.3 34.7 ± 1.2 
3 Zhupo Chuanbei Hou Zao San 4.8 ± 0.2 5.0 ± 0.2 
4 Fu Fang Chen Chu Ho Chou San 11.2 ± 0.1 47.7 ± 3.0 
5 Mee Tao Chin Hong San 181.6 ± 5.4 106.1 ± 1.0 
6 Ban Kah Chai Serbuk Batuk 4.3 ± 0.3 13.3 ± 0.1 
7 Jing Feng powder 3.2 ± 0.2 10.9 ± 3.3 
8 Pai Pau Choo Pau Ying Tang 241.5 ± 10.5 53.2 ± 1.2 
9 Pak Po Chen Chu Chin Hong 243.5 ± 18.2 144.3 ± 7.1 
10 Bo Ying Compound 425.7 ± 28.2 62.8 ± 3.1 
 
As can be seen from the Table 6.17, all 10 products were found to contain 
more than recommended amount by EMEA of β-asarone (1mg/kg for alcoholic 
beverages and 0.1mg/kg for other food stuffs). Product “Bo Ying Compound was 
found to contain highest amount of β-asarone from the 10 products. Table 6.20 shows 
estimated exposure of β-asarones to the consumers of baby products that were found 
to contain asarones. This estimation was based on the average body weights of normal 




Table 6.20 Estimated exposure of β-asarone to the consumers of analyzed products based on quantification of β-asarone 
 
No. Name Dose Estimated 
Weight of 
product per 
 dose unit 
Daily exposure of β-




allowance as per EMEA 
guidelines based on body 
weight calculations (µg/day) 
1  Zhen Zhu Chuan Bei 
Jing Feng San  
Infants 6 mths to 1 yr: ½ tsp; 
1-3 yrs: 1 tsp; 3-6 yrs: 1-2 tsp; 
Adults: one bottle each time. 3 
times a day.  
One tsp: 0.42 g  ≤ 1 year:     172   
   1-3 yrs:    344  
   3-6 yrs:    344-688    
   Adults:    1067  
  ≤ 1 year:     17-22 
    1-3 yrs:     22-27 
    3-6 yrs:     41 
    Adults:     115 
2  Babao Zhupo Wao San  1-6 yrs: ½ tsp flat; 7-12 yrs: 1 
tsp flat; Adults:1/2 bottle. 3 
times daily  
One tsp:  
0.5 g  
  1-6 yrs:     180  
7-12 yrs:     360  
  Adults:     2880  
    1-6 yrs:     22-41 
  7-12 yrs:     41-72 
    Adults:     115 
3  Zhupo Chuanbei Hou 
Zao San  
1-6 yrs: ½ tsp flat; 7-12 yrs: 1 
tsp flat; Adults:1/2 bottle. 3 
times daily  
One tsp: 0.55g     1-6 yrs:     4   
 7-12 yrs:     8 
   Adults:     58  
     1-6 yrs:     22-41   
   7-12 yrs:     41-72 
     Adults:     115 
4  Fu Fang Chen Chu Ho 
Chou San  
1-3 yrs: 1 tsp each time; 3-6 
yrs:1 or 2 tsp each time; 
Adults:1 bottle each time, 3 
times a day  
One tsp: 0.63 g     1-3 yrs:    21 
   3-6 yrs:    21-42 
   Adults:     84  
     1-3 yrs:    22-27 
     3-6 yrs:    41 
     Adults:    115 
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5  Mee Tao Chin Hong 
San  
1-5 yrs: 1 tsp each time; 5 year 
or more; 1-2 tsp each time. 4 
times a day  
One tsp: 0.51 g    1-5 yrs:    370  
≥  5  yrs:    370-741  
   1-5 yrs:    22-41  
    ≥5 yrs:    41-115 
6  Ban Kah Chai Serbuk 
Batuk  
1-3 yrs: 400mg each time; 
adults: 650 mg (1 bottle) each 
time. 2-3 times a day  
One bottle: 0.65 g     1-3 yrs:    3.5 
   Adults:    5.6- 8.4  
    1-3 yrs:    22-27 
    Adults:    115 
7  Jing Feng powder  One bottle each time, 2 times 
daily; infant mth old ½ bottle 
each time, 2 times a day  
One bottle: 2 g     Infants:    6.4  
   Adults:    12.8  
    Infants:    14 
    Adults:    115 
8  Pai Pau Choo Pau 
Ying Tang  
Baby 3 mths-1 year: ½ bottles 
each time; children 1-5 yrs 
old: 1 bottle each time; 
Children 5 yrs old and above: 
1-2 bottles each time, 4 times 
a day.  
One bottle: 0.4 g  ≤ 1 year:    193 
  1-5 yrs:    386  
  > 5 yrs:    386-773  
    ≤ 1 yr:     14-22 
   1-5 yrs:    22-41 
   > 5 yrs:    52-115 
9  Pak Po Chen Chu Chin 
Hong  
1-5 yrs: 1 tsp each time; 5 yrs 
and above: 1-2 tsp each time. 
Four times a day.  
One spoon: 0.64 g    1-5 yrs:    623 
  > 5 yrs:    623-1247  
  1-5 yrs:    22-41 
  > 5 yrs:    52-115 
10  Bo Ying Compound 
(3 mths old baby, 
weight: 8.5 Kg)  
1-3 yrs: one tube per day; 4-10 
yrs: 2 tubes per day.  
One tube: 0.3 g    1-3 yrs:    128 
 4-10 yrs:   255 
 
   1-3 yrs:   22-41 
 4-10 yrs:   41-72 
   Patient:  17 
* This is calculated as per the recommended dose mentioned on the label of products. Red colored numbers indicate estimated amounts 
exceeding the recommended limits. Body weights were used from website of the Health Promotion Board, Singapore.
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Table 6.21 Estimation of recommended maximum allowable exposure of β-asarone 





body weight (kg) 
Recommended maximum 
exposure 
( based on 2 μg/kg body 
weight/day) 
3 - < 6 months 7 14 
6 - < 9 months 8.5 17 
9 - < 12 months 9.5 19 
1 - < 2 years 11 22 
2 - < 3 years 13.5 27 
3 - < 7 years 20.5 41 
7 - < 10 years 27 52 
10 - < 12 years 36 72 
 
The above data of quantification and estimation of exposure indicates that 
consumers are likely to get exposed to the levels of β-asarones well above the 
recommended exposure levels. Of the 10 products found to contain β-asarone, 6 
products were found to contain β-asarone more than the daily recommended exposure 
levels. These products were found to contain as much as 4 to 25 times more amount of 
β-asarone than the recommended amount. For example, product, Babao Zhupo Wao 
San was found to contain more than 25 times of the allowable levels of β-asarone. 
These results suggest that the β-asarone (in varied concentrations) is prevalent in 
commercial botanical health products available in the local market.  
In some products, in presence could be attributed to the presence of herbs 
containing asarones such as rhizoma Acori tatarinowii or Acori graminei and Radix 
ET Rhizoma asari. These herbs belong to same genus Acorus as A. Calamus, a herb 
prohibited from use in any medicinal or food preparations in US.   In this study, we 
have also quantified the concentration of β-asarone in the herb Acori tatarinowii. The 
authentic herb Acori tatarinowii was found to contain 7679.8 ± 85.7 mg/kg of β-
asarone and 679.1 ± 20.3 mg/kg of α asarone. According to Chinese Pharmacopoeia, 
the recognized dose of this herb is 3-9 g (Chen et al., 2009). Based on this, β-asarone 
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exposure levels would be 23000 to 69000 µg which is extremely higher than the 
recommended amounts. As mentioned earlier, the limit of exposure from herbal 
medicinal products has been set at 115 µg β-asarone/day. Therefore, the amount of 
this herb should not exceed 15 mg in daily dose of botanical health products 
containing this herb to ensure safe usage of this herb. This means, stricter quality 
control measures and regulatory actions would be required to monitor such a small 
amount of this herb in botanical health products. At present, this herb is not controlled 
by any regulatory authorities for its concentration in herbal preparations and no limits 
have been set up expect Health Canada. The Canadian regulations do not allow this 
herb in food without prior licensing because of its potential health risks. (Health 
Canada, 2012). The results of this study indicate that there is a need to conduct 
detailed evaluation of this herb to consider its regulation in herbal preparations. 
Similarly, assuming the daily intake of the herbal drug to be 3 g for adults 
(Chen et al., 2009), the content of β-asarone per gram of herbal drug should not 
exceed 38 µg per daily dose (Chen et al., 2009).  If we apply this limit to the 10 
products which were found to contain β-asarone, 8 products would exceed this limit. 
As per out best knowledge, this is the first report of quantification of β-asarone in 
baby products. The results of this study highlight the importance of monitoring the 
levels of β-asarone in botanicals and botanical health products. The GC-MS method 
developed in this study could be used to monitor the levels of β-asarones in botanicals 
and botanical health products.  
Chen et al., (2009), proposed extraction method involving preparation of 
decoction by heating to reduce the concentration of β-asarone in the A, tatarinowii 
extract. Their results indicated that by heating for one hour, the concentration of β-
asarone was reduced by 85%. However, even after this reduction, in comparison to 
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desired limit (0.038 mg/g), the β-asarone content was still very high (Chen et al., 
2009). They proposed that extended heating for 1 to 3 hours is required to achieve 
acceptable β-asarone levels. However, it is practically unfavourable process for herbal 
praparations. Moreover, in multi-component botanical health products, when this herb 
is added in powder form, the proposed extended heating method is not possible to 
adopt and would be inconvenient to use. Therefore, further studies are required to 
have practical and acceptable method of processing of this herb if it has to be used. 
In the case Product “Bo Ying compound “, the patient was 3 month old baby 
who suffered worsening acute liver failure. This product was found to contain more 
than 7 times the recommended limit of β-asarone based on body weight calculations. 
This product was not meant for its usage in infants. However, it was given to the baby 
by his parents. This suggests that there is a need to improve awareness amongst the 
consumer for correct use of botanical health products. Furthermore, by including label 
warnings such as “not for children‟s below one year” could also help to prevent such 
dangerous adverse events. In summary, in this Chapter, potentially hepatotoxic 
components have been identified in the implicated samples by use of chemical 
standards. Some of the potentially toxic compounds such as anthraquinones, 5-
hydroxymethylfurfural and asarones were also quantified in the implicated samples. 
 
6.6 Conclusion 
Analyses by HPLC and GC-MS suggest that in some products implicated in 
DILI, potential hepatotoxic compounds are present. These include anthraquinones (e.g. 
emodin, aloe-emodin), -asarone and -asarone. The HPLC and GC-MS method 
developed and validated in this study could be used for quality control and monitoring 
of such hepatotoxic components in botanicals and botanical health products. 
 187 
 
Chapter 7  
 
Evaluation of hepatotoxicity of botanical 
health products implicated in drug induced 
liver injury (DILI) 
 
7.1 Introduction 
As discussed in Chapter 1 (Section 1.3), DILI is a major health concern not 
only for health care professionals but also for the pharmaceutical industry and drug 
regulatory agencies.  In the pharmaceutical industry, a new drug candidate is tested in 
a array of in vitro tests to assess its stability, bioactivation, mutagenicity, cytotoxicity, 
interactions with drug-metabolizing enzymes, and other parameters (Willet et al., 
2004). Moreover, new drugs have to be evaluated in vivo in at least two species for a 
variety of safety end points including liver injury (Willet et al., 2004).  Moreover, 
because of the low incidence of DILI, idiosyncratic nature and poor prognosis of 
DILI, the hepatotoxic nature of drugs may not be detected during clinical trials, as the 
maximum number of patients involved in a clinical trial ranges between 2000 and 
5000 (Holt and Ju et al., 2006).   
It has been postulated that in order to detect a single case of DILI (with 95% 
confidence), the clinical trial would require ~30 000 patients (Lee et al., 2003). Even 
with this rigorous pre-marketing screening, the incidence of DILI is not uncommon. 
However, such evaluation of botanicals and their derived products are complex 
because of their complex chemistry and unclear dosing of offending components. As a 
result, sometimes herbal compounds are also implicated in DILI as discussed in the 
Chapter 4. Therefore, the clinical diagnosis and prediction of DILI associate with the 
use of botanical health products remain a major challenge.  
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In vivo animal studies for determining the hepatotoxic potential of herb related 
toxic compounds are expensive and time consuming. Various in vitro models 
involving human primary hepatocytes, human liver microsomes, rat hepatocytes, 
human liver cell lines in cell culture are usually employed to study the hepatotoxicity 
of botanicals. Primary human hepatocytes represent a very good model to study 
metabolism of botanical constituents and to identify the toxic reactive metabolites as 
they have drug metabolizing enzymes. They also can be used to study the herb-drug 
interaction. However, due to limited availability of tissue, limited survival and large 
batch to batch variation (Willet et al., 2004; Sahu, 2007), it is difficult to use primary 
human hepatocytes to study the underlying mechanism of hepatotoxicity (Willet et al., 
2004; Sahu, 2007). Hence, analogous approaches with human liver cell lines have 
been used to study mechanisms of hepatotoxicity. Although these may lose some of 
their differentiated metabolic pathways, it is possible to select some with most of the 
desired characteristics.  Various cell lines such as Human WRl-68, HepG2, HepaRG 
and THLE cell lines have been used to screen for the hepatotoxic potential of drug 
candidates.  
THLE-2 cells were derived from primary normal human liver cells by 
infection with SV40 large T antigen. These immortalized human liver cells constitute 
an in vitro model for pharmacotoxicological studies (ATCC, Pfeifer et al., 1993). 
THLE-2 cells are able to metabolize benzo[a]pyrene, N-nitrosodimethylamine, and 
aflatoxin B1 to their metabolites that adduct DNA, causing cancer. This indicates 
functionality similar to human liver (ATCC, Pfeifer et al., 1993). THLE-2 cells have 
been used to study the hepatotoxicity of oral hypoglycaemic agents such as 
triglitazone (Saha et al., 2010a). Saha et al., (2010b) also reported that THLE-2 cells 
were able to metabolize triglitazone into its reactive metabolites. THLE-2 cells are 
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also increasingly being used as control cells representing normal human liver cells by 
various researchers (Mayoral et al., 2005; Datta et al., 2007; Zimmerman et al., 2012; 
Krajka-Kuźniak et al., 2012). Currently, at the major pharmaceutical players such as 
Pfizer, Astra Zeneca and Bristol-Mayer-Squibb, in vitro hepatic liability assays using 
THLE cells are being developed from screening of hepatotoxic potential of drug 
candidates (Greene et al., 2010; Thompson et al., 2011). At Pfizer (Greene et al., 
2010), THLE assay can be used as a high throughput assay to prioritize compound 
selection for in vivo toxicity screening. 
 
Mechanisms of hepatotoxicity 
Reactive oxygen species (ROS) are generated in the liver during the 
detoxification of exogenous chemicals and toxins which leads to oxidative stress. 
These free radicals are implicated in a variety of cellular functions (Das et al., 2004; 
Tripathi et al., 2009). Disturbances in the cellular redox status and increased 
formation of oxidants surpass the cells antioxidant defense mechanisms resulting in 
oxidative stress. ROS are involved in the pathogenesis of many human diseases, such 
as cancer, diabetes, cataract, neuronal disorders and atherosclerosis. Formation of 
ROS in hepatocytes is reported to be one of the main reasons for drug induced 
hepatotoxicity.  
This ROS induced hepatic cell toxicity leads to a variety of manifestations of 
liver diseases such as ischemia–reperfusion injury, fibrosis and liver failure (Novo 
and Parola, 2008). One of the consequences of oxidative stress is the peroxidation of 
lipids. These radicals causes peroxidation of the cell membrane phospholipids which 
result into accumulation of lipid peroxides resulting into the disruption of membrane 
structure and function. Measuring the end products of lipid peroxidation such as MDA 
is one of the most widely accepted assays for oxidative damage. 
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The ROS also affect the anti-oxidant defense system involving glutathione. 
Glutathione (GSH) is a three amino acid peptide (L-cysteine, L-glutamic acid and 
glycine). It is an abundant antioxidant, which protects cells from ROS such as free 
radicals and peroxides (Sies, 1999; Griffith, 1999). GSH is converted to its oxidized 
form glutathione disulfide (GSSG) during oxidative stress. In healthy cells and tissue, 
more than 90% of the total glutathione pool is in the reduced form (GSH) and less 
than 10% exists in the oxidized form (GSSG). The ratio of GSH to GSSG within cells 
is used as an indicator of cellular toxicity. The depletion of GSH is either manifested 
via adduct formation with reactive metabolites (in the form of GSH conjugates) or via 
oxidation to GSSG implying oxidative stress. Therefore, reduction of GSH/GSSG 
ratio is an indicator of cellular injury due to oxidative stress (Ballatori N. et al., 2009; 
Rebrin and Sohal, 2008; Ghezzi, 2005). GSH depletion and MDA increase are 
frequently reported indicators of oxidative damage (Tripathi et al., 2009). 
 
7.2 Objective 
The objective of this study is to evaluate the hepatotoxicity of botanical health 
products implicated in drug induced liver injury and to elucidate of the mechanisms of 




7.3.1 Materials and reagents 
Products implicated in DILI were obtained from the Vigilance branch of HSA. 
The complete list is shown in Chapter 6 (Section 6.3.1.1). The solvents used for 
fractionation of extract and various pure chemical standards were the same as 
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specified in Chapter 6. Paracetamol and N-nitrofenfluramine were used as a positive 




7.3.2.1 Sample preparation for hepatotoxicity evaluation 
Samples were extracted using either water or methanol as a solvent by 
ultrasonication as specified in Chapter 6, Section 6.3.1.2.1.  
 
7.3.2.2 WST-1 assay to determine cytotoxicity against hepatocytes (THLE-2 cells) 
THLE-2 cells were obtained from ATCC (Manassas, VA, USA).  LHC-9 
media supplemented with 10% FBS was used for culturing THLE-2 cells.  
Samples: methanol extracts of products were dissolved in DMSO while water 
extracts were dissolved in sterile water. The pure chemical standards namely, N-
nitrosofenfluramine, emodin, aloe-emodin, rhein, physcion, psoralen, hydroxymethyl 
furfural, paracetamol, α-asarone, β-asarone and trans-trimethoxycinnamic acid were 
dissolved in DMSO. The final concentration of DMSO exposed to the cells was less 
than 0.5 %. 
Assay procedure: 
First Day 
THLE-2 cells were suspended at optimum density (5 x 10
3
 cells/mL) in LHC-9 media 
supplemented with 10% FBS. 100 µl of this suspension was dispensed into 96 well 




The media was then discarded from the wells.  100 µl of appropriate concentration of 
extracts and/or pure components were then added to the wells separately. The plates 
were then incubated for 72 hours at 37ºC with 5% CO2.   
Fifth Day 
The supernatant from all the wells was discarded. Then 100μl of WST-1 solution 
(10% in media) was added into each well. The plates were then incubated for 1.5 
hours at 37ºC with 5% CO2. After incubation, the absorbance was recorded at 440 nm. 
Statistical Analysis 
The average percentage cell viability was expressed as a percentage of the 
control wells by comparing the average absorbance of six treated wells against the 
average absorbance of six control wells in triplicate manner. The results obtained 
were expressed as a mean for three cell line passages and the standard deviations (SD) 
were also calculated. Statistical analysis was performed according to student‟s t-test 
by one way analysis of variance. Significant difference was taken as p < 0.05. The 
IC50 values were determined by Calcusyn 3.0 software (Biosoft, Cambridge, UK). 
Each reported value was the mean ± S.D from 3 independent experiments. 
 
7.3.2.3 Thiobarbituric Acid Reactive Substances (TBARS) assay to measure lipid 
peroxidation as an indicator of oxidative stress 
Chemicals: Analytical grade (ACS) Ethanol was purchased from Tedia Company 
(Fairfield, OH, USA).  Water with Milli-Q water purification system (Millipore, 
Bedford, USA) was used. Trichloroacetic acid (TCA), sodium dodecyl sulfate (SDS) 
dialdehyde (MDA), diethyl maleate (DEM, positive control), thiobaribituric acid 
(TBA), butylated hydroxy toluene, sodium hydroxide (NaOH) were obtained from 
Sigma-Aldrich (Singapore).  
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Samples: Methanol extracts of products dissolved in DMSO or pure components 
dissolved in DMSO were prepared. The final concentration of DMSO was less than 
0.5 %. 
Assay procedure 
Culturing of cells  
THLE-2 cells (2 x 10
5 
cells/well) were seeded into pre-coated 6 well plates. 
The cells were then incubated for 24 hours at 37ºC with 5% CO2.  After 24 hours of 
incubation at 37ºC with 5% CO2, the media was discarded. Extracts of products, pure 
components and positive control (Diethyl maleate, 2.5 mM) dissolved in DMSO were 
then added at different concentrations. The plates were then incubated for 24 hours of 
incubation at 37ºC with 5% CO2.  The media was then discarded from the wells and 
the wells were washed with 500 µl of phosphate buffer saline (PBS) twice. The cells 
were then harvested for the preparation of cell lysate. 
Preparation of cell lysate 
Cells from 6 well plates were scraped into a 1.5 mL centrifuge tube containing 
500 µl of 2.5 % trichloroacetic acid (TCA) using cell scraper. The TCA solution 
containing cells was then centrifuged at 13,000 rpm for 5 min. After centrifugation, 
the supernatant was collected for lipid peroxidation assay. The cell pellets were stored 
at -20
0
 C until analysis by Bradford assay for protein estimation. 
Measurement of Malondialdehyde (MDA) 
To 80 µl of cell lysate solution or appropriate MDA standards in 96 well 
plates, 10 µl of 1 mM BHT in ethanol, 50 µl of 50 % TCA in water and 75 µl of 1.3% 
TBA in 75 mM NaOH were added. The plate was then incubated for 45 min at 60
0 
C 
and the reaction was stopped by addition of 10 µl of 20% SDS in water. The plate was 
then centrifuged at 2000 rpm for 10 min at 4
0 
C. The supernatant was then transferred 
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carefully to another micro plate and fluorescence was measured (Ex: 485/Em: 535). 
Nano moles of MDA formed per mg of protein (determined using Bradford‟s assay as 
specified below) were then calculated using MDA standard calibration curve. Each 
reported value was the mean ± S.D from 3 independent experiments. 
Bradford assay for protein estimation 
2 mg/mL bovine serum albumin (BSA) solution was diluted with 0.05 N 
NaOH to prepare a series of concentrations in the range 0.125-1 mg/mL to plat the 
calibration curve. The cell pellets obtained from cell lysate were dissolved in 500 µl 
of 0.05 N NaOH. 5 µl of BSA standard, re-suspended protein pellets or 0.05 N NaOH 
blank is added to microtitre plate. 250 µl of Bradford 1X dye reagent was then added 
to above solution in plate. The plate was then read at 595 nm after 15 min of 
incubation at room temperature. The protein concentration was then determined from 
BSA standard calibration curve. 
Statistical Analysis 
Statistical analysis was performed according to student‟s t-test by one way 
analysis of variance. Significant difference was taken as p < 0.05. Each reported value 
was the mean ± S.D from 3 independent experiments. 
 
7.3.2.4 Glutathione assay to measure total glutathione (GSH) and oxidized 
glutathione (GSSG) 
Chemicals 
This assay was performed by using GSH-Glo™ Glutathione assay kit from 
Promega (Madison, Wisconsin, USA). The kit contain total Glutathione (GSH) lysis 





Methanol extracts of products dissolved in DMSO or pure components 
dissolved in DMSO were prepared. The final concentration of DMSO was less than 
0.5 %. 
Assay procedure 
THLE-2 cells (10 x 10
3 
cells/well) were seeded into pre-coated 96 well plates. 
The cells were then incubated for 24 hours at 37ºC with 5% CO2.  After 24 hours of 
incubation, the media was discarded. Two sets of product extracts and pure 
components dissolved in DMSO were then added at different concentrations in serum 
free media (one set for reduced glutathione (GSH) measurement and second set for 
oxidized glutathione (GSSG) measurement). Appropriate concentrations of 
glutathione standards were also added to wells without cells to obtain the glutathione 
calibration curve. The plates were then incubated for 72 hours of incubation at 37ºC 
with 5% CO2.  The media were then discarded from the wells and the wells were 
treated with glutathione measurement kit as per the manufacturer instructions. Briefly, 
after removal of media 50μl/well of total Glutathione (GSH) lysis reagent or Oxidized 
Glutathione (GSSG) lysis reagent, as appropriate for desired endpoint was added. To 
the wells containing glutathione standards, 50μl/well of total Glutathione (GSH) lysis 
reagent was added. The plate was then shaken at room temperature for 5 min. Then 
50μl/well of luciferin generation reagent was added to all wells. The plate was then 
shaken briefly and incubated at room temperature for 30 min. After incubation, 
100μl/well of luciferin detection reagent was added. The plate was then shaken briefly 






Calibration curves for GSH and GSSG were then plotted (Note: Two moles of 
GSH are generated per 1 mole of GSSG. Dividing the GSH concentrations by two 
gives the concentration of GSSG). GSH and GSSG in THLE-2 cells after treatment 
were then calculated and the ratio of GSH/GSSG was calculated by following formula:  
Ratio GSH/GSSG treated = [μM GSH – (μM GSSG × 2)] / μM GSSG  
Statistical Analysis 
Statistical analysis was performed according to student‟s t-test by one way 
analysis of variance. Significant difference was taken as p < 0.05. Each reported value 
was the mean ± S.D from 3 independent experiments. 
 
7.3.2.5 Measurement of cell viability and caspase-3/7 activation 
Chemicals 
ApoTox™ Triplex assay kit from Promega (Wisconsin, USA) was used for 
the simultaneous measurement of caspase-3/7 activation and cell viability in the same 
sample well.  The kit contains GF-AFC Substrate (for cell viability), bis-AAF-R110 
Substrate (for cytotoxicity) and luminogenic DEVD-peptide substrate for caspase-3/7 
and Ultra-Glo™ Recombinant Thermostable Luciferase (to measure caspase-3/7 
activation). 
Samples 
Methanol extracts of products dissolved in DMSO or pure components 
dissolved in DMSO. Final concentration of DMSO was less than 0.5 %. 
Assay procedure 
THLE-2 cells (10 x 10
3 
cells/well) were seeded into 96 well plates with white 
background. The cells were then incubated for 24 hours at 37˚C with 5% CO2. After 
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incubation extracts and pure compounds were then added at different concentrations 
in media to the well containing cells. The plate was then incubated for two different 
incubation periods (6 hours and 12 hours). After incubation, 20 μl each of GF-AFC 
substrate (for cell viability) and bis-AAF-R110 substrate (for cytotoxicity) reagent 
were added to all wells, and briefly mixed by orbital shaking (300–500 rpm for ~30 




30 min. Then the fluorescence 
was measured at following wavelengths: viability (Ex: 400/Em: 405), cytotoxicity: 
(Ex: 485/Em: 520). To the same plate, 100 μl of Caspase-Glo® 3/7 reagent was added 
to all wells, and briefly mixed by orbital shaking (300–500rpm for ~30 seconds). The 
plates were then incubated for 30 min at room temperature before measuring 
luminescence (caspase activation, a hallmark of apoptosis).  
Calculation 
Average percentage cell viability, cytotoxicity and caspase-3/7 activation for a 
well was expressed as a percentage of the control wells by comparing the average 
fluorescence and luminescence of treated wells against that of control wells in a 
triplicate manner. The results obtained were expressed as a mean ± S.D for three cell 
line passages. 
 
7.4 Results and discussion 
7.4.1 Screening for toxicity 
7.4.1.1 Comparison of different solvent for extraction 
Water and methanol were used to extract products implicated in DILI for 
hepatotoxicity screening. Traditionally, such products are taken by consumers with 
water. However, in the experimental set up, water may not able to extract all 
components (especially mid-polar to non-polar compounds) from the botanical health 
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product. Therefore, methanol which can extract polar to non-polar components was 
also used for extraction. Table 6.1 shows the IC50 values against THLE-2 cells of 
different extracts of three products and positive control, paracetamol. 
Table 7.1 Comparison of IC50 values of products extracts obtained by water and 











Merit 0.520 ± 0.110 0.181 ± 0.020   3 tablets a day 
Slim10 1.590  ± 0.130 0.938 ± 0.146 4 capsules 3 
times a day  
Control Plus 
capsules 
0.210 ± 0.040 0.016 ± 0.001 One capsule 
per meal 
 
As can be seen from the Table 7.1, methanol extracts has much lower IC50 
values than the water extracts. This might be due to the inability of water to extract 
some of potential toxic components of non-polar nature such as anthraquinones in the 
“Merit”, N-nitrosofenfluramine in “Slim10”. Anthraquinones and N-
nitrosofenfluramine are poorly soluble in water. However, they could be extracted by 
methanol. Based on these results, in the subsequent experiments, methanol extracts of 
implicated products were used for the evaluation of hepatotoxicity. 
 
7.4.1.2 Screening of various products and suspected toxic components 
 
Figure 7.1 shows the plot of percentage cell viability ± SD of THLE-2 cells 
upon treatment with methanol extracts of different products implicated in DILI and 





Figure 7.1 Plot shows the average percentage cell viability of THLE-2 cells ± 
standard deviation as compared to the vehicle control of three independent 
experiments conducted in six wells each upon 72 hours of treatment with methanol 
extracts (1 mg/mL) of different products implicated in DILI and suspected potential 
hepatotoxic components dissolved in DMSO. The cell viability was measured by 
WST-1 assay. Statistical significance (*) was set at p < 0.05. 
 
All the products screened were found to be toxic except “Intra”. The product 
“Intra” was not found to have significant cytotoxic effects against THLE-2 cells at a 
concentration of 1 mg/mL. Potential hepatotoxic components such as anthraquinones 
(aloe-emodin, chrysophanol, emodin, physcion and rhein), N-nitrosofenfluramine, 
psoralen, HMF were also found to have toxic effects on hepatocytes. From all the 
potential toxic components screened, emodin was found to be most toxic. Figure 7.2 
shows the plot of percentage cell viability ± SD of THLE-2 cells upon treatment with 
methanol extracts of three baby products and suspected toxic components β-asarone 
and α-asarone. Out of these three baby products, two products (Bo Ying Compound 
and Houzao Zhenzhu Babao Jingfensan) were implicated in DILI in infants. The third 
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product (Pak Po Chen Chin Hong) which was not implicated in DILI was screened as 
it was also found to contain similar suspected hepatotoxic components (asarones). 
 
Figure 7.2 Plot of percentage cell viability ± SD of THLE-2 cells as compared to the 
vehicle control of three independent experiments conducted in six wells each upon 72 
hours of treatment with methanol extracts of three baby products and suspected toxic 
components (β-asarone and α-asarone) dissolved in DMSO. The cell viability was 
measured by WST-1 assay. Statistical significance (*) was set at p < 0.05.  Of the 
three products, “Bo Ying Compound” was found to be most toxic. 
 
 
Based on above results, methanol extracts of eight products were further 
screened at 6-7 different concentrations to determine their IC50 values (Table 7.2). 
Similarly, five potential toxic components identified in implicated products and 
positive control paracetamol were also screened at different concentrations to 
determine their IC50 values. As can be seen from the Table 7.2, all the implicated 
products have lower IC50 values than the positive control product “Slim10”.  
The IC50 values of five suspected toxic components were also very much 
lesser than that of paracetamol. It is known that paracetamol when taken at a dose 
exceeding the maximum stated dose of 4 g/day (eight tablets a day) will greatly 
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increase the risk of toxicity (Bolesta and Haber, 2002). The product “Control Plus” 
was found to be most toxic product. 
Table 7.2 IC50 values of methanol extracts of implicated products and potential 
hepatotoxic toxic components against THLE-2 cells 
 





Slim10 0.938 ± 0.146 - 4 capsules 3 times a day 
Merit 0.181 ± 0.020 - 3 tablets a day 
Anti-constipation 
Capsules 
0.211 ± 0.011 - 3-4 capsules two times 
a day 
Control Plus 0.016 ± 0.001 - One capsule per meal 
Hydroxycut 0.264 ± 0.041 - Not stated 
Vitiligo Tabs 0.324 ± 0.020 - 2 tablets 3 times a day 
Bo Ying Compound 0.050 ± 0.008 - One tube per day for 
children up to 1-3 years 
Houzao Zhenzhu 
Babao Jingfengsan 
0.484± 0.032 - One spoon each time, 4 
times a day for children 
up to 1-5 years 
Paracetamol 0.229 ± 0.023 1.516 ± 0.132 Maximum dose of 8 
tablets per day 
N-
nitrosofenfluramine 
     0.068 ± 0.008 0.263 ± 0.031 - 
Emodin 0.008 ±  0.001 0.031 ± 0.001 - 
Rhein 0.022 ± 0.002 0.078 ± 0.006 - 
Aloe-emodin 0.038 ± 0.005 0.141 ± 0.018 - 
Cis-asarone  
(β-asarone) 
0.040 ± 0.002 0.193 ± 0.001 0.002 mg/kg bw/day 
could be accepted 
Trans-asarone  
(α-asarone) 
0.046 ± 0.001 0.221 ± 0.001 - 
 
The implicated products can be arranged in descending order of their IC50 
values as Control Plus < Bo Ying Compound < Merit < Anti-constipation capsules < 
Hydroxycut < Vitiligo Tabs < Houzao Zhenzhu Babao Jingfengsan < Slim10. 
Similarly, the suspected hepatotoxic components can also be arranged in descending 
order of their IC50 values as emodin < rhein < aloe-emodin < β-asarone < α-asarone. 
The IC50 value of “Slim10” appears to be high. However, it has a higher dosage 
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regime (total 12 capsules a day). Therefore, if we were to factor in the daily dose to 
account for its exposure to the consumers, its toxicity could be more. An extract may 
have a high IC50 value but it might be more toxic than the others if large amounts are 
ingested per day. This will lead to a higher probability of accumulation of toxic 
constituents and thus increased risk of toxicity.  
The IC50 value of Vitiligo Tabs was found to be 0.324 ± 0.02 mg/mL. As 
discussed in Chapter 6, this product was found to contain furanocoumarins such as 
psoralen and isopsoralen. The furano coumarins could be metabolised by 
hydroxylation at positions 3, 7 and 8 which giving rise to hepatotoxicity (Hadidi et al., 
1997; da Silva et al., 2009). Furocoumarins-containing herbs are also reported to 
cause adverse hepatic events (Cheung et al., 2009). This suggests that psoralen and 
isopsoralen could cause potential hepatotoxic effects. As can be seen from the Figure 
6.1, upon treatment with 100 µg/mL of psoralen, only ~40% of cells were alive. In 
addition, there are also reports of teratogenicity and carcinogenicity of 
furanocoumarins (Diawara et al., 1999; Kreimer-Erlacher et al., 2003). Therefore, 
furanocoumarins could be responsible for the observed toxicity of Vitiligo Tabs. 
However, further work is required to fully assess the hepatotoxic potential of 
furanocoumarins. 
Hydroxycut was not implicated in DILI in Singapore but it was voluntarily 
withdrawn from the local market by the manufacturer because of several cases of 
DILI associated with its use in the USA. G. cambogia, C. sinensis (green tea) and 
chromium are proposed as the possible components responsible for its hepatotoxicity 
(Dara et al., 2008). Reports of G. Cambogia toxicity causing increase in hepatic 
enzymes are also reported in WHO database. Dietary Reference Intakes (DRI) for 
Chromium was established as ranging from 0.2 mg (infants) to a maximum of 45 mg 
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(lactating mothers). The tolerable upper intake level for chromium has not been 
established by any regulatory agencies. Chromium picolinate, a listed ingredient of 
Hydroxycut and many weight loss supplements is reported to cause hepatitis and renal 
failure in one patient (Cerulli et al., 1998). Recent study in US under the National 
Toxicology Program (NTP) found that chromium picolinate could cause preputial 
gland cancer in male rats (National Toxicology Program (NTP), US, 2010). 
Camellia sinensis or green tea, is widely regarded by the public as safe, and is 
frequently added into many supplements. There have been reports of hepatotoxicity of 
green tea. In a systematic review of the available literature by the United State 
Pharmacopoeia (USP), it was concluded that “there is reason to be concerned as 
extracts of green tea may predispose to hepatotoxicity” (Sarma et al., 2008). 
Preclinical data point to the green tea catechin as the cause of hepatotoxicity. 
However, the exact cause of such adverse effects of green tea is not fully understood.  
Despite all the above proposed toxic components of Hydroxycut, the 
responsible components are not known and causation is poorly understood. In this 
study, attempts were made to screen for toxicity. Hydroxycut extract was found to 
have IC50 value of 0.264 ± 0.04 mg/mL. Chemical analysis could not identify any 
potential toxic components except one pyrogallol-like compound based on GC-MS 
results. Pyrogallol is potentially hepatotoxic component. Pyrogallol-mediated 
hepatotoxicity is caused by alteration in mRNA or protein expressions of liver 
enzymes (Upadhyay et al., 2010). 
The product “Houzao Zhenzhu Babao Jingfengsan” was also found to show 
toxicity against THLE-2 cells with IC50 value of 0.484 ± 0.03 mg/mL. As discussed in 
the Chapter 6, this product was found to contain high concentrations of borneol and 
hesperidin. Although these components are not reported to be associated with any 
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adverse events, this may not hold true in the case of infants. This product was 
implicated in a four-month-old baby whose liver may not have developed and 
therefore these compounds might have accumulated and resulted in acute liver failure. 
Therefore, it seems that the improper usage of this product could be the main reason 
for the observed serious adverse hepatic event. 
Likewise, the product “Bo Ying Compound” was also implicated in three-
month- old baby who suffered worsening acute liver failure. As can be seen from the 
Table 6.2, this product was the second most toxic product against THLE-2 cells with 
IC50 value of 0.050 ± 0.008 mg/mL. This product was found to contain potentially 
toxic components such as cis-asarone, trans-asarone and 5-hydroxymethylfurfural. As 
discussed in the chapter 6, asarones are potentially mutagenic and genotoxic 
components, particularly β-asarone (European Medicines Agency, 2005; 
Hasheminejad and Caldwell, 1994). Therefore, use of β-asarone has been restricted in 
the European Union and it is prohibited as a food additive and medicine in the US. 
The two asarones were also found to be toxic in this study with IC50 values of 0.040 ± 
0.002 mg/mL and 0.046 ± 0.001 mg/mL for β and α-asarone respectively. These 
results show that asarones could have harmful effects on hepatocytes. 
Pharmacokinetic study of β-asarone by Fang et al., (2012) to study the 
transformation and excretion of β-asarone in rabbits have shown that about 22% of β-
asarone is converted to α-asarone in rabbits.  β-asarone is rapidly excreted in urine, 
faeces and bile with highest concentrations in urine. Previous studies conducted on rat 
hepatocytes have identified trans-trimethoxycinnamic acid (trans-TMC) as the major 
metabolite of α-asarone. Trans-TMC was also identified as metabolites of asarones in 
C. elegans, microbial model for mammalian drug metabolism (Björnstad et al., 2009). 
In contrast, in humans, cis-TMC and hydroxylated β-asarone were identified as major 
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metabolites of asarones in an analysis of urine samples of patients with A. calamus oil 
intoxications in Sweden (Björnstad et al., 2009).  
As trans-TMC is commercially available, further experiments were conducted 
to determine the toxicity of trans-TMC in hepatocytes. Figure 7.3 shows the plot of 
percentage cell viability ± SD of THLE-2 cells as compared to the vehicle control of 
three independent experiments conducted in six well each upon 72 hours of treatment 
with different concentrations of trans-TMC. It can be seen that The IC50 value of 
trans-TMC is more than 1.50 mM because at the concentration of 1.50 mM (0.354 
mg/mL), it could not kill 50% of hepatocytes. Therefore, it is five times less toxic 
than the β-asarone (IC50 value: 0.192 mM). Therefore, the trans-TMC does not seem 
to be the toxic metabolite of asarones. This results and the study by Björnstad et al., 
(2009) suggests that metabolites other than trans-TMC, such as cis- TMC could be 
involved in the toxicity of asarones.  Cis-TMC is not commercially available; 
therefore, its toxicity could not be assessed in the current study.  
 
 
Figure 7.3 Plot of percentage cell viability ± SD of THLE-2 cells as compared to the 
vehicle control of three independent experiments conducted in six well each upon 72 
hours of treatment with different concentrations of trans-TMC.  




From the above two incidences of involvement of botanical health products in 
infants highlight the importance of consumer education regarding the proper usage of 
these products. Inappropriate use of botanical health products could result in 
undesirable adverse events. Moreover, regulatory actions such implementing 
compulsory label warning to warn consumers not to use in children below certain age 
as one year or as appropriately determined. Such actions could avoid serious adverse 
events resulting from the improper use of botanical health products. 
In the case of the products “Merit and “anti-constipation capsules”, the 
observed adverse hepatic events could be due to the presence of anthraquinones. As 
discussed in Chapter 6, anthraquinones are reported to cause genotoxicity and 
carcinogenicity in mammals (Mueller SO et al., 1998a; Mueller SO et al., 1998b). In 
addition to their hepatopreotective effects, there are also case reports of implications 
of herbs containing anthraquinones in DILI in the literature as discussed in the 
Chapter 6. Public alerts have been issued by the various drug regulatory authorities of 
countries such as Canada (Canadian Adverse Reaction Newsletter, 2003), Britain 
(Medicines and Healthcare Products Regulatory Agency, 2006a; b) and Australia 
(Therapeutic Goods Administration, 2008) on the potential hepatotoxicity associated 
with the consumption of herb Polygonum multiflorum. Rhubarb (Rheum palmatum L.) 
is also reported to have heptotoxic effects (Zhang et al., 2004; Xu et al., 2005; Tian et 
al., 2008; Wang et al., 2011; Wang et al., 2009 ). Implicated products, “Merit”, 
“ Anti-constipation capsules” were fond to contain anthraquinones. In particular, 
“Merit” was found to contain high concentration of athraquinones.  
  The IC50 value of Emodin was 8.4 µg/mL (31 µM), the lowest among the 
seven pure suspected toxic components. This is similar to previously reported IC50 
value of 11.5 μg/mL in HepG2/3A cells. HepG2 cells are liver cancer cells which 
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possess some of the metabolic function of liver cells and have been used to study the 
hepatotoxic potentials of botanicals. Besides emodin, rhein and aloe-emodin were also 
found to be toxic with IC50 values of 22 and 38 μg/mL. Aloe-emodin was reported to 
have IC50 value of 11.8 μg/mL. This is difference could be due to differences in the 
cell line used. Different cell lines have different phenotypic characteristics and hence 
could give different responses. In this study, IC50 values of chrysophanol and 
physcion could not be determined as at the highest achievable test concentration 
(based on their solubility), their toxicity was less than 50%.  
 
7.4.1.3 Screening of different fractions of methanol extract of Merit 
The results of screening of three different fractions of methanol extract of 
“Merit” are presented in Figure 7.4. 
 
Figure 7.4 Plot shows the average percentage cell viability ± standard deviation of 
THLE-2 cells as compared to the vehicle control of three independent experiments 
conducted in six wells each upon 72 hours of treatment with methanol extract of 
product, Merit and its three fractions. The cell viability was measured by the WST-1 
assay. Statistical analysis was performed according to student‟s t-test by one way 
analysis of variance. Significant difference was taken as p < 0.05 in comparison with 
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crude methanol extract. Fraction 1, an anthraquinone rich fraction was found to be 
most toxic.  
In order to ascertain that anthraquinones are the toxic components in the 
product “Merit”, the methanol extract of product was fractionated to obtain 
anthraquinone rich fraction. This fraction was then compared with other fractions 
without anthraquinones and the crude methanol, extract of the product. The IC50 of 
anthraquinone rich fraction, fraction 1, was found to be 0.113 ± 0.01 mg/mL 
compared to 0.181 ± 0.02 mg/mL of the crude methanol extract. This further supports 
the findings that anthraquinones could be responsible for the observed DILI. 
 
7.4.1.4 Screening of different fractions of methanol extract of Control Plus 
Figure 7.5 shows the screening of three different fractions of methanol extract 
of “Control Plus” at two different concentrations 10 and 30 µg/mL.  
 
Figure 7.5 Plot shows the average percentage cell viability ± standard deviation of 
THLE-2 cells as compared to the vehicle control of three independent experiments 
conducted in six wells each upon 72 hours of treatment with methanol extract of 
product, Control Plus and its three fractions. The cell viability was measured by the 
WST-1 assay. Statistical analysis was performed according to student‟s t-test by one 
way analysis of variance. Significant difference was taken as p < 0.05 in comparison 




As discussed earlier, the methanol extract of “Control Plus” was found to be 
most toxic among all the products screened (Table 7.2). However, the responsible 
components could not be identified. Therefore, further attempts were made to identify 
the fraction which contained the most toxic components. Fraction 2 and fraction 3 
were found to be toxic at 30 µg/mL concentration. In particularly, fraction 2 was 
found to be very toxic with cell viability of only 12.56 ± 6.32 % at a concentration of 
10 µg/mL. However, the toxic components are yet to be identified. Further work is 
required to identify responsible toxic components by isolating and purifying different 
components of fraction 2. 
 
7.4.2 Mechanisms of observed toxicity 
7.4.2.1 TBARS assay for the measurement of lipid peroxidation  
Lipid peroxidation is a well-defined mechanism of cellular damage in animals 
and plants and is an indicator of oxidative stress. Lipid peroxidation is quantified by 
measuring malondialdehyde (MDA), a breakdown product formed from 
polyunsaturated fatty acids (PUFA) hydroperoxides. Thiobarbituric Acid Reactive 
Substances (TBARS) is a well-established assay for screening and monitoring lipid 
peroxidation. MDA forms a 1:2 adduct with thiobarbituric acid (TBA). The MDA-
TBA adduct formed from the reaction of MDA in samples with TBA can be measured 
colorimetrically or fluorometrically. TBARS levels are then determined from the 
malondialdehyde standard calibration curve. The results are expressed as nano moles 
of MDA formed per mg of protein by determining the protein content of the cells or 
tissues. 
Based on the results presented in earlier Section 7.1, product containing 
anthraquinones and asarones were further evaluated for involvement of oxidative 
stress for their toxicity in hepatocytes. Figure 7.6 shows the effects of anthraquinones 
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and the methanol extract of the product Merit on THLE-2 cells. Figure 7.7 shows the 
effects of the methanol extracts of the products BYC, HZBJ as wells as the 
compounds, α-asarone and β-asarone in THLE-2 cells.  
 
 
Figure 7.6 The Plot shows the average nano moles of MDA per mg of protein ± 
standard deviation of three independent experiments upon treatment with 
anthraquinones, diethyl maleate and methanol extract product “Merit” against THLE-
2 cells for 24 hours. Significant difference was taken as p < 0.05 in comparison with 
untreated control cells. 
 
Five anthraquinones (aloe-emodin, chrysophanol, emodin, physcion and 
rhein), asarones (α and β-asarone) and products, Merit, Bo Ying Compound (BYC) 
and Houzao Zhenzhu Babao Jingfengsan (HZBJ) were evaluated by TBARS assay to 
measure lipid peroxidation as an indicator of oxidative stress. Increased formation of 
lipid peroxide (formation of MDA) was found upon treatment with methanol extract 
of Merit. Particularly, at the concentration of 1.2 mg/mL, the peroxidation was similar 
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to that of the positive control, diethyl maleate. This suggests that the methanol extract 
of Merit induces oxidative stress. This could be mediated by the formation of ROS. 
 
 
Figure 7.7 The Plot shows the average nano moles of MDA per mg of protein ± 
standard deviation of three independent experiments upon treatment with methanol 
extracts of products “Bo Ying Compound” (BYC) and “Houzao Zhenzhu Babao 
Jingfengsan” (HZBJ), compounds α and β-asarones against THLE-2 cells for 24 hours. 
Significant difference was taken as p < 0.05 in comparison with untreated control 
cells. 
 
Among the five anthraquinones, emodin and aloe-emodin were found to cause 
lipid peroxidation at the tested concentrations. Emodin was found to have the highest 
lipid peroxidation inducing effects among the anthraquinones. Rhein, chrysophanol 
and physcion were not found to have significant lipid peroxidation inducing effects at 
the tested concentrations. 
Emodin or emodin containing extracts were reported to have anti-oxidant 
activities by various mechanisms such as inhibition of radical formation, radical 
scavenging and inhibition of lipid peroxidation (Sato et al., 2000; Choi et al., 2000). 
212 
 
However, in these studies, oxidative stress was deliberately induced by using an 
oxidant and then the effect of emodin as an anti-oxidant was tested. In contrast to the 
above studies, some studies reported emodin as a pro-oxidant in cancer cells (Su et 
al., 2005; Yang et al., 2004; Wang et al., 2005).  
Emodin, having a quinone structure could act as an effective electron acceptor 
intracellularly to produce ROS (Rahimipour et al., 2001).  Many studies have shown 
that emodin generates ROS in a variety of tumor cells (Su et al., 2005; Yang et al., 
2004; Wang et al., 2005). In this study, emodin was found to cause twice as much 
compared to control cells. The results of this study are in agreement with such studies 
which reported generation of ROS by emodin. Generation of ROS by emodin would 
cause oxidative stress in the hepatocytes which could lead to the cell toxicity and 
death. 
Similar to emodin and aloe-emodin, α and β-asarones were also found to cause 
oxidative stress in dose dependant manner. The levels of MDA were increased as the 
concentrations of asarones were increased from 0.3 mM to 0.8 mM. The methanol 
extract of product Bo Ying Compound was also found to have significant lipid 
peroxidation inducing effects at 0.2 mg/mL concentration. This data suggests that 
asarones and products containing asarones are producing cellular damage in 
hepatocytes by oxidative stress. This stress could be mediated by the formation of 
reactive metabolites which would generate ROS.  
 Hasheminejad and Caldwell (1994) reported that genotoxicity of asarones 
could be due to their oxidized metabolites such as trans- 2,4,5-trimethoxycinnamic 
acid (trans-TMC) which is the product of ω-oxidation. Their conclusion was based on 
the observation that the CYP-450 inhibitor, cimetidine was able to block the 
genotoxicity of asarones (Hasheminejad and Caldwell, 1994). However, similar to 
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results of this study, the major metabolite identified from rat hepatocytes, trans- 2,4,5-
trimethoxycinnamic acid (trans-TMC), was not found to be genotoxic (Hasheminejad 
and Caldwell, 1994). This is also in accordance with the study by Björnstad et al., 
(2009) where they identified cis-TMC and hydroxylated β-asarone as major 
metabolites of asarones in urine samples of patients in Sweden.  
Another mechanism of their metabolism could be that the carbon-carbon 
double bond of asarones could undergo epoxidation which might lead to a reactive 
intermediate (Hasheminejad and Caldwell, 1994). Therefore, the presence of a 2-
methoxy substituent in the asarones was proposed to have a critical role, either by 
affecting the metabolism either by steric hindrance or by altering the conformation of 
the propenyl side-chain (Hasheminejad and Caldwell, 1994). It could also aggravate 
the reactivity of oxidative metabolites by electronic effects (Hasheminejad and 
Caldwell, 1994). Moreover, the w-hydroxylation and subsequent sulfation of asarones 
could also lead to formation of carbonium ions (Tsai et al., 1994). However, the exact 
mechanisms of the toxicity of asarones are not known. Therefore, further work is 
required to characterize the metabolites responsible for the observed toxicity of 
asarones. 
 
7.4.2.2 Glutathione depletion assay  
Another approach to measure the oxidative stress inducing effects is to 
measure the glutathione levels. Increased levels of oxidized form of glutathione 
(formed as results of ROS scavenging) are indicative of oxidative stress. Therefore, 
samples screened in TBARS assay were further assessed for their effect on 
glutathione levels in the hepatocytes (THLE-2 cells). The Figure 7.8 shows the effects 
of anthraquinones and methanol extract of product Merit on glutathione levels in 
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THLE-2 cells whereas Figure 7.9 shows the effects of methanol extracts of products 
BYC, HZBJ, α-asarone and β-asarone in THLE-2 cells.  
 
 
Figure 7.8 The Plot shows the ratio of GSH (reduced form)/GSSG (oxidized form) 
(mean ± SD, n=3) upon treatment with different anthraquinones and methanol extract 
product “Merit” against THLE-2 for 72 hours. Significant difference was taken as p < 
0.05 in comparison with untreated control cells. 
 
 
As it is evident from Figure 7.8, methanol extract of merit emodin, aloe-
emodin and rhein reduced the ratio of GSH/GSSSG in THLE-2 cells. Among the 
anthraquinones, similar to the results of TBARS assay emodin had the most 
glutathione depletion effects. But unlike TBARS assay, rhein was found to have 
significant glutathione depletion effects followed by aloe-emodin. However, 







Figure 7.9 The Plot shows the ratio of GSH (reduced form)/GSSG (oxidized form) 
(mean ± SD, n=3) upon treatment with different methanol extracts of products “Bo 
Ying Compound” (BYC) and “Houzao Zhenzhu Babao Jingfengsan” (HZBJ), 
compounds α and β-asarones against THLE-2 cells for 72 hours. Significant 
difference was taken as p < 0.05 in comparison with untreated control cells. 
 
Similar to anthraquinones, asarones were also found to have GSH depletion 
effects in THLE-2 cells (Figure 7.9). The methanol extracts of BYC and HZBJ baby 
products were also fund to have significant GSH depletion effects. Compared to 
HZBJ, BYC was found to be very potent in GHS depletion. BYC was also found to 
have stronger GSH depletion effects than Merit. This data are in accordance with the 
results of WST-1 cell viability assay where methanol extract of BYC was found to 
have lower IC50 than those of Merit and HZBJ. 
The above results of TBARS assay and glutathione depletion assay underscore 
the oxidative stress inducing potential of methanol extract of three products (Merit, 
BYC and HZBJ). These data reinforced that the toxicity of anthraquinones and 
asarones could be attributed to their oxidative stress inducing effects. However, 
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further work is required to investigate if this toxicity is a direct toxicity of these 
compounds or if it is mediated by their toxic metabolites. This could be done by 
identifying various metabolites and these compounds and comparing their toxicity 
with the non-metabolised compounds.  
 
7.4.2.3 Measurement of cell viability and caspase-3/7 activation 
After investigating the oxidative stress inducing effects as one of the 
responsible cause of cell death, it is important to determine the type of cell death. 
There are two major types of cell death, apoptosis (programmed cell death) and 
necrosis (death by injury). Apoptosis is usually manifested by activation of specific 
proteases known as caspases such as caspase-3 and 7. Therefore monitoring of 
caspase-3/7 levels could be used to identify the type of cell death. The Figures 7.10 
and 7.11 shows the effects of methanol extract of Merit and emodin on caspase-3/7 
activation in THLE-2 cells. The effects of α asarone and β-asarone on caspase-3/7 
activation cells are shown in Figure 7.12 and 7.13 respectively. Figure 7.14 shows the 







Figure 7.10 Effects of methanol extract of Merit on caspase activation and cell 
viability after treatment for (A. 6 hours, B. 12 hours). The plot represents average % 
caspase-3/7 levels on primary Y-axis and % cell viability on secondary Y-axis ± 








Figure 7.11 Effects of methanol extract of emodin on caspase activation and cell 
viability after treatment for (A. 6 hours, B. 12 hours). The plot represents average % 
caspase-3/7 levels on primary Y-axis and % cell viability on secondary Y-axis ± 








Figure 7.12 Effects of methanol extract of β-asarone on caspase activation and cell 
viability after treatment for (A. 6 hours, B. 12 hours). The plot represents average % 
caspase-3/7 levels on primary Y-axis and % cell viability on secondary Y-axis ± 







Figure 7.13 Effects of methanol extract of α-asarone on caspase activation and cell 
viability after treatment for (A. 6 hours, B. 12 hours). The plot represents average % 
caspase-3/7 levels on primary Y-axis and % cell viability on secondary Y-axis ± 







Figure 7.14 Effects of methanol extract of methanol extracts of baby products BYC 
and HZBJ on caspase activation and cell viability after treatment for (A. 6 hours, B. 
12 hours). The plot represents average % caspase-3/7 levels on primary Y-axis and % 
cell viability on secondary Y-axis ± standard deviation at different concentrations 






The effect of methanol extract of products Merit, Anti-constipation capsules, 
BYC and HZBJ were investigated to determine the type of cell death induced by them. 
Anthraquinones (aloe-emodin, chrysophanol, emodin, physcion and rhein) and 
asarones (α and β asarones) were also screened at two different time points, 6 hours 
and 12 hours to determine the type of cell death.  
As can be seen from the Figure 7.10, the methanol extract of Merit was found 
to reduce cell viability accompanied by reduction in caspase-3/7 levels for both 6 
hours and 12 hours of incubation. This suggests that the cells do not induce the 
activation of caspase-3/7. Similar results are also obtained with the methanol extract 
of Anti-constipation capsules (Appendix 3). Similarly, emodin was also found to 
cause cell death by mechanisms without activation of caspase-3/7 (Figure 7.11). 
Among the anthraquinones, similar to the results of TBARS assay emodin had the 
most glutathione depletion effects. But unlike TBARS assay, rhein was found to have 
significant glutathione depletion effects followed by aloe-emodin. However, 
chrysophanol and physcion were not found to have any significant effects on 
glutathione levels. When THLE-2 cells were incubated with emodin for 6 hrs and 12 
hrs, a dose dependent decrease in cell viability accompanied by reduction in caspase-
3/7 levels was observed. Likewise, aloe-emodin, rhein, chrysophanol and physcion 
did not cause any activation of caspase-3/7 levels after 12 hours of incubation 
(Appendix 3). This reinforces that anthraquinones cause THLE-2 cell death by 
mechanism other than caspase-3/7 dependant apoptosis. 
In contrast to the results of this study,  in previous studies, emodin, aloe-
emodin and rhein were reported to cause apoptosis in various cancer cells via 
activation of caspases (Yu et al., 2012; Suboj et al., 2012; Wei et al., 2011; Chiu et 
al., 2009; Lai et al., 2009). These differences could be due to differences in detection 
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reagents, incubation time, no. of cells and cell types used. In this study, the effect was 
tested against immortalized normal hepatocytes (THLE-2 cells) while in studies 
reporting apoptosis inducing effects, cancer cells were used. However, Shieh et al., 
(2004) reported that emodin did not affect caspase-3 levels in HepG2 cells up to 24 
hours of treatment. It only showed significant changes in caspase-3 levels after 48 
hours of treatment. Therefore further work is required to confirm these differences. 
Measurement of other markers such as annexin V of apoptosis using flow cytometry 
could give better explanations of cell death mechanism of anthraquinones. 
 Unlike methanol extract of Merit and anthraquinones, α-asarone and β-
asarone were found to induce caspase-3/4 activation implying cell death by apoptosis 
(Figure 7.12). Increased levels of caspase-3/7 accompanied by reduced cell viability 
were observed upon treatment with asarones for both 6 hours as well as 12 hours. 
However, the methanol extract of BYC and HZBJ baby products were found to cause 
reduction in cell viability without activation of caspase-3/7 levels. 
 β-asarone is reported to have anti-proliferative activity against colon cancer 
cells (Zou et al., 2012). Similar to the results of this study, it directly induces 
apoptosis in LoVo colon cancer cells by up-regulation of caspases through a 
mitochondrial pathway in vitro and in vivo (Zou et al., 2012). However, β-asarone is 
also reported to reduce apoptosis by inhibiting caspase-3 activation (Liu et al., 2012; 
Li et al,. 2010). However, direct comparison cannot be made as their study involved 
investigations of effect of β-asarone after deliberately inducing apoptosis by use of 
neurotoxin. They did not report the direct effects of β-asarone alone.  
 In summary, the above results showed that some of the products implicated in 
DILI were found to have hepatotoxicity against THLE-2 cells. In some products, the 
toxicity could be attributed to the presence of potentially toxic components such as 
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anthraquinones and asarones. The potentially toxic anthraquinones and asarones were 
also found to cause toxicity in THLE-2 cells. This toxicity might be mediated by 
oxidative stress caused by ROS generated by toxic components present in implicated 
products. Further work needs to be done to determine other potentially hepatotoxic 




The hepatotoxicity of ten products implicated in DILI and ten pure potentially toxic 
components was successfully evaluated. Four products were found to be more toxic 
than the positive control paracetamol. Anthraquinones (in particular emodin) and 
asarones might be in part responsible for the hepatotoxicity seen with some of the 
products implicated in DILI. Potential mechanisms of hepatotoxicity and cell death 













Conclusion and future work 
 
Botanical medicine has been used for centuries for health promotion and 
therapeutic purposes. However, some herbs may cause adverse or toxic effects. This 
study explores the holistic viewpoint that some botanicals may have beneficial effects 
(e.g anti-proliferative effects) whereas some may cause adverse or toxic effects (e.g. 
hepatotoxicity). In this thesis, a well-known TCM herb, P. notoginseng, is used as a 
model herb to study its potential anti-proliferative effects while 15 botanical health 
products suspected to cause drug induced liver injury (DILI) are evaluated for 
potential hepatotoxicity. 
Chapter 1 gives an overview of various safety issues related to botanical 
medicine, in particular, the hepatotoxicity associated with the use of botanicals and 
botanical health supplements. It also gives a general overview of medicinal plants as 
sources of new lead compounds and presents a review of P. notoginseng, the 
medicinal plant of interest in this study. Chapter 2 describes the hypotheses and 
objectives of this study.  
Chapter 3 presents the phytochemical investigations of steamed P. 
notoginseng and evaluation of the anti-proliferative activity of its marker constituents. 
Investigations of the effects of ginsenosides Rg5, Rh4, Rk1 and Rk3 on the anti-
proliferative activity of two chemotherapeutic agents, namely, doxorubicin and 
paclitaxel, are also carried out. Seven major markers that play key roles in the 
differentiation of raw and steamed P. notoginseng were successfully isolated and 
purified from steamed P. notoginseng.  These isolated ginsenosides were found to 
possess anti-proliferative activity against liver cancer cell lines (SNU449, SNU182 
226 
 
and HepG2), breast cancer cell lines (MDA-MB-231), cervical cancer cell line 
(C33A), colon cancer cell line (HCT-116) and ovarian cancer cell line (PA1). Among 
these, ginsenosides Rh2, Rk1 and Rk3 were found to be the most active with IC50 
values ranging from 23-36, 65-110 and 78-105 µg/mL respectively against various 
liver cancer cell lines. These ginsenosides were also more active than ginsenoside 
20(S)-Rg3 (IC50 values ranging from 134-145 µg/mL) which has been approved as an 
anti-cancer drug in China and Taiwan. The results also showed that the cis-epimers of 
ginsenosides (RK1, Rk3) are more active than the corresponding trans-epimers (Rh4, 
Rg5). To the best of our knowledge, although ginsenosides Rh1, Rg3, Rg5, Rh4, Rk1 
and Rk3 have been reported previously to have anti-proliferative effects, this is the 
first report where the relative anti-proliferative activities of these marker ginsenosides 
were compared in one experimental set up. The anti-proliferative activity of 
ginsenosides in descending order of activity is Rh2 > Rk1 > Rk3 > 20(S)-Rg3 > 
20(S)-Rh1 > 20(R)-Rh1 ~Rg5 > Rh4. In addition, ginsenoside Rk1 and Rk3 were also 
found to have higher selectivity than ginsenoside 20(S)-Rg3 against the liver cancer 
cells in this study. Selectivity indices of 20(S)-Rg3, Rk1 and Rk3 were found to be 
1.5, 2.3 and 2.1 respectively. This is the first report on the selectivity of ginsenosides 
20(S)-Rg3, Rk1 and Rk3 against the liver cancer cells.  
 Investigations on the mechanism of anti-proliferative activity of ginsenoside 
Rk3 showed that ginsenoside Rk3 exhibits apoptosis inducing effects by arresting 
cells in sub-G1 phase via activation of caspase-3/7. This is the first report of the 
potential mechanism of anti-proliferative activity of ginsenoside Rk3. Furthermore, 
ginsenosides Rk3, Rk1, Rg5 and Rh4 were found to increase the anti-proliferative 
activity of doxorubicin by more than two folds but did not affect the anti-proliferative 
actions of paclitaxel against liver cancer cells. This suggest that the concurrent use of 
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these ginsenosides with doxorubicin could help to reduce the dosage of doxorubicin 
required for chemotherapy and hence could potentially reduce the side effects due to 
doxorubicin. To the best of our knowledge, this is the first report of the beneficial 
interactions of ginsenosides Rg5, Rh4, Rk1 and Rk3 with doxorubicin. 
The above findings on the different ginsenosides of steamed P. notoginseng 
supported the hypothesis that steamed P. notoginseng could serve as a potential 
source of new anti-proliferative lead molecules.  Exploratory screening using various 
cancer cell lines is a first step towards identifying potential anti-proliferative agents. 
Hence, the promising results obtained in this study should also be confirmed in vivo in 
suitable animal models. The selectivity indices of ginsenosides were found to be not 
high in this study. Therefore, future work is also required to carry out in vivo toxicity 
in animal models. The structure activity relationship for the anti-proliferative 
activities of ginsenosides should also be studied by more accurate and quantitative 
methods such as the QSAR modelling, mechanistic and/or functional experiments. 
Moreover, further research is also needed to further investigate the down-stream 
molecular pathways involved in the anti-proliferative activity of ginsenoside Rk3. 
Assays such as the annenxin V staining and cytochemical methods could also provide 
additional supportive data for the anti-proliferative activity of ginsenoside Rk3. In 
addition, it should be noted that the effectiveness of combination therapy depends on 
concentrations of drugs and their ratios. The ginsenosides and doxorubicin would 
have distinct pharmacokinetic properties when they are being administered in vivo. 
The failure to control drug ratios in the application of drug combinations in vivo could 
lead to the exposure of cancer cells to undesirable effects such as a loss of therapeutic 
activity. One potential approach to maintain the appropriate drug concentrations and 
ratio in vivo is to employ a suitable drug delivery system. The use of drug delivery 
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systems such as liposomes or polymeric nanoparticles could increase bioavailability, 
co-deliver and maintain synergistic drug ratios of therapeutic agents at the tumour site. 
In Chapter 4, a simple, sensitive and reliable LC-MS/MS method is developed 
and validated for the quantification of two epimers, namely, ginsenosides Rh4 and 
Rk3. The pharmacokinetic profiles of Rh4 and Rk3 were subsequently assessed in 
Sprague-Dawley rats in vivo. Rh4 and Rk3 were found to have low oral 
bioavailabilities after oral administration at 20 mg/kg. This is consistent with the 
reported low oral bioavailabilities of other ginsenosides (e.g. Ra3, Rb1, Rd, Re and 
Rg1). The oral bioavailabilities of Rh4 and Rk3 could be improved by modulationg 
their solubility and /or dissolution. Upon intravenous administration (5 mg/kg), both 
Rh4 and Rk3 were detected in the rat plasma and showed moderate clearances (Cl = 




, respectively) and terminal elimination half-
lives (t1/2 Z = 157 ± 65 and 99.5 ± 37.8 min, respectively). However, these data 
suggest that it may not be possible to achieve the desired effective concentration in 
vivo. Higher dose might be required to achieve effective in vivo concentrations even 
after I.V. administration. This presents additional challenge for their clinical use. The 
findings of this study provided important information for the further exploration on 
medicinal application of ginsenosides Rh4 and Rk3.  
From the perspective of safety of herbal medicine, an analysis of adverse 
events reports submitted to the Vigilance Branch of HSA over a 12-year period (1998-
2009) is presented in Chapter 5. Information on adverse events associated with the use 
of botanicals and botanical health supplements was collated. In this period, it was 
found that only 3.8 % cases (627 cases) out of a total of 16,696 cases of adverse 
events were due to complementary medicine and health supplements. The detailed 
analyses of these reports have provided important trends and signals for 
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pharmacovigilance purposes. Outbreaks of severe hypoglycemia in 2008 and 2009 
were associated with the use of adulterated and illegal sexual performance 
enhancement products. Adulteration of CAM products with western medicine and/or 
their synthetic analogues appears to be one of the major known causes of the 
associated adverse events. Common adulterants were found to be drugs associated 
with the specific indications of the products. However, in 55% of the products tested, 
common adulterants were not found. In such products, the exact causes of the adverse 
events are not known. Patients might have experienced adverse reactions due to 
allergies, improper usage of products or the intrinsic toxicity of components of 
implicated products. 22 fatalities were reported and hepatotoxicity was responsible for 
the deaths of 10 patients during the study period. Therefore, besides screening for 
adulterants, other measures to assess toxicity are also necessary. 
Although the majority of the cases were associated with conventional 
medicine, CAM products should be used with caution. Reporting of suspected adverse 
events is important to allow rapid regulatory actions to be taken. These findings assert 
that the analysis of spontaneously reported adverse events is important in monitoring 
the safety of CAM products and helps in the understanding of the associated risks 
with the use of CAM products. In this study, reports were analyzed retrospectively 
and not all the reports contained complete information. As such, it was not possible to 
determine whether the product contains ingredients that were intrinsically toxic, 
without carrying out toxicity tests. The adverse reactions might also be due to the 
concomitant drugs taken or due to the adulterants in the products. Therefore, a causal 
relationship cannot be confidently drawn. Moreover, under reporting might also be 
possible. Regulatory authorities and healthcare professionals should educate patients 
to disclose the use of CAM to aid the detection of potential drug- herb interactions or 
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to elucidate the cause of the adverse events. They should also follow up on the 
adverse events reported and be vigilant in detecting adverse effects.  
In Chapter 6, chemical analyses of 15 products suspected of causing DILI in 
Singapore are delineated. Potential hepatotoxins such as anthraquinones, β-asarone, 
N-nitrosofenfluramine and 5-hydroxymethylfurfural were identified in some of the 
implicated products. The concentrations of anthraquinones and asarones were also 
quantified by validated HPLC and GC-MS methods respectively. The developed 
methods were simple, reliable and faster than previously reported methods. These 
methods could be used for quality control of botanicals and botanical health products. 
The product “Merit” was found to contain 9.84 ± 0.02 mg of anthraquinones per unit 
dose, equivalent to an intake of 29.52 ± 0.02 mg of anthraquinones per day. This is 
very close to the maximum daily allowance of 30 mg as recommended by the 
European Medicines Agency for the safe use of anthraquinones. Furthermore, analysis 
of two different batches of implicated product “Merit” revealed large batch to batch 
variation (> 50 fold variation). This could be due to poor quality control measures by 
the manufacturer. Anthraquinones are reported to be mutagenic and genotoxic 
compounds. Moreover, in addition to the reports of hepatoprotective effects, there are 
also reports of hepatotoxicity of anthraquinones and herbs containing anthraquinones 
(e.g. Rheum palmatum L. and Polygoni multiflori). It is possible that herbs or natural 
products may have bidirectional effects and various factors such as dose and disease 
condition may determine the beneficial effects or adverse effects. Therefore, further 
work is required to investigate those determinant factors. Similarly, β-asarone is also 
reported as genotoxic and hepatocarcinogenic but its hepatotoxicity is not reported in 
humans or animals. However, due to its other toxic effects, its concentration in health 
products is controlled by the various regulatory authorities. A limit of exposure from 
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herbal medicinal products of approximately 115 μg/day for β-asarone (based on 2 
μg/kg body weight/day) has been set by the European Medicines Agency.  
From the 15 implicated products, two products (including one baby product) 
were found to contain asarones. To further investigate the prevalence of asarones in 
botanical health products used for babies, analyses of 20 baby products (17 were 
purchased from the local market) were carried out. Of these 20 products, 10 products 
were found to contain β and α-asarones. In 4 of those 10 products, the presence of 
asarones could not be attributed to any of the labeled ingredients. Subsequently, 
asarones were quantified in these 10 products by the validated GC-MS method. Of the 
10 products found to contain β-asarone, 6 products were found to contain β-asarone 
more than the daily recommended exposure levels. These products were found to 
contain as much as 4 to 25 times more amounts of β-asarone than the recommended 
amount estimated based on body weights for different age groups. For example, the 
product Babao Zhupo Wao San was found to contain more than 25 times of the 
allowable levels of β-asarone. In the case of product “Bo Ying Compound” where a 3 
month old infant was affected, it was found to contain more than 7 times of the 
recommended limit of β-asarone. There is a need to improve awareness among the 
consumers for the correct use of botanical health products. Furthermore, warnings 
label such as “not for infants and children below one year” could also help to prevent 
such dangerous adverse events. In addition, this study shows the importance of 
consulting a qualified practioner before consuming any CAM products to avoid 
potential unwanted effects of CAM products. To the best of our knowledge, this is the 
first report of analysis of baby products for the presence of asarones. 
These results suggest that β-asarone (in varied concentrations) is prevalent in 
commercial botanical health products available in the local market. In view of the 
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toxicity of β-asarone, it is important to monitor its concentration in herbal medicinal 
products particularly products used for babies and children who are more prone to 
adverse events.  Moreover, in this study, the authentic herb Acori tatarinowii (one of 
the labeled ingredients) was found to contain high concentrations (7679.8 ± 85.7 
mg/kg of β-asarone and 679.1 ± 20.3 mg/kg of α asarone) of asarones. The EMEA 
recommends maximum of 0.1 mg/kg of β-asarone in food stuffs. Therefore, further 
work is required to investigate the toxic potential of Acori tatarinowii because of its 
high asarone content. The results of this study indicate that there is a need to conduct 
detailed evaluation of this herb to consider its regulation in herbal preparations. The 
results of this study shed light on the importance of monitoring the levels of 
potentially toxic components like β-asarone in botanicals and botanical health 
products. Detailed investigation of the toxicity of asarones is warranted. 
In order to evaluate the hepatotoxic potential of implicated products, the ten 
potentially toxic components identified in Chapter 6 and extracts of 10 products were 
screened against normal human hepatocytes (THLE-2 cells) in Chapter 7. The ten 
products are Slim10, Merit, Anti-constipation capsules, Hydroxycut, Control Plus, 
Vitiligo Tabs, Intra, Bo Ying Compound, Houzao Zhenzhu Babao Jingfengsan and 
Pak Po Chen Chu Chin Hong while the ten compounds are  N-nitrosofenfluramine, 
aloe-emodin, chrysophanol, emodin, physcion, rhein, psoralen, α-asarone, β-asarone 
and 5-hydroxymethylfurfural. Four products, namely, Merit, Anti-constipation 
capsules, Control Plus and Bo Ying Compound with IC50 values of 0.181, 0.211, 
0.016 and 0.050 mg/mL respectively were found to be more toxic than the positive 
control paracetamol which has an IC50 value of 0.229 mg/mL. Further fractionation of 
the product “Merit” showed that the anthraquinone rich fraction was the most toxic, 
hence confirming the hepatotoxicity of components in the product. This suggests that 
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anthraquinones could cause unwanted adverse effects on liver. From the five 
anthraquinones (aloe-emodin, chrysophanol, emodin, physcion, rhein) screened, 
emodin was found to be the most toxic with an IC50 value of 8.4 µg/mL (31 µM) 
against THLE-2 cells. Emodin has been reported in the literature to be genotoxic and 
mutagenic and is also toxic to zebra fish and L-02 liver cells. Similarly, α-asarone and 
β-asarone with IC50 values of 0.046 and 0.040 mg/mL respectively are also found to 
be more toxic to liver cells than paracetamol in this study. 
Results from the lipid peroxidation assay and glutathione depletion assay 
suggest that the observed liver toxicity could be due to the formation of reactive 
oxygen species (ROS). Studies on the mechanism of cell death suggest that extracts of 
Merit, Anti-constipation capsules, Bo Ying compound, Houzao Zhenzhu Babao 
Jingfengsan and the anthraquinones cause caspase-3/7 independent cell death while 
the asarones ( and β) cause cell death by activation of caspase-3/7. However, further 
work is required to determine the exact type of cell death.  Studies such as cell cycle 
analyses, Annexin V staining and/or cytochemical methods should be conducted to 
determine type of cell death. Implicated products and identified potentially toxic 
components may cause cell death by apoptosis, necrosis or other type of cell death e.g. 
autophagy. Furthermore, one of the proposed metabolite of asarones, trans-
trimethoxycinnamic acid, was not found to be toxic in this study. This suggests that 
other metabolites such as cis- trimethoxycinnamic acid could be involved in the 
toxicity of asarones. Therefore, further work is required to identify the toxic 
metabolites of asarones. The presence of high concentration of potentially toxic 
components, especially anthraquinones and asarones in these products and their 
consumption for long duration could be one of the possible reasons for their 
hepatotoxicity. To the best of our knowledge, this is the first report of the effects of 
234 
 
asarones on human liver cells. The results of chemical analyses and toxicity screening 
in liver cells shed light on the importance of controlling the concentration of 
potentially toxic components, in particular, anthraquinones and asarones, in botanical 
health products to safeguard patient safety. 
The amounts of samples obtained from patients who experienced DILI were 
very limited and hence in vitro methods which require relatively small amounts of 
sample were employed. The toxicity of identified toxic components which are 
available commercially should be studied using in vivo animal models to further 
confirm the results obtained in this study. In this study, the direct toxicity of suspected 
products and potentially toxic components was carried out on normal human 
hepatocytes in vitro. The role of various genetic and environmental risk factors was 
not evaluated as only products were available for evaluation.  
In conclusion, the work presented in this thesis scientifically evaluated the 
anti-proliferative activity of P. notoginseng and identified some of its active 
components. Potential beneficial interactions (synergistic and/or additive effects) 
between ginsenosides (e.g. Rg5, Rh4, Rk1 and Rk3) of steamed P. notoginseng and 
doxorubicin were also identified. These results could provide a better understanding 
of potential anti-proliferative activity of steamed P. notoginseng and its use in 
potential combination therapy with established chemotherapeutic drug. In addition, 
chemical and toxicological evaluations have identified potentially toxic components 
products implicated in DILI. These findings suggest that the intrinsic toxicity of 
components present in botanical medicine such as the anthraquinones (in particular, 
emodin) and asarones should not be neglected. Consumers should be alerted to the 
common misconception of “natural means safe”. 
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In today‟s world of evidence based medicine, continuous research is required 
to discover new drugs from natural products and to evaluate the safety and toxicity of 
botanical health products. The holistic approach presented in this thesis is a step 
towards understanding and increasing awareness of the benefits and risks associated 
with the use of botanical medicine. The results of this work help to further harness the 
health benefits from botanicals and provide greater insights to the perceived safety or 
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Figure 1. LC-ESI-MS/TOF total ion Chromatograms and mass spectra of ginsenoside 
20S-Rh1 (a). TIC of 20S-Rh1 standard, (b). High resolution mass spectra of 20S-Rh1 
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Figure 2. LC-ESI-MS/TOF total ion Chromatograms and mass spectra of ginsenoside 
20R-Rh1 (a). TIC of 20S-Rh1 standard, (b). High resolution mass spectra of 20R-Rh1 
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Figure 3. LC-ESI-MS/TOF total ion Chromatograms and mass spectra of ginsenoside 
Rk1 (a). TIC of Rk1 Std. (b). High resolution mass spectrum of Rk1 Std. (c). TIC of 
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Figure 4. LC-ESI-MS/TOF total ion Chromatograms and mass spectra of ginsenoside 
Rk3 (a). TIC of Rk3 Std. (b). High resolution mass spectrum of Rk3 Std. (c). TIC of 
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Figure 5. LC-ESI-MS/TOF total ion Chromatograms and mass spectra of ginsenoside 
20S-Rg3 (a). TIC of 20S-Rg3 Std. (b). High resolution mass spectrum of 20S-Rg3 Std. 
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Details of baby products purchased from local market in Singapore to screen for the 
presence of asarones 
 
No. Name Distributor Manufacturer 
1 
Mild Hot Cough San She 
Dan Chun Bei Mo 
Eu Yan Sang Weng Li Sdn Bhd 
2 
Mild Cold Cough San 
She Dan Chen Pi Mo 
Eu Yan Sang Weng Li Sdn Bhd 
3 
Zhen Zhu Chuan Bei Jing 
Feng San 
H.W traditional 
Medicine Pte Ltd 
H.W traditional Medicine Pte 
Ltd 
4 
Cordyceps & Fritillaria 
Powder 
Poli Medical Co. Poli Medical Co. 
5 Babao Zhupo Wao San 
H.W traditional 
Medicine Pte Ltd 
Ecolite Biotech Mfg Sdn Bhd. 
6 
Zhupo Chuanbei Hou Zao 
San 
H.W traditional 
Medicine Pte Ltd 
Ecolite Biotech Mfg Sdn Bhd. 
7 
Fu Fang Chen Chu Ho 
Chou San 
Lee Fah trading Co. 
S. H.Uniflex Chinese Medical 




Kinhong Pte. Ltd 
Shijiazhuang Shineway 
Pharmaceutical Co., Ltd 
9 





China Tangshan Chinese 
Pharmaceutical Co 
10 
Ban Kah Chai Hou Tsao 
San 
Chong Park Medical 
Hall (S) Pte Ltd. 
Hong Kong Ban Kah Chai 
MED. FTY. Sdn. Bhd. 
11 Mee Tao Chin Hong San Lee Fah trading Co. 
S. H.Uniflex Chinese Medical 
Factory Sdn. Bhd 
12 
Ban Kah Chai Serbuk 
Batuk 
Chong Park Medical 
Hall (S) Pte Ltd. 
Hong Kong Ban Kah Chai 
MED. FTY. Sdn. Bhd. 
13 Jing Feng powder 
Kiat Ling Health 
Products & Trading 
Kiat Ling Health Products & 
Trading 
14 





China Tangshan Chinese 
Pharmaceutical Co 
15 Ba Bao Jing Feng San Poli Medical Co. Poli Medical Co. 
16 
Pearl & Amber Powder 
for Infantile 
Tong Jum Chew Pte 
Ltd 




Tong Jum Chew Pte 
Ltd 













Figure 1. Effects of methanol extract of Anti-constipation capsules on caspase 
activation after (a). 6 hours and (b). 12 hours of treatment. The plat represents 
average % caspase-3/7 levels on primary Y-axis and % cell viability of secondary Y-










Figure 2. Effects of (a). Aloe-emodin and (b). Rhein on caspase activation after. 12 
hours of treatment. The plat represents average % caspase-3/7 levels on primary Y-














Figure 3. Effects of (a). Physcion and (b). Chrysophanol on caspase activation after. 
12 hours of treatment. The plat represents average % caspase-3/7 levels on primary Y-
axis and % cell viability on secondary Y-axis ± standard deviation at different 
concentrations.  
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